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IntroductIon 







Cardiovascular diseases, such as Myocardial Infarction (MI) are the main cause of mortality 
leading to approximately 30% of all annual global deaths (www.heartstats.org, 
www.who.org).  Myocardial Infarction occurs as a consequence of occlusion of the branches 
of the coronary artery system, which results in myocardial ischemia and damage to the 
surrounding tissues. In the early post-MI phase, the loss of efficient perfusion (hypoxia) 
coincides with massive death of cardiomyocytes and the vasculature. Together these events 
activate the innate immune system and cause a rapid influx of inflammatory cells [1, 2]. The 
course of inflammation in a hypoxic post-MI microenvironment dictates the subsequent 
remodeling and repair of the cardiac wall. In the events following MI, the debris of cardiac 
mass is cleared by the infiltrated inflammatory cells and the wound healing process is 
activated. The adult heart is a highly plastic organ with variable renewal rate: absent or low 
for cardiomyocytes (CM) but higher for fibroblasts and vascular cells [3]. The adult CM or 
existing cardiac progenitor cells do proliferate in adults and lead to total replacement of up 
to 50% of the total heart tissue during healthy life span [4]. Remarkably the regenerative 
programs of damaged heart are even further accelerated compared to physiologically aged 
cardiac tissue [5]. Yet, the replicative potential of adult cardiomyocytes is not sufficient to 
repair the severely damaged heart such as after acute MI. In response to that, myofibroblasts 
are activated to help maintain the structural integrity of the heart by formation of 
collagenous scar. In the subsequent remodeling phase, the remaining cardiomyocytes 
compensate for the loss of contractile mass through hypertrophic growth. Eventually, the 
imbalance of the cardiac contraction i.e. arrhythmia and cardiac dilatation hamper the 
cardiac function, which results in heart failure. Most published post-MI intervention studies 
aim to improve perfusion, reduce apoptosis and acute inflammatory responses. These 
approaches often involve the administration of pharmacological agents, yet do not prevent 
the ongoing tissue damage nor induce the regenerative processes. To compensate for the loss 
of cardiac mass it is essential to provide a new source of cardiomyocytes with proper 
perfusion and tissue stiffness. Unfortunately, despite early intervention and the advances in 
the treatment of cardiovascular diseases such as myocardial infarction there is still no cure to 
regenerate the heart tissue after the injury, thus the developments of alternative cardiac 
therapies are required.  
Mesenchymal Stem Cells/Adipose Derived Stromal Cells therapy 
Currently, stem cells emerged as an additional treatment of patients after myocardial 
infarction [6]. To achieve cardiac repair it is necessary to modulate and tune the post-MI 
microenvironment. The post-MI microenvironment consists of cells, mediators and 
extracellular matrix in constant interactions under pro-inflammatory and hypoxic 
conditions. The orchestration of those interactions by stem cells might reduce adverse 
remodeling such as cardiomyocyte hypertrophy, scar formation, cardiac dilatation, 
appearance of arrhythmia and heart failure. Several clinical trials for cardiac stem cell 
therapy proved that the most promising cells for the cardiac repair are of mesenchymal 
origin, which is actually similar to the origin of a cardiac tissue itself [7]. Mesenchymal 
Stem/Stromal Cells (MSC) are defined as highly regenerative, fibroblast-like cells that 
adhere to tissue culture polystyrene. MSC occur in all organs and can differentiate into 
various cell types such as osteoblasts, adipocytes, chondrocytes, neurons, cardiomyocytes 
among others [8-10]. MSC can be easily isolated and immediately used in the autologous 
applications [11]. The advantage of use of MSC is their secretion of a plethora of 
immunoregulartory, mitogenic and pro-angiogenic cytokines, growth factors and the 
extracellular matrix components [12, 13]. Furthermore, the regenerative potential of MSC is 
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promoted by hypoxic and inflammatory stimuli, which render them as the preferential cells 
for cardiac repair [14, 15]. Bone marrow is the major reservoir of MSC but their harvest is 
cumbersome and associated with the donor site morbidity. Currently, adipose tissue gained 
interest as an available source of therapeutic stem and multipotent progenitor cells [11]. 
Adipose tissue is highly vascularized and at least part of the heterogeneous population of 
Derived Stem/Stromal Cells (ADSC) is derived from the perivascular cells known as Stromal 
Vascular Fraction [16-19]. The isolation of therapeutic cells through lipoaspiration procedure 
is less invasive and less painful compared to the bone marrow aspiration.  Additionally, cells 
can be obtained in the clinically relevant numbers or rapidly expanded in vitro. ADSC 
isolated from patients that suffered MI can be used for autologous cell transplantation into 
the site of injury to drive cardiac repair (Figure 1). Recent reports from experimental clinical 
trials with intracoronary infusion of ADSC indicate that the procedure is safe and lead to the 
improved cardiac function mainly through enhanced perfusion and reduced scar size [20]. 
Although clinical and pre-clinical studies on safety and efficiency of ADSC therapy for 
cardiac repair are consistent, the mechanisms by which ADSC repair cardiac damage are still 
not fully understood [21, 22]. Randomized clinical trials with intramyocardial injection of 
ADSC after aMI suggest that therapeutic potential of ADSC is mainly due to their pro-
angiogenic, anti-apoptotic and immunomodulatory properties [20-22]. 
 This thesis aims to further dissect the regenerative potential of ADSC under pro-
inflammatory and hypoxic conditions such as occurring after aMI. Furthermore, we studied 
the ADSC guided stimulation of cardiomyocyte proliferation, organization and maturation 
(part I). In part II we elaborate on ADSC mediated vascular network formation, acquisition 
of the pericyte function and vascular stabilization (Figure 2).   
 




                                                     
 
Figure 2. Outline of the thesis. 
 
Our focus within ADSC-guided cardiac repair is the modulation of the early post-MI cardiac 
microenvironment. The recipient environment influences the functioning of the stem cells, 
their retention, incorporation, survival, proliferation, differentiation and secretion of the 
regenerative mediators. The post-MI repair mechanism is initiated by the inflammatory 
response followed by activation of a wound healing phase in the infarcted area. At that 
moment injected therapeutic cells should function optimally to modulate adverse tissue 
remodeling i.e. formation of the stiff scar tissue, while maintaining the structural integration. 
To obtain optimal repair, initiation of the regenerative processes must occur in an early post-
MI inflammatory phase i.e. shortly after MI and before appearance of scar tissue [23]. This 
leaves a small window of opportunity for intervention with stem cells. The local infarcted 
microenvironment might hamper the functioning of stem cells. Therefore, the aim of this 
thesis is to understand how the hypoxic and inflammatory stimuli found in the post 
myocardial infarction microenvironment effect the therapeutic potential of Adipose Derived 
Stem/Stromal Cells (ADSC) in the process of cardiac repair i.e. induction of cardiomyocyte 
proliferation, organization and maturation (PART I, Chapter 2-5) together with vascular 
structures formation and tissue remodeling (PART II, Chapter 6-9). Indicating how ADSC 
can be used to improve regenerative outcome of post-MI repair (Figure 2). Therefore, an 
extensive overview of the state in the field of cardiac regeneration by application of 
Mesenchymal Stem Cells i.e. ADSC is given in Chapter 2. We discuss the novel concepts 
and findings that are prerequisite of stem cell therapy for cardiac repair. Furthermore, we 
focused on the recent data obtained from the ongoing randomized clinical trials for 
prevention of heart failure by MSC or ADSC application. In Chapter 3 and Chapter 4 we 
identified that the inflammatory and hypoxic host post-MI microenvironment enhances 
regenerative potential of ADSC to promote cardiomyocyte proliferation. We identified that 
ADSC promote cardiomyocyte proliferation by paracrine stimulation of CM by secretion of 
IL-6 (Chapter 3) and Heparin-binding EGF-like growth factor (HB-EGF) (Chapter 4) 
15
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among others. IL-6 and HB-EGF has been described as respectively a pleiotrophic cytokine 
and growth factor that exerts mitogenic activities on mesenchymal cells such as muscles or 
cardiomyocytes [24-26]. The treatment of cardiomyocytes with conditioned medium of 
ADSC activated mitogenic signaling pathways i.e. JAK-STAT and MAPK resulting in 
enhancement of cardiomyocyte proliferation rate. In Chapter 5 we focused on the role of 
ADSC derived extracellular matrix on cardiomyocyte proliferation, organization or 
maturation. Due to the loss of cardiac mass after the MI, the existing 
fibroblasts/myofibroblasts are activated to produce scar and prevent the cardiac rapture. In 
the heart, the extracellular matrix components act as a cardiac scaffold that maintains tissue 
homeostasis. In the post-MI addition of exogenous i.e. ADSC-derived elastic extracellular 
matrix and matricellular components would provide a new cardiac niche for the activation of 
cardiac repair mechanism i.e. induction of cardiomyocyte proliferation and reduced scar 
size. During the wound healing phase after aMI the accompanied vascularization is initiated, 
albeit insufficient. It suffices to “feed’ inflammation, yet falls short to reperfuse the 
myocardium. Hence, the primary standard treatment of MI aims on the revascularization of 
the ischemic area. The commonly used methods are coronary artery bypass grafting (CBAG), 
percutaneous transluminal coronary angioplasty (PTCA) or VEGF therapy. Unfortunately, 
this treatment does not prevent the ongoing damage. Stem cells such as BM-MSC or 
endothelial progenitor cells (EPC) have been shown to augment the vascular perfusion and 
reduce ongoing damage i.e. reduced apoptosis of cardiomyocytes and improved cardiac 
function [27-29]. Thus in PART II, we focused on the role of ADSC in the vascular network 
formation and tissue remodeling. Essential cells to accomplish the microvascular 
homeostasis are pericytes. These cells orchestrate endothelial cells proliferation, survival, 
vascular tone and permeability [30]. Pericytes are present in the vasculature of all organs 
including retina, brain, skeletal muscle or adipose tissue among others. Pericytes originate 
from neuroectoderm or embryonic mesenchyme, thus sharing a mesenchymal phenotype 
with ADSC. Adipose tissue is a highly vascularized organ with abundant number of Stromal 
Vascular Fraction (SVF) cells. SVF reside in the perivascular i.e. pericyte-like position and in 
culture are equivalent to ADSC. Thus, in Chapter 6 we focused on the pericyte overview in 
their ontogeny, function and regenerative prospective of ADSC as pericytes. In Chapter 7 
we identified that ADSC acquired pericyte-like function in vitro and in vivo. ADSC, when in 
direct contact with endothelial cells, induced vascular network formation. In vitro and in 
vivo ADSC incorporated into the existing vasculature to promote vessel normalization. 
Additionally, in the model of oxygen induced retinopathy ADSC replaced the loosed pericytes 
and promoted vascular normalization by acquisition of pericyte function as well as by 
modulation of the damaged microenvironment to drive the vasculature homeostasis. To 
achieve the higher therapeutic potential of stem/progenitor cells it is possible to instruct the 
cells in vitro before their administration in vivo. The understanding of stem/progenitor 
plasticity in the presence or absence of post-damage microenvironmental factors will help to 
develop and improve therapies. Recently, the concept of “of the shelf” stem cell therapy 
might be achieved by use of the secretors derived from stem cells. In Chapter 8 we 
identified that the conditioned medium of ADSC promote vascular network formation in 
vitro.  Furthermore, ADSC have higher proangiogenic potential compared to other 
fibroblasts like cells. Upon stimuli such as hypoxia and inflammation ADSC increased their 
expression of inflammatory and pro-angiogenic cytokines and growth factors, which render 
them as preferential cells for revascularization of the ischemic cardiac tissue. One of the risks 
in stem cell guided cardiac repair by MSC is accelerated fibrosis and scar formation. The 




size and scarring. Thus in Chapter 9, we focused on the impact of ADSC in tissue 
remodeling in vitro. We identified the conditioned medium of ADSC as inhibitor of TGF-β 
induced differentiation and maturation of human dermal fibroblasts (HDF). This might have 
an impact on limited scar formation. In Chapter 10, the observations described in this 
thesis are summarized and future perspectives of MSC/ADSC mediated cardiac regeneration 
are discussed.  
 
References 
[1] Vandervelde S, van Amerongen MJ, Tio RA, Petersen AH, van Luyn MJ, Harmsen MC. 
Increased inflammatory response and neovascularization in reperfused vs. non-reperfused 
murine myocardial infarction. Cardiovasc Pathol 2006; 15:83-90.  
[2] Vandervelde S, van Luyn MJ, Rozenbaum MH, Petersen AH, Tio RA, Harmsen MC. Stem 
cell-related cardiac gene expression early after murine myocardial infarction. Cardiovasc Res 
2007; 73:783-793.  
[3] Anversa P, Kajstura J, Rota M, Leri A. Regenerating new heart with stem cells. J Clin 
Invest 2013; 123:62-70.  
[4] Bergmann O, Bhardwaj RD, Bernard S, Zdunek S, Barnabe-Heider F, Walsh S et al. 
Evidence for cardiomyocyte renewal in humans. Science 2009; 324:98-102.  
[5] Kajstura J, Rota M, Cappetta D, Ogorek B, Arranto C, Bai Y et al. Cardiomyogenesis in 
the aging and failing human heart. Circulation 2012; 126:1869-1881.  
[6] Clifford D M, Fisher SA, Brunskill SJ, Doree C, Mathur A, Watt S et al. Stem cell 
treatment for acute myocardial infarction. Cochrane Database Syst Rev 2012; 2:CD006536.  
[7] Lalu M M, McIntyre L, Pugliese C, Fergusson D, Winston BW, Marshall JC et al. Safety of 
cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-
analysis of clinical trials. PLoS One 2012; 7:e47559.  
[8] Nery A A, Nascimento IC, Glaser T, Bassaneze V, Krieger JE, Ulrich H. Human 
mesenchymal stem cells: from immunophenotyping by flow cytometry to clinical 
applications. Cytometry A 2013; 83:48-61.  
[9] Krampera M, Galipeau J, Shi Y, Tarte K, Sensebe L, On behalf of the MSC Committee of 
the International Society for Cellular Therapy (ISCT). Immunological characterization of 
multipotent mesenchymal stromal cells-The International Society for Cellular Therapy 
(ISCT) working proposal. Cytotherapy 2013.  
[10] Daher S R, Johnstone BH, Phinney DG, March KL. Adipose stromal/stem cells: basic 
and translational advances: the IFATS collection. Stem Cells 2008; 26:2664-2665.  
[11] Atsma D E, Fibbe WE, Rabelink TJ. Opportunities and challenges for mesenchymal stem 
cell-mediated heart repair. Curr Opin Lipidol 2007; 18:645-649.  
[12] Caplan A I, Dennis JE. Mesenchymal stem cells as trophic mediators. J Cell Biochem 
2006; 98:1076-1084.  
[13] Caplan A I, Correa D. The MSC: an injury drugstore. Cell Stem Cell 2011; 9:11-15.  
[14] Singer N G, Caplan AI. Mesenchymal stem cells: mechanisms of inflammation. Annu 
Rev Pathol 2011; 6:457-478.  
[15] Luo Y, Wang Y, Poynter JA, Manukyan MC, Herrmann JL, Abarbanell AM et al. 
Pretreating mesenchymal stem cells with interleukin-1beta and transforming growth factor-
beta synergistically increases vascular endothelial growth factor production and improves 
mesenchymal stem cell-mediated myocardial protection after acute ischemia. Surgery 2011.  
[16] Traktuev D O, Parfenova EV, Tkachuk VA, March KL. Adipose stromal cells--plastic type 
of cells with high therapeutic potential. Tsitologiia 2006; 48:83-94.  
17
Introduction and aim of the thesis
8 
 
[17] Zimmerlin L, Donnenberg VS, Pfeifer ME, Meyer EM, Peault B, Rubin JP et al. Stromal 
vascular progenitors in adult human adipose tissue. Cytometry A 2010; 77:22-30.  
[18] Bourin P, Bunnell BA, Casteilla L, Dominici M, Katz AJ, March KL et al. Stromal cells 
from the adipose tissue-derived stromal vascular fraction and culture expanded adipose 
tissue-derived stromal/stem cells: a joint statement of the International Federation for 
Adipose Therapeutics and Science (IFATS) and the International Society for Cellular 
Therapy (ISCT). Cytotherapy 2013; 15:641-648.  
[19] Amos P J, Shang H, Bailey AM, Taylor A, Katz AJ, Peirce SM. IFATS collection: The role 
of human adipose-derived stromal cells in inflammatory microvascular remodeling and 
evidence of a perivascular phenotype. Stem Cells 2008; 26:2682-2690.  
[20] Panfilov I A, de Jong R, Takashima S, Duckers HJ. Clinical study using adipose-derived 
mesenchymal-like stem cells in acute myocardial infarction and heart failure. Methods Mol 
Biol 2013; 1036:207-212.  
[21] Houtgraaf J H, den Dekker WK, van Dalen BM, Springeling T, de Jong R, van Geuns RJ 
et al. First experience in humans using adipose tissue-derived regenerative cells in the 
treatment of patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol 
2012; 59:539-540.  
[22] Houtgraaf J H, de Jong R, Kazemi K, de Groot D, van der Spoel TI, Arslan F et al. 
Intracoronary Infusion of Allogeneic Mesenchymal Precursor Cells Directly Following 
Experimental Acute Myocardial Infarction Reduces Infarct Size, Abrogates Adverse 
Remodeling and Improves Cardiac Function. Circ Res 2013.  
[23] Vandervelde S, van Luyn MJ, Tio RA, Harmsen MC. Signaling factors in stem cell-
mediated repair of infarcted myocardium. J Mol Cell Cardiol 2005; 39:363-376.  
[24] Bersell K, Arab S, Haring B, Kuhn B. Neuregulin1/ErbB4 signaling induces 
cardiomyocyte proliferation and repair of heart injury. Cell 2009; 138:257-270.  
[25] Ieda M, Tsuchihashi T, Ivey KN, Ross RS, Hong TT, Shaw RM et al. Cardiac fibroblasts 
regulate myocardial proliferation through beta1 integrin signaling. Dev Cell 2009; 16:233-
244.  
[26] Toth K G, McKay BR, De Lisio M, Little JP, Tarnopolsky MA, Parise G. IL-6 induced 
STAT3 signalling is associated with the proliferation of human muscle satellite cells 
following acute muscle damage. PLoS One 2011; 6:e17392.  
[27] Kocher A A, Schuster MD, Szabolcs MJ, Takuma S, Burkhoff D, Wang J et al. 
Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts 
prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat 
Med 2001; 7:430-436.  
[28] Schuster M D, Kocher AA, Seki T, Martens TP, Xiang G, Homma S et al. Myocardial 
neovascularization by bone marrow angioblasts results in cardiomyocyte regeneration. Am J 
Physiol Heart Circ Physiol 2004; 287:H525-32.  
[29] Krenning G, van Luyn MJ, Harmsen MC. Endothelial progenitor cell-based 
neovascularization: implications for therapy. Trends Mol Med 2009; 15:180-189.  
[30] Pfister F, Feng Y, vom Hagen F, Hoffmann S, Molema G, Hillebrands JL et al. Pericyte 
migration: a novel mechanism of pericyte loss in experimental diabetic retinopathy. Diabetes 






mesenchymal stem cells: 
promising for myocardial 
regeneration?
ewa przybyt, martin c. harmsen
university of Groningen, university medical center Groningen, department 
of pathology and medical Biology, cardiovascular regenerative medicine 
research Group (caVarem), hanzeplein 1 (ea11), 9713 GZ Groningen, 
the netherlands










The pandemic of cardiovascular disease is continuously expanding as the result of changing 
life styles and diets throughout the Old and New World. Immediate intervention therapy 
saves the lives of many patients after acute myocardial infarction (MI). However, for many 
this comes at the price of adverse cardiac remodeling and heart failure. Currently, no 
conventional therapy can prevent the negative aftermath of MI and alternative treatments 
are warranted. Therefore, cardiac stem cell therapy has been put forward over the past 
decade, albeit with modest successes. Mesenchymal Stem Cells (MSC) are promising because 
these are genuine cellular factories of a host of secreted therapeutic factors. MSC are 
obtained from bone marrow or adipose tissue (ADSC). However, the heart itself also 
contains mesenchymal-like stem cells, though more difficult to acquire than ADSC. 
Interestingly, mesenchymal cells such as fibroblasts can be directly or indirectly 
reprogrammed to all myocardial cell types that require replacement after MI. To date, the 
paracrine and juxtacrine mechanisms of ADSC and other MSC on vessel formation are best 
understood. The preconditioning of, otherwise naïve, stem cells is gaining more interest: 
previously presumed deleterious stimuli such as hypoxia and inflammation, i.e. causes of 
myocardial damage, have the opposite effect on mesenchymal stem cells.  MSC gain a higher 
therapeutic capacity under hypoxia and inflammatory conditions. In this review, 
mesenchymal stem cells and their working mechanisms are put into the perspective of 























Cardiovascular disease (CVD) has developed into a pandemic over the past decades. 
Dramatic changes in life, changes to high caloric diets, lack of exercise, smoking and 
increased socioeconomic stress all contribute to increased risk for CVD, in particular as co-
morbidity of obesity, overweight and type 2 diabetes (1). The vascular system responds to the 
constant exposure of the CVD risk factors with endothelial dysfunction which is underlying 
atherosclerosis. In end-stage atherosclerosis, branches of the coronary arteries may occlude 
and cause an acute myocardial infarction (MI). Downstream of an occluded coronary artery 
the myocardium is severely ischemic. Prolonged ischemia causes death of cardiomyocytes 
and surrounding vasculature. Subsequently, the death signals from apoptotic and necrotic 
cells induce an inflammatory reaction (2-5). In experimental MI in mice, the inflammation 
dominates the early post-MI cardiac microenvironment with a rapid influx of neutrophils, 
followed by macrophages that clear debris, dead cells and that promote the wound healing 
process. Macrophages are known to shift their phenotype from the classically polarized 
(inflammatory macrophages) to alternatively polarized (anti-inflammatory macrophages) in 
the transition process from inflammation to scar formation after MI (6). Indeed, the 
systemic depletion of macrophages led to impaired wound healing and delayed, if not 
prevented, remodeling after myocardial injury (4). The highest inflammatory cellular influx 
after the MI is within seven days and followed by increased numbers of myofibroblasts that 
facilitate the formation of a rigid scar (7). Unfortunately, the limited proliferation capacity of 
adult cardiomyocytes cannot meet the demands to replace lost cardiomyocytes and hence the 
cardiac damage is beyond adequate repair. The functional repair comprises of a rigid scar 
that prevents the ventricular wall from rupture. The loss of cardiomyocytes and the lack 
contractility of the scar together cause a compensatory reaction which features hypertrophy 
of the surviving cardiomyocytes. This is the onset of a secondary remodeling process that 
causes cardiac fibrosis. Without appropriate intervention, these events lead to cardiac 
dilatation, deterioration of cardiac function and eventually heart failure. To prevent this 
adverse cardiac remodeling, it is essential to provide the damaged myocardium with a source 
of cardiomyocytes and to revascularize the damaged microenvironment. To obtain optimal 
regeneration, initiation of the regenerative processes must occur in an early post-MI 
inflammatory phase i.e. immediately after MI and before appearance of scar tissue. This 
leaves no more than a small window of opportunity for intervention with stem cells. Recent 
findings indicate that cardiac tissue has an endogenous repair capacity too. During healthy 
life, cardiomyocytes are replaced every eight years, this frequency is even accelerated after 
insults such as MI (8,9). In spite of attempts to differentiate cardiomyocytes from stem 
cells(10) or to tissue engineer entire cardiac constructs(11) or even hearts(12), the 
observation that postnatal cardiomyocytes show physiological turnover is of no less 
importance. Obviously, this is an opportunity for novel therapeutic treatments that engage 
on the stimulation of the proliferation of the surviving cardiomyocytes. Thus, application of 
therapeutic stem cells that modulate the post-MI microenvironment is desirable, in 
particular to increase the proliferation of cardiomyocytes that surround the damaged area. 
This would circumvent the need to form a scar and it would prevent subsequent adverse 
cardiac remodeling and the onset and progression of heart failure. In this review, we discuss 
the opportunities of mesenchymal stem cell therapy for the treatment of MI, in the light of 
the microenvironmental influence on stem cells and their function. A main focus is on 
mesenchymal stem cells from adipose tissue (ASDC).  





Alternative therapies for treatment of the consequences of myocardial infarction are still in 
high demand, because conventional pharmaceutics do not provide repair or regeneration. On 
the other hand, heart transplantation is the ultimate replacement therapy, yet the number of 
patients by far exceeds the donor heart availability. Thus, late mortality due to the heart 
failure continues to increase. Stem cell-based or progenitor cell-based therapies have 
emerged as an alternative treatment of cardiovascular diseases such as MI. Stem cell therapy 
aims on the induction of angiogenesis as well as on induction of myogenesis, the latter of 
which is inefficient.  The restoration of blood flow to ischemic regions by itself appears to 
help reduce scar formation and improved the contractile activity of the damaged 
myocardium. In the early days, research on the regeneration of the damaged heart focused 
on the healing properties of fetal and neonatal cardiomyocytes and cardiac progenitor cells. 
Many of these studies reported that those cells could functionally integrate and improve 
cardiac function in various animal models for MI (13,14). The efficiency of these integrations 
was generally low. Recent findings by Kaushal and co-workers indicate that cardiac stem 
cells from newborns have a higher regenerative capacity to restore cardiac function 
compared to adult cardiac stem cells (15). Although the embryonic or neonatal stem cell 
therapies show beneficial influence on the regenerative process after MI, the cells are 
difficult to obtain and are ethically compromised (16-18). The advent of inducible pluripotent 
stem cells (iPSC) (19) paved the way to generate autologous ‘repair’ cells. By using the 
patient’s own fibroblasts, reprogramming can be achieved by introduction of no more than 
four transcription factors that are pivotal in maintenance of a primitive i.e. embryonic stem 
cell state. The iPSC technology solved the potential immune rejection of embryonic stem cell-
derived myocardial cells, yet leaves the possibility that teratomas develop unsolved as yet. A 
giant leap forward was achieved by retroviral delivery of a specific set of cardiac 
developmental transcription factors, which directly reprogrammed fibroblasts into 
cardiomyocytes albeit it with low effiency(20). Meanwhile, iPSC technology has progressed 
from gene delivery by permanently integrating retroviruses to transient overexpression by 
plasmid-encoded defined (cardiac) factors or even delivery of microRNA  to yield mature and 
functional cardiomyocytes (20-24). In vivo, iPSC-derived cardiomyocytes ameliorated 
cardiac function in rodents after myocardial infarction (25-27). Remarkably, highly 
proliferative cardiomyocytes could be generated through derivation of iPSC from neonatal 
cardiomyocytes and their redifferentiation to cardiomyocytes (28). The authors attributed 
this efficient ‘cycling’ of reprogramming to the maintenance of the cardiomyocyte epigenetic 
status (28). Reprogramming is primarily based on rewiring the epigenome of the source 
cells, but the epigenetic makeup is at least partly maintained in reprogrammed fibroblasts 
(29-31). Therefore, the use of fibroblasts for cardiac reprogramming deserves caution 
because fibroblasts are also the culprit cells in heart failure and cardiac fibrosis.  
Unfortunately, most, if not all, studies in which stem cell-derived cardiomyocytes were 
employed to treat MI were performed in small animals such as mice. The task to scale up 
stem cell differentiation, administration and integration of cardiomyocytes into the human 
heart, which may require billions of cardiomyocytes, is formidable. However, as the heart in 
principle is a specialized muscle, therapies have been investigated that made use of skeletal 
myoblasts. Myoblasts are easy to obtain and are readily expanded in vitro to the large 
numbers required for cardiac cell therapy. Unfortunately, the patients that received the 
intramyocardial transplantation of skeletal myoblasts experienced severe tachycardia. This 
was due to the lack of electromechanical coupling with the host cardiomyocytes (32,33). 
13
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Taken together, the application of stem derived-derived cardiomyocytes as replacement 
therapy is still in its infancy, despite significant scientific breakthroughs. 
Mesenchymal stem cells in cardiac therapy 
The great discovery in cardiovascular research that bone marrow-derived stem cells are able 
to differentiate not only into blood cells but also into muscle, cardiomyocytes, vascular 
components, liver and brain cells opened new opportunities for cardiac tissue regeneration 
(34-37). Besides hematopoietic stems, the bone marrow contains stromal cells which harbor 
stem cell-like features. These mesenchymal stromal cells or mesenchymal stem cells (MSC) 
were first isolated and characterized by Caplan and co-workers, who opened up new 
opportunities for cardiac stem cell therapy (38-40). MSC are isolated from many different 
sources such as bone marrow, adipose tissue, cord blood or amniotic fluid. They can be easily 
obtained in clinically relevant numbers, rapidly expanded in vitro and cultured in simple 
media (41). The benefit of mesenchymal stem cells has been shown in animals models to 
improve cardiac function and reduce adverse remodeling (35,42,43). Bone marrow-derived 
mesenchymal stem cells (BM-MSC) appear to contribute to the regeneration of cardiac tissue 
after the MI, albeit modest (44,45). Interestingly, every organ in the body appears to harbor 
a set of mesenchymal-like stem cells that are more or less predisposed to a cellular fate of 
that organ. Also the heart is a source of cardiac stem cells (46) or cardiac progenitor cells, 
some of which resemble hematopoietic stem cells while others resemble mesenchymal stem 
cells (47). These endogenous cardiac stem cells (CSC) are usually isolated using a typical 
surface marker such as c-Kit, Sca-1, Islet-1 or SSEA-1, while mere plastic adherence of 
aggregation growth as cardiospheres is employed too. Finally, the heart contains so-called 
side population cells which are negatively FACS-sorted based on dye-exclusion through an 
ABC transporter (CSC are excellently reviewed in (48). 
Mesenchymal stem cells in clinical trials. 
Ever since bone marrow-derived stem cells and cardiac stem cells were isolated, they have 
been exploited in clinical trials to evaluate their therapeutic potential after myocardial 
infarction. Readouts generally comprise of general clinical features, functional cardiac 
parameters and quality of life. Several clinical trials demonstrated improved cardiac function 
after administration of bone marrow-derived stem cells, both hematopoietic stem cells and 
MSC, such as cardiac c-kit stem cells in the SIPIO trial or cardiospheres in the CADUCEUS 
trial (49,50). Recently, the POSEIDON clinical trial showed a beneficial effect of after acute 
MI. Remarkably, in this trial administration of autologous and allogeneic BM-MSC was 
compared and it was shown that they had similar therapeutic benefit (51). This is an 
important study, because it shows for the first time, that cardiac stem cell therapy does not 
depend on the patient’s own cells. This allows for standardization and better control of 
future therapies. In addition, a dose comparison study was performed in the POSEIDON 
trial. Surprisingly, the investigators observed an inverse relation between therapeutic 
outcome and the number of administered stem cells: a mere twenty million cells resulted in 
better improved cardiac parameters compared to two hundred million cells (51). Low dose 
concentration of MSC resulted in greater reduction of left ventricular volumes (LV) and 
increased ejection fraction (EF). Yet, this remarkable inverse dose response must be further 
studied in larger clinical trials. Although, bone marrow- derived stem cells lead to the 
functional improvement of a damaged cardiac tissue, their isolation is cumbersome and 





isolated is limited and may demand culture expansion, although Hare and colleagues may 
contradict this (51). Expansion of (stem) cells in vitro always bares the risk of reduced 
genome stability and may have long-term adverse effects after administration. Yet, this risk 
may not be present as yet, because the retention of stem cells after their administration is 
low. In an acute MI model in pigs, retention of mesenchymal-like stem cells was higher than 
of bone marrow-derived mononuclear stem cells (52). Yet, within one hour after 
intramyocardial injection the majority of administered cells had left the heart (52). 
Nevertheless, over the past decade mesenchymal stem cells emerged as the most promising 
type of stem cell for the cardiovascular regeneration. Besides bone marrow and heart, 
scientists focused on other tissue sources for mesenchymal stem cells with a high 
regenerative potential (53). Adipose tissue is rich in MSC too, while it is easier accessible 
than bone marrow. The biology of adipose tissue-derived stem cells or ADSC will be 
addressed in the following section. ADSC have rapidly reached the clinic. The APOLLO 
double-blind randomized clinical trial for treatment of acute myocardial infarction employs 
autologous ADSC. These ADSC are harvested from lipoaspirates and enriched through 
processing with the Celution system of Cytori. This closed system procedure takes only a few 
hours which allows for administration of the ADSC during the conventional treatment of the 
acute MI. The clinical trial involved ten patients that received ADSC and four placebo group 
36 h after the infarction occurred. So far, APOLLO showed two important benefits for the 
intraoperative use of ADSC. Firstly, an up to sixty percent reduction of infarct size was 
observed and secondly an improved revascularization of the ischemic tissue was observed 
which ameliorated blood flow. In addition, contractility was improved, while no arrhythmias 
(54). According to the investigators not only the short term follow up (six months) but also 
the  long term follow up (eighteen months) of the APOLLO clinical trial showed a persistent 
benefit for the patient that had been treated with ADSC. This substantiates the need for 
further development of the ADSC-based therapies for cardiac regeneration. Meanwhile, 
ADVANCE has started which is a follow-up clinical trial focusing to prevent heart failure. It 
includes a near 375 patients that will be treated with ADSC within twenty-four hours after 
acute myocardial infarction. Whereas several trials focus on early intervention, other clinical 
trials, like PRECISE and ATHENA, focus on the aftermath of myocardial infarction i.e. 
treatment of chronic myocardial ischemia with ADSC (reviewed in mortality) (55).  Thus, the 
coming years will be high in anticipation for the long-term efficacy of ADSC-based cardiac 
stem cell therapy. 
Mesenchymal stem cells from adipose tissue 
Adipose tissue is an abundant source of mesenchymal stem cells, known as adipose tissue-
derived stem or stromal cells (ADSC) (56). By definition, ADSC are the plastic adherent 
fraction of the stromal vascular fraction of adipose tissue. In our experience, several tens of 
millions of ADSC can be easily isolated from as little as one liter of lipoaspirate (Przybyt, 
unpublished). This sheer abundance of cells almost contradicts them being named as stem 
cells. Also their limited number of population doublings supports the suggestion to call 
ADSC adipose tissue-derived stromal cells, more than stem cells. Not uncommon for ‘stem’ 
cells, the origin of ADSC is debated. In fact, multiple types of stromal-derived cum vascular 
bed-associated cells may give rise to ADSC, (57). Similar to all other types of MSC, ADSC are 
per definition in vitro culture (d) artifacts that acquire a phenotype that may strongly differ 
from their in vivo phenotype. To date, the vasculature of adipose tissue is thought to give rise 
of at least three types of multipotent precursor cells. Firstly, at luminal side these are 
endothelial precursor cells, while both other types are either supra-adventitial (58) or 
15
2
Mesenchymal Stem Cells: promising for myocardial regeneration?
15 
 
perivascular (59, 60). These perivascular ADSC are likely a subfraction of the pericytes, while 
the supra-adventitial ADSC may relate to a specific subset of advential fibroblasts (61). 
Others, provide evidence that ADSC originate from perivascular and adventitial vascular 
regions but are more similar to smooth muscle cells (61-63). It is likely that the cells in these 
locations form a continuum, while the local microenvironment dictates their resident 
phenotype. Once disrupted from their original environment these cells appear to show a high 
degree of interchangeability (60). In comparison to BM-MSC, ADSC yields are consistently 
higher, while the growth rate of ADSC in a simple mesenchymal medium is higher too (64). 
In vitro, ADSC have a mesenchymal phenotype and a morphology that is virtually 
indistinguishable from ‘common’ fibroblasts. Unanimous markers or marker panels that 
discriminate between mesenchymal stem cells and fibroblasts do not exist. However, surface 
markers expressed by cultured ADSC include CD90, CD105, CD29, CD44, CD73, CD271, 
while others are absent such as the endothelial markers CD31 or CD34 and hemotopoietic 
markers such as CD45, CD14 among others (65). Other criteria may differentiate between 
ADSC and fibroblasts, because MSC are multipotent. As such ADSC are generally assessed 
for their multipotency through differentiation to the typical trilineage of adipocytes, 
chondrocytes, osteoblasts. Furthermore, ADSC also easily differentiate into smooth muscle 
cells, which comes as no surprise in view of their vascular origin. Interestingly, both 
fibroblasts and ADSC are amenable to reprogramming into iPSC. Yet, this process is by far 
more efficient in ADSC (66). In the previous section we discussed the use of freshly isolated 
ADSC for clinical experimental therapy. Yet, cultured ADSC have proven beneficial in several 
animal models for acute MI too (67-70). 
Requirements for cardiac regeneration 
Myocardial infarction causes dramatic spatiotemporal changes in the ventricular wall. This 
hostile microenvironment is characterized by lack of perfusion and massive cell death and 
thus is a non-attractive playground for therapeutic stem cells. By definition, stem cells are 
‘naïve’ and are readily persuaded to change their phenotype upon microenvironmental 
stimuli. Therefore, the concept to use stem cells to adjust a damaged and hostile tissue 
microenvironment would appear naive too. The fact that therapeutic benefits have been 
reached is likely caused by the relatively large numbers of stem cells that are administered in 
cardiac stem cell therapies. In the future, major improvements could be reached by 
educating stem cells prior to their administration, while their retention should be improved 
too e.g. by using biomaterial-based delivery systems.  
In the post-infarct period, the major processes that occur are cell death, inflammation, 
wound healing, followed by need for the formation of blood vessels. These processes are all 
tightly associated but, importantly, ADSC can influence all four of them. As mentioned 
earlier, a major ‘flaw’ of the mammalian heart after infarction is the almost complete absence 
of proliferation of cardiomyocytes. Despite their being naive stem cells, the main mode of 
action of MSC, including ADSC, is through secretion of a plethora of paracrine factors. These 
trophic factors include mitogens such as hepatocyte growth factor (HGF), insulin growth 
factor (IGF), and  fibroblasts growth factors (FGF), but also immunological factors such 
interleukin 6 (IL-6) and tumor growth factor beta (TGF-beta) as well as matrix remodeling 
enzymes such as matrix metalloproteases (MMPs) (71-73). All of these factors are 
constitutively produced by in vitro cultured ADSC. This fact alone shows that ADSC are 
genuine culture artifacts, because it would seem highly unlikely for any tissue cell to produce 





single factors produced by ADSC. Moreover, most if not all, of the ADSC-secreted factors are 
pleiotropic by nature (73, 74). The ‘secretome’ of ADSC, in terms of composition and 
concentration, dictates their therapeutic capacity. However, the redundant nature of the 
secretome of ADSC might warrant a balanced response in the post-infarction 
microenvironment. Ever since the discovery of the proangiogenic capacity of vascular 
endothelial growth factor (VEGF), cardiovascular therapy has strongly focused on the 
improvement of perfusion, i.e. the upregulation of vascularization, in cardiovascular disease. 
This quest was continued with the revolutionary discovery of Asahara and coworkers that 
part of the hematopoietic stem cells in bone marrow were vasculogenic as well as 
proangiongenic (75). This set the stage for the use of stem cells in provasculogenic therapies 
after myocardial infarction. Also ADSC are strongly proangiogenic through secretion of e.g. 
VEGF, FGFs, and angiopoeitins. Importantly, ADSC can promote vessel formation in vitro 
through juxtacrine interaction with endothelial cells as well (76, 77). Part of this juxtacrine 
interaction that promotes stable vessels, is governed by secretion of extracellular matrix 
components by ADSC (78). The ‘pericytic’ ADSC fraction from adipose tissue, could stabilize 
vascular structures in vitro, which depended on cell-cell contacts and on mutual signaling 
with paracrine factors (79). This suggests that in vivo ADSC not only promote angiogenesis 
through paracrine signaling, but also through juxtacrine signaling i.e. by acquiring a pericyte 
function.  
An exciting feature of MSC that is shared by ADSC is their immunosuppressive behavior. 
Earlier we referred to the POSEIDON trial, in which allogeneic ADSC were administered 
after MI without noticeable side effects (51). In fact, human ADSC could by transplanted not 
only allogeneically, but also over a xeno barrier i.e. in rats, dogs and rabbits (68, 80-82). 
These were different disease models, but in all cases the human ADSC exerted an 
immunomodulatory effect, primarily through secretion of prostaglandin E2 (PGE-2) (83). In 
general, the immunomodulatory effect of MSC and ADSC comprises of suppression of T 
lymphocyte function (84). Immunosuppression is exerted through secretion of 2.3-
dioxygenase (IDO), PGE-2, or  nitric oxide (NO), some of which reprogram the microphages 
into the anti-inflammatory phenotype and upregulate production of the anti-inflammatory 
cytokine interleukin 10 (IL-10) (85). In vitro, ADSC reduced proliferation of T and B 
lymphocytes as well as Natural Killer cells but also by directed macrophages to alternatively 
activated i.e. type 2 macrophages, shifting the acute remodeling phase into the genuine 
tissue repair (86). 
Stem cell responses to the host microenvironment  
The secretion profile and the fate of stem cells change in response to microenvironmental 
cues (87). Strong cues in the post-infarction myocardium are hypoxia and pro-inflammatory 
mediators that might negatively influence the regenerative properties of therapeutic cells. 
Surprisingly, hypoxia and stimulation with proinflammatory cytokines such as interleukin 1 
beta (IL-1beta) augmented the regenerative capacity and secretome of ADSC In particular. 
Under hypoxia or in the presence of IL-1beta, tumor necrosis factor alpha (TNF alpha) or IL-
6, neither ADSC survival nor their proliferation were significantly reduced (88, 89). 
Similarly, aged ADSC were not negatively affected by hypoxia or proinflammatory factors 
(90). Moreover, hypoxia promoted the capacity of ADSC to augment in vitro sprouting of 
endothelial networks on matrigel. This increased therapeutic capacity was associated with 
increased levels of proangiogenic factors. Similarly, ADSC promoted vascularization of 
matrigel plugs in vivo (91).. Older ADSC did, however, show a reduction on proangiongenic 
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proteases such as MMPs, which suggests that aging might influence the therapeutic behavior 
of these stem cells. Others confirm that ADSC acquire a ‘stronger’ therapeutic capacity under 
hypoxia, although this response mounts slower than in hypoxic BM-MSC (92). Thus hypoxia 
and inflammation render ADSC more angiogenic. As mentioned earlier, ADSC can acquire a 
pericytic phenotype in co-cultures with endothelial cells. This suggests that ADSC make a 
fate choice, because pericytes are vessel-stabilizing mural cells, more than pro-angiogenic 
cells. In rats with chemically-induced mesenteric damage which is a model for hypoxia and 
inflammatory induced damage, injected ADSC showed to promote healing angiogenesis, 
while part of the ADSC acquired a perivascular position (93). This suggests that also in vivo 
ADSC might serve a bifunctional role. It remains to be investigated whether in clinical trials 
such as APOLLO or POSEIDON, ADSC also end up as pericytes.  
These findings imply that a potentially hostile microenvironment is of no concern to 
administered ADSC. Moreover, hypoxic or proinflammatory preconditioning might even 
augment the ADSC’s capacity to promote tissue revascularization and repair (94). MSC pre-
conditioned with TGF-beta or a combination of TGF-beta and IL-6 showed a stronger 
cardioprotective effect than untreated MSC (95, 96). This is both remarkable and exciting, 
because TGF beta and IL-6 are the culprit factors in the onset and progression of cardiac 
fibrosis and subsequent heart failure It again emphasizes that cardiac therapy should not be 
judged on the effect of single factors alone. Pretreatment of MSC with TGF-beta and IL-1beta 
prior the injection also synergistically improved vascularization of the ischemic cardiac 
tissue through augmented production of vascular endothelial growth factor (97). 
Thus, cardiac stem cell therapy with ADSC still needs to be further fine-tuned in terms of 
preconditioning with oxygen concentration and preconditioning with distinct inflammatory 
mediators. 
The conditioned medium in cardiovascular regeneration 
We have come a long way from the discovery of the peculiar phenomenon that plastic 
adherent cells from the stromal vascular fraction of adipose tissue secrete a plethora of 
therapeutic factors to the fact that these paracrine factors secreted by cultured ADSC are 
their major mode of action in cell and tissue regeneration. Yet, the interdonor variation of 
ADSC can be significant (Przybyt et al, unpublished data). Therefore, the question rises 
whether it would be possible to replace ADSC with their secreted factors i.e. conditioned 
culture media. The advantages are that a clonal ADSC line or an immortialized ADSC line 
could be selected with an optimal therapeutic spectrum. It would also allow for an off-the-
shelf product which is available at all times for cardiac intervention. Recent data indicate the 
use of the conditioned medium from human ADSC improved cardiac regeneration and 
function in a pig model for MI (98, 99).  
Potential of ADSC in attenuation of cardiac fibrosis 
As mentioned, one of the major findings in the APOLLO clinical trial with use of therapeutic 
ADSC in the treatment of MI is the significant reduction in the scar size and improved 
perfusion of the myocardium. The juxtacrine and paracrine interactions exerted by ADSC in 
the post-MI microenvironment, strongly reduce the acute ventricular remodeling which 
results in reduced long term fibrotic remodeling too (100). Beside the secretion of pro-
angiogenic and anti-fibrotic growth factors and cytokines, ADSC produce and remodel 





perfusion and stiffness (101,102). The concept of improved post-MI cardiac stiffness is also 
currently a new approach that employs nature-inspired biomaterials for the treatment of MI 
(103). ADSC have been proven beneficial in skin regeneration by accelerated wound healing 
and the reduction of dermal fibrosis (104-107). According to Spiekman et. al.  ADSC 
suppress fibrotic remodeling through inhibition of TGF-beta driven cellular hypertrophy and 
myofibroblast differentiation. Furthermore, ADSC have shown antifibrotic properties after 
transplantation to the various organs such as liver or lungs (108,109). Thus, current data 
suggest that ADSC might carry limited risk in appearance of cardiac fibrosis after the 
administration to the post-Mi microenvironment.  
Conclusions 
The therapeutic benefit of cardiac stem cell therapy is at best similar to conventional 
therapeutics such as ACE inhibitors or beta blockers. This raises continues concern and 
debate on the use of stem cells in regenerative medicine. Nevertheless, costly clinical trials 
with therapeutic stem cells are ongoing and are engaged on a continuous basis. In this review 
we have shown that after the initial hype of cardiac stem cell therapy, we started to 
understand that mesenchymal stem or stromal cells might be more potent than 
hematopoietic stem cells or other blood-born therapeutic cells. In contrast to the traditional 
view on stem cells, which is to differentiate parenchymal cells from stem cells, cardiac stem 
cell therapy relies primarily on the secretion of trophic factors by mesenchymal stem cells. 
The understanding of the working mechanism of MSC has greatly increased and led to the 
discovery that these cells can be primed to a higher level a therapeutic capacity by potentially 
deleterious stimuli such as hypoxia and inflammation. As ADSC are of perivascular origin, 
this raises the question why cardiac perivascular cells apparently do not respond to the 
stimuli in a ‘therapeutic fashion’. This is likely due to the fact that only upon culturing on 
plastic and in simple growth media, MSC and ADSC acquire their highly active and diverse 
secretome. 
Future experiments will further dissect the paracrine functioning of ADSC as well as their 
juxtacrine function as pericytes in neovasculature. 
Abbreviations: MI – myocardial infarction, MSC – mesenchymal stem cell, ADSC – 
adipose tissue-derived stem cell, IL – interleukin, TGF – transforming growth factor, TNF – 
tumor necrosis factor, VEGF – vascular endothelial growth factor, HGF – hepatocyte growth 
factor, IGF – insulinlike growth factor, FGF – fibroblast growth factor, CVD – cardiovascular 
disease, iPSC – induced pluripotent stem cell 
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Background: Experimental clinical stem cell therapy has been used for more than a decade to 
alleviate the adverse aftermath of acute myocardial infarction (aMI). The post-infarcted 
myocardial microenvironment is characterized by cardiomyocyte death, caused by ischemia 
and inflammation. These conditions may negatively affect administered stem cells. As 
postnatal cardiomyocytes have a poor proliferation rate, while induction of proliferation 
seems even more rare. Thus stimulation of their proliferation rate is essential after aMI. In 
metaplastic disease, the pro-inflammatory cytokine interleukin-6 (IL-6) has been identified 
as potent mediators of the proliferation rate. We hypothesized that IL-6 could augment the 
proliferation rate of (slow-)dividing cardiomyocytes. Methods: To mimic the behavior of 
therapeutic cells in the post-infarct cardiac microenvironment, human Adipose Derived 
Stromal Cells (ADSC) were cultured under hypoxic (2% O2) and pro-inflammatory 
conditions (IL-1β) for 24h. Serum-free conditioned medium from ADSC primed with 
hypoxia and/or IL-1β was added to rat neonatal cardiomyocytes and adult cardiomyocytes 
(HL-1) to assess paracrine-driven changes in cardiomyocyte proliferation rate and induction 
of myogenic signaling pathways. Results: We demonstrate that ADSC enhance the 
proliferation rate of rat neonatal cardiomyocytes and adult HL-1 cardiomyocytes in a 
paracrine fashion. ADSC under hypoxia and inflammation in vitro had increased the 
interleukin-6 (IL-6) gene and protein expression. Similar to conditioned medium of ADSC, 
treatment of rat neonatal cardiomyocytes and HL-1 with recombinant IL-6 alone also 
stimulated their proliferation rate. This was corroborated by a strong decrease of 
cardiomyocyte proliferation after addition of IL-6 neutralizing antibody to conditioned 
medium of ADSC. The stimulatory effect of ADSC conditioned media or IL-6 was 
accomplished through activation of both Janus Kinase-Signal Transducer and Activator of 
Transcription (JAK/STAT) and Mitogen-Activated Protein (MAP) kinases (MAPK) mitogenic 
signaling pathways. Conclusion: ADSC are promising therapeutic cells for cardiac stem cell 
therapy. The inflammatory and hypoxic host post-MI microenvironment enhances the 
regenerative potential of ADSC to promote the proliferation rate of cardiomyocytes. This was 
achieved in paracrine manner, which warrants the development of ADSC conditioned 
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Postnatal cardiomyocytes (CM) have a limited proliferation rate that does not suffice to 
replenish the CM that are massively lost after Myocardial Infarction (MI). During human life 
span approximately half of the cardiomyocytes are replaced [1,2]. This indicates that there is 
a significant level of physiological proliferation of cardiomyocytes. Thus, novel therapies that 
promote the proliferation of CM after acute Myocardial Infarction (aMI) may alleviate post-
infarct complications such as heart failure. Over the past decade, mesenchymal stem cells 
(MSC) emerged as promising candidates for cardiac therapy. Stem cells and progenitor cells 
from sources that vary from bone marrow to adipose tissue and the heart itself have shown 
to be beneficial in animal models of aMI and in clinical trials [3-5]. The current dogma is 
that stem cells act primarily through paracrine intervention in the damaged cardiac 
microenvironment i.e. through secretion of trophic factors [6,7]. The secretion profile and 
the fate of administrated cells change upon a host microenvironment. Current research on 
preconditioning BM-MSC with the hypoxic and the inflammatory factors found in post-MI 
microenvironment improve the cardioprotective outcome of the therapeutic cells [8-10]. 
Thus priming Adipose tissue-derived stem cells (ADSC) for the treatment of MI with hypoxic 
and inflammatory conditions might result in the improvement of cardiac function. ADSC 
belong to the family of MSC and are derived from the adipose vascular stromal fraction as 
fibroblastic, spindle-shaped, plastic adherent cells and co-express several mesenchymal 
markers such as CD105, CD90, CD44, CD29 or CD73 [11,12]. In vitro, ADSC secrete a 
plethora of factors that are cytoprotective, promote angiogenesis and induce proliferation of 
various cell types [13-15]. Indeed, in animal models of myocardial infarction, the 
intramyocardial administration of ADSC improved cardiac remodeling and function [16, 17]. 
Yet, the influence of administered stem cells on the proliferation rate of cardiomyocytes is 
poorly studied. In damaged tissues, interleukin-6 (IL-6) is both cytoprotective and anti-
apoptotic [18, 19]. However, during the late post-MI healing phase IL-6 is upregulated in the 
myocardium. This chronic exposure to IL-6 activates as a compensatory hypertrophic 
reaction of the surrounding cardiac tissue and may contribute to cardiac fibrosis. IL-6 acts as 
a mitogen on several cell types, e.g. on hepatocytes during liver regeneration. Furthermore, 
IL-6 facilitates healing of damaged skeletal muscle through mitotic stimulation of muscle 
progenitor cells [20, 21]. IL-6 binds to the IL-6/gp130 receptor complex and activates the 
associated Janus Kinase (JAK), which phosphorylates, i.e. activates STAT3 (signal 
transduction and activator of transcription) to p-STAT3. The p-STAT3 translocates to the 
nucleus and initiates transcription of its responsive genes. STAT3 activation can also occur 
through cross-talk between other mitogenic signaling pathways, such as the mitogen 
activated protein kinase (MAPK) pathway [22]. One of the trophic factors readily secreted by 
ADSC is IL-6. Therefore, we hypothesized that IL-6 secreted by ADSC could stimulate the 
rate of cardiomyocyte proliferation through JAK/STAT and MAPK-dependent pathways. 
Materials and methods 
ADSC isolation and culture 
Human subcutaneous adipose tissue samples were obtained after liposuction surgery, which 
was donated upon informed consent of the healthy patients with BMI below 30 (Bergman 
Clinics, The Netherlands). Adipose tissue was stored at 4°C and processed within 24h post 
surgery. Following extensive washing with PBS, the tissue was enzymatically digested with 
0.1% Collagenase A, (Roche Diagnostic, Mannheim, Germany) 1:1 in PBS, containing 1% 
bovine serum albumine (BSA; Sigma-Aldrich, Boston, MA) at 37°C for 1h. Digested tissue 





resuspended in PBS, 1% BSA and subjected to Lymphoprep (Axis-Shield PoC, Oslo, Norway) 
density gradient centrifugation. The cells from the interface were collected and washed with 
PBS, 1% BSA and resuspended in DMEM (Lonza Biowhittaker, Verviers, Belgium), 10% FBS 
(Thermo Scientific, Hemel Hempstead, UK), 100 U/mL penicillin, 100 mg/mL streptomycin 
(Gibco, Invitrogen, Carlsbad, CA) and 2 mM L-glutamine (Lonza Biowhittaker, Verviers, 
Belgium). Cells were seeded in culture flasks at 4x104/cm2, expanded till Passage 3 and used 
for experiments. The use of liposuction material as source of ADSC was approved by of the 
local Ethics Committee of University Medical Centre Groningen, given the fact that it was 
considered the use of anonymised waste material. Yet, for every one of these anonymous 
donations the clients gave their consent after information. 
Cardiomyocytes isolation and culture 
Rat neonatal cardiac tissues were collected and kept in a head-over-head rotator at 4°C in 
trypsin (Gibco, Invitrogen, Carlsbad, CA) overnight. Afterwards, the tissues were 
enzymatically digested with 550 U of Collagenase A, (Roche Diagnostic, Mannheim, 
Germany) and filtered through 0.22 μm filter into the cold FCS solution (Gibco, Invitrogen, 
Carlsbad, CA). The cell suspension was resuspended in DMEM (Lonza Biowhittaker, 
Verviers, Belgium), 10% FCS (Gibco, Invitrogen, Carlsbad, CA), 100 U/mL penicillin, 100 
mg/mL streptomycin (Gibco, Invitrogen, Carlsbad, CA) and 2 mM L-glutamine (Lonza 
Biowhittaker, Verviers, Belgium). Fibroblasts were depleted through plastic adhesion, non-
adhered cells i.e. cardiomyocytes were re-seeded at 20,000 cells/cm2 in fibronectin-coated 
flasks (25 μg/ml, Harbor Bio-products, Noordwood, MA). Animal experiments, i.e. the use of 
neonatal rat heart for the isolation of cardiomyocytes was approved by the local committee 
for animal experiments of the Amsterdam University Medical Centre. Animal 
experimentation was approved by the local committee for care and use of laboratory animals 
and performed according to strict governmental and international guidelines. The 
investigation conformed to Guide for the Care and Use of Laboratory Animals published by 
the US National Institutes of Health (NIH Publication No. 85-23, revised 1996). 
HL-1 murine cardiomyocytes were a kind gift of Dr. William C. Claycomb (Department of 
Biochemistry and Molecular Biology, Louisiana State University Health Science Center, New 
Orleans, LA, USA). Cells were maintained in fibronectin-coated flasks in Claycomb 
expansion medium (Sigma-Aldrich, Boston, MA,) supplemented with 10% FBS (Sigma-
Aldrich, Boston, MA), 0.1 mM norepinephrine (Sigma-Aldrich, Boston, MA), 100 U/mL 
penicillin, 100 mg/mL streptomycin (Gibco, Invitrogen, Grand Island, NY) and 2mM L-
glutamine (Lonza Biowhittaker, Verviers, Belgium) and kept semi-confluent at all times. 
Experimental culture conditions 
Prior to co-cultures of ADSC and rat neonatal cardiomyocytes (rnCM) the cells were labeled 
with the CFDA SE (green) and CM-DiI (red) respectively according to the manufacturer’s 
instructions (both Molecular probes, Invitrogen, Grand Island, NY). Co-cultures of ADSC 
and HL-1 cardiomyocytes were done after lentivirus tagging with resp. lentiviruses encoding 
eGFP and dTomato. Briefly, on the day of transduction, cells were plated at 1×106 cells/well 
in serum-free growth medium containing 5 μg/ml polybrene (Sigma-Aldrich, Boston, MA). 
Following overnight incubation, medium was replaced with normal growth medium 
containing 10% FBS. The medium of HL-1 cells was changed once per 24h while ADSC 
medium was replenished three times a week. At five days post-transduction, cells were FACS 
sorted based on expression of eGFP or dTOMATO to obtain pure cell population. To 
determine the influence of the ADSC density on cardiomyocyte proliferation, ADSC were 
treated with 10 μg/ml mitomycin-C (Sigma-Aldrich, Boston, MA) for 3h, followed by 
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extensive washing with PBS prior the co-culture with rnCM and HL-1 cells. The ADSC cell 
ratios plated in co-culture conditions varied from 1:1 to 1:3 for rnCM, while keeping the 
rnCM at 20,000 cells/cm2. The ADSC ratios in co-cultures with HL-1 cells varied from 1:1 to 
1:4, while keeping the HL-1 cells at 6,000 cells/cm2. Simultaneously, cells were labeled with 1 
μM BrdUrd-bromodeoxyuridine (Sigma-Aldrich, Boston, MA) for 6h at the end of the 
experiment. In order to study the effect of the post-MI microenvironment on 
cardiomyocytes, rnCM and HL-1 cells and ADSC were cultured at ambient oxygen tension 
21% O2 (normoxia) or at 2% O2, (hypoxia). At these oxygen tensions inflammation was 
mimicked by continuous treatment with TNF-α or IL-1β (both 10 ng/ml Peprotech, Rocky 
Hill, NJ) or none as a control for 24 and 48h respectively. ADSC conditioned medium was 
collected after pre-treatment according to the experimental procedures for 24h. 
Subsequently, followed by medium replacement without the stimuli and conditioning in 0% 
FBS Claycomb Medium for 24h. 
Gene transcript analysis 
ADSC were seeded in 12 well plates at 10,000 cells/cm2 in DMEM and treated according to 
the experimental procedures. HL-1 cardiomyocytes were seeded in 12 well plates at 10,000 
cells/cm2 in 5% FBS Claycomb medium, afterwards cells were incubated with 10% FBS 
(control) and 0% FBS Claycomb medium or 0% FBS ADSC conditioned medium for 24h and 
treated according to the experimental procedures. Cells were harvested at the pre-
determined time points and RNA was extracted using the Rneasy Mini Kit (Qiagen Inc., 
Valencia, CA) for ADSC and Trizol Reagent (Life technologies, Carlsbad, CA) method for HL-
1 cells according to manufacturer’s protocol. Afterwards, 1 μg of total RNA was reverse 
transcribed using the First Strand cDNA synthesis kit (Fermentas UAB, Vilnius, Lithuania) 
according to manufacturer’s instructions. The cDNA equivalent of 5 ng RNA was used for 
amplification in 384-well microtiter plates in a TaqMAN ABI7900HT cycler (Applied 
Biosystem, Foster City, CA) in a final reaction volume of 10 μl containing 5 μl SyberGreen 
universal PCR Master Mix (BioRad, Richmond, CA) and 6 μM primer mix (forward and 
reverse). 6 μM of mouse Beta-2 microglobulin and human GAPDH primer mix were used as 
a reference gene. Cycle threshold (CT) values for individual reactions were determined using 
ABI Prism SDS 2.2 data processing software (Applied Biosystem, Foster City, CA). To 
determine the differences in expression, the CT values were normalized to reference gene 
using the ΔΔCt method, normalizing for the expression of the reference gene and related to 
the control treatment. All cDNA samples were amplified in duplicate. (Table 1) 
Table 1 Primer sequence for qRT-PCR 
Mouse Primer  Forward  Reverse  
IL-6  5’TTCCTCTGGTCTTCTGGAG-3’  5’-TGAGGAATGTCCACAAACTG-3’  
gp80  5‘-AAACAGTGTGGGAAGCAAGT-3’  5’ATGGCTGATACCACAAGGTT-3’  
gp130  5’-AGCGTTGTGGAAATAGAAGC-3’  5’-GGACTTCAGGTCATCTGGAC-3’  
Cyclin D1  5’-AGCTGGTGTTTGGAAGTAGG-3’  5’-AAAAGCCTCCTGTGTGAGAC-3’  
Cyclin D2  5’-TTTGCCATTTCTTTCCTCTC-3’  5’-AGTGCTTCCCTTACCTCCTT-3’  
c-myc  5’-GAGGAAACGACGAGAACAGT-3’  5’-AGTGCTTCCCTTACCTCCTT-3’  
Bclx  5’-CCCCTGCAATTAGCTTTCTA-3’  5’-AGGCCAAGAGAACTGAGATG-3’  
B2M  5’-AGAATGGGAAGCCGAACTA-3’  5’-CCGTTCTTCAGCATTTGGAT-3’  
Human Primer  Forward  Reverse  
IL-6  5’-ACTTGCCTGGTGAAAATCAT-3’  5’-CAGGAACTGGATCAGGACTT-3’  







ADSC conditioned medium was collected and filtered through 0.2 μm filter to remove any 
residual debris. To quantify the IL-6 production by ADSC, collected media were assessed by 
enzyme-linked immunosorbent assay (ELISA) (R&D Systems, Minneapolis, MN) according 
to manufacturer’s protocol. Absorbance values for individual reactions were determined 
using VersaMax™ Microplate Reader with SoftmaxPro 3.0 data processing software. To 
assure statistically relevant data, samples were run in triplicate from three independent 
donors. 
Immunoblot analysis 
Confluent rnCM or HL-1 cardiomyocyte cultures were serum-starved overnight. 
Subsequently, 50 μM Stattic (STAT3 inhibitor) (Calbiochem, Darmstadt, Germany) or 10 μM 
UO126 (MEK-1 inhibitor) (Promega, Madison, WI) and solvent controls were added to HL-1 
cells for 2h. Next, rnCM or HL-1 cultures were treated with ADSC conditioned medium for 
30min. Protein lysates from serum depleted, confluent cultures of HL- 1 cells were prepared 
in RIPA buffer (Thermo Scientific, Rockford, IL) supplemented with 1% protease inhibitor 
cocktail and 1% phosphatase inhibitors cocktail 2, 3 (Sigma-Aldrich, Boston, MA). Cell 
lysates (20 μg) were run on 10% polyacrylamide electrophoresis gel and blotted onto 
nitrocellulose membrane according to standard protocol. Blots were blocked in Tris-buffered 
saline (TBS) containing 5% BSA (Sigma-Aldrich, Boston, MA) for 1 h. Subsequently, blots 
were incubated in TBS-1% Tween containing 5% BSA with primary antibodies to human p-
STAT3 (Y705), STAT3 (Cell Signaling Technology, Beverly, MA), p-Erk1/2 (Thr 202/Tyr 
204), Erk1/2 (42/44) (Cell Signaling Technology, Beverly, MA), diluted 1:1000, overnight. 
Afterwards, blots were washed and incubated with alkaline phosphatase-conjugated 
antibodies to mouse or rabbit IgG, at the dilution 1:2000 for 1h. NBT/BCIP (Bio-Rad, VA) 
was used as a substrate for detection. Densitometric analysis was performed using Totallab 
120 (Nonlinear Dynamic, Newcastle upon Tyne, England). 
Immunofluorescence microscopy and image analysis 
rnCM and HL-1 cardiomyocytes were seeded semi-confluent onto polystyrene 8-chamber 
slides (Thermo Scientific, Hemel Hempstead, UK). Subsequently, cells were serum-starved 
in serum-free Claycomb Medium overnight. Afterwards, samples were stimulated with 10 
ng/ml IL-6 (Peprotech, Rocky Hill, NJ), conditioned media of ADSC and conditioned media 
of ADSC supplemented with IL-6 neutralizing antibody (1.2 μg/ml) or Mock IgG (5.33 
μg/ml) as a control (all R&D Systems, Minneapolis, MN) for 24h. As a growth control, 10% 
FBS Claycomb Medium was used. Simultaneously, cells were labeled with 1 μM BrdUrd 
(Sigma-Aldrich, Boston, MA) for last 6h. Next, cells were fixed using 2% paraformaldehyde 
at room temperature for 20 min. After extensive washing, cells were permeabilized with 
0.5% Triton X-100 in PBS (Sigma-Aldrich, MA). Samples were treated with 0.7 M HCl and 
0.05% pepsin at 37°C and post-fixed with paraformaldehyde (4% in PBS). Subsequently, 
samples were incubated with primary antibody sheep polyclonal biotinylated α-BrdUrd 
(Abcam, Cambridge, UK) diluted 1:100 in PBS with 10% goat serum (First Link Ltd, UK) 
overnight. Samples were washed extensively and incubated with secondary antibody 
Streptavidin-FITC for HL-1 cells and Streptavidin-Cy 3 for rnCM (Dako, Carpinteria, CA) 
diluted 1:400 in 3 μM DAPI in PBS with 10% mouse serum (Sanquin, Amsterdam, The 
Netherlands) for 30 minutes. 
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To determinate the working mechanism of cardiomyocyte proliferation, serum-free cultured 
HL-1 cardiomyocytes were cultured in the presence of 50 μM JAK1 inhibitor (AG490) or 50 
μM STAT3 inhibitor (Stattic) (Calbiochem, Darmstadt, Germany), 10 μM RAS inhibitor 
(FTS) (Cayman Chemical Co., Ann Arbor, MI) or 10 μM MEK inhibitor (U0126) (Promega, 
Madison, WI) and according controls with DMSO for 2h. Afterwards, cells were extensively 
washed with PBS and cultured in 5% Claycomb medium or ADSC conditioned medium in the 
presence of 1μM BrdUrd for 6 h. Next, samples were fixed using 2% paraformaldehyde and 
proceed with BrdUrd staining as mentioned above. Stained samples were extensively washed 
and proceed with Tissue FAXS analysis to quantify percentage of BrdUrd positive HL-1 
cardiomyocytes. Examination was performed by immunofluorescent microscopy using a 
Leica DMRXA microscope and Leica software (Leica Microsystems), and further 
quantification was performed by TissueFAXS using a Zeiss AxioObserver.Z1 microscope and 
TissueQuest cell analysis software (TissueGnostics). 
Statistics 
All the data are presented as a means +/− SEM and were analysed by GraphPad Prism 
(version 5, GraphPad Software Inc.). Statistical significance was determined using one-way 
ANOVA with Bonferroni post hoc analysis. Values of p < 0.05 were considered statistically 
significant. 
Results 
ADSC promote the rate of cardiomyocyte proliferation in direct co-culture 
We determined whether enhance the rate of cardiomyocyte proliferation in direct co-culture. 
In a 1:1 ratio, mitomycin-C-treated ADSC enhanced proliferation rate of rnCM 1.4-fold 
compared rnCM cultures alone (p < 0.05, Figure 1 A, F). Higher ratios (1:3) of ADSC had no 
significant benefit (p < 0.05, Figure 1A, F). At the 1:1 ratio, the rnCM density increased 2.5-






Figure 1 ADSC promote cardiomyocyte proliferation rate in direct co-culture. A) 
Rat neonatal cardiomyocytes and C) HL-1 cardiomyocytes were co-cultured with mitomycin-
C treated ADSC in a 1:1 and 1:3 ratio or none, for 24h. ADSC enhanced rnCM in 1:1 ratio and 
HL-1 cells proliferation in both ratios (1 F, H). Representative micrographs of BrdUrd 
fluorescent staining (A, C) and phase contrast (D) are shown. Proliferation was assessed by 
immunofluorescent detection of 6h incorporated BrdUrd and quantification with Tissue 
Gnostics Tissue FAXS equipment. B) CM-DiI (red) labeled rnCM were co-cultured in 
absence, 1:1 and 1:3 ratio of CFDA SE (green) labeled ADSC. Increase densities of rnCM were 
detected in 1:1 ratio co-culture with ADSC (p < 0.05 1 G) dTomato lentivirally-tagged HL-1 
cardiomyocytes were co-cultured in absence, 1:1, 1:2, 1:3 or 1:4 excess of eGFP lentivirally-
tagged ADSC. Increased densities of dTomato HL-1 cardiomyocytes were detected after co-
culture with eGFP positive ADSC in all ratios (p < 0.05, 1 I). E) Representative 
immunofluorescent micrographs of dTomato HL-1 cells in co-culture with eGFP ADSC are 
shown. Cardiomyocyte density was assessed by immunofluorescence detection of dTomato 
positive HL-1 cells and quantification with Tissue Gnostics Tissue FAXS equipment. Graphs 
represent triplicates (with SEM) data from n = 3 independent experiments from 3 donors. 
 
As preparations of neonatal cardiomyocytes comprise are heterogeneous, we also assessed 
our findings with rnCM in the murine cardiomyocyte cell line HL-1. The proliferation rate of 
HL-1 cardiomyocytes was dramatically reduced by serum starvation and served to assess 
changes in the rate of proliferation by ADSC. HL-1 cardiomyocytes were co-cultured with 
ADSC in ratios 1:1 to 1:4. ADSC were pre-treated with mitomycin-C to induce cell cycle 
arrest. This allowed for the quantification of BrdUrd incorporation in actively proliferating 
HL-1 cardiomyocytes. ADSC significantly enhanced the rate of proliferation of HL-1 
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cardiomyocytes by 45% and 46% in 1:1 and 1:3 ratios compared to HL-1 cardiomyocyte alone 
(p< 0.05, Figure 1C, H). To investigate if various ratios of ADSC influence cardiomyocyte 
density, lentivirally eGFP-tagged ADSC (green) were co-cultured with lentivirally dTomato-
tagged HL-1 cardiomyocytes (red). The HL-1 cell density doubled in a 1:1 and 1:2 ratio and 
further increased in a 1:3 and 1:4 ratio compared to HL-1 cardiomyocytes alone (p< 0.05, 
Figure 1B, D). ADSC enhanced HL-1 cardiomyocyte proliferation rate in all ratios, no 
significant differences were found between various ratios of ADSC to HL-1 cardiomyocytes 
(p< 0.05, Figure 1E, I). 
Conditioned medium of ADSC promotes the rate of proliferation of HL-1 
cardiomyocytes 
Possibly, secreted factors of ADSC could cause the enhanced proliferation rate of 
cardiomyocytes. The putative beneficial influence of conditioned media from ADSC was 
assessed on rnCM and HL-1 cardiomyocytes subjected to hypoxia (2% oxygen) and 
inflammation (TNF-α or IL-1β) (Figure 2A, B). In serum-containing media, approximately 
10% and 12% of the rnCM proliferated respectively under normoxia and hypoxia. Serum 
starvation reduced the rate of proliferating rnCM to approximately 8% irrespectively of 
additional inflammatory factors (TNF-α or IL-1β) (p< 0.05, Figure 2 A). Normoxic 
conditioned medium of ADSC did not change the rate of rnCM proliferation in high serum. 
Yet, after serum starvation the proliferation rate of rnCM increased 1.4-fold after treatment 
with normoxic conditioned medium of ADSC (p< 0.05, Figure 2A). The pre-conditioning of 
ADSC with TNF-α or IL-1β for the formation of the primed conditioned medium of ADSC 
resulted in respectively 1.2-fold increase in the proliferation rate of rnCM compared to TNF-
α or IL-1β primed rnCM under hypoxia (p< 0.05, Figure 2A). To confirm the positive effect 
of the conditioned medium of ADSC on the enhancement of the cardiomyocyte proliferation 
rate, we performed the readout on the pure cardiomyocytes HL-1 cells. 
 
Figure 2 Conditioned medium of ADSC promotes proliferation rate of 





cardiomyocytes (A) and HL-1 murine cardiomyocytes (B) both under normoxic (21% 
oxygen) and hypoxic (2% oxygen) conditions compared to the serum control (10% FBS). This 
proliferation rate was not significantly influenced by treatment with TNF-α or IL-1β. 
Incubation of rnCM and HL-1 cardiomyocytes for 24h with serum-free conditioned media of 
human ADSC (n = 3 donors) pre-stimulated with TNF-α, IL-1β or none, restored the 
proliferation of HL-1 cardiomyocytes (p< 0.05). The stimulatory capacity of hypoxically 
preconditioned ADSC medium on the proliferation rate of rnCM and HL-1 cardiomyocytes 
under hypoxia was significantly larger than under normoxic conditions (p< 0.05). 
Proliferation was assessed by immunofluorescence detection of 6h incorporated BrdUrd and 
quantification with Tissue Gnostics Tissue FAXS equipment. C) Representative micrographs 
of immunofluorescence staining for BrdUrd of HL-1 cardiomyocytes in normal serum (10% 
FBS), serum-free or with serum-free ADSC conditioned medium after stimulation with IL-
1β. Proliferation, i.e. BrdUrd incorporation – green, nuclei (DAPI) – blue. Graphs represent 
triplicates (with SEM) data from n = 3 independent experiments from 3 donors. 
 
In normal culture medium, approximately 85% of the HL-1 cardiomyocytes proliferated 
under both normoxic and hypoxic conditions. Serum starvation reduced the fraction of 
proliferating HL-1 cardiomyocytes almost two fold under normoxia or hypoxia. Treatment of 
serum-free HL-1 cardiomyocytes with TNF-α or IL-1β did not alter proliferation, irrespective 
of oxygen concentration. Serum-free-conditioned medium from normoxically cultured ADSC 
increased the proliferation rate of serum-free HL-1 cardiomyocytes by 18% compared to 
serum-free HL-1 cardiomyocytes control (p< 0.05). The proliferation rate of HL-1 
cardiomyocytes under normoxic conditions was even further stimulated (35%, p< 0.05) 
upon incubation with conditioned medium from ADSC prestimulated with TNF-α or IL-1β 
compared to TNF-α or IL-1β stimulated serum-free HL-1 cardiomyocytes controls. The pro-
inflammatory stimulation of ADSC with TNF-α or IL-1β to obtain primed ADSC conditioned 
medium ameliorated the cardiomyocyte proliferation rate as well. Furthermore, IL-1β 
primed conditioned medium of ADSC significantly increased (12%, p< 0.05) the HL-1 
proliferation rate compared to nonstimulated conditioned medium of ADSC. Moreover, 
conditioned medium from hypoxia cultured ADSC ameliorated the proliferation rate of 
cardiomyocytes even further in comparison to conditioned medium of normoxia cultured 
ADSC (31% vs. 18% increase, p< 0.05). In addition, conditioned medium of hypoxia cultured 
ADSC in the presence of pre-stimulation with TNF-α or IL-1β showed only marginally 
improvement resulting in 40% increase in HL-1 cardiomyocyte proliferation rate (p< 0.05). 
Hypoxia and pro-inflammatory mediators upregulate IL-6 secretion by ADSC 
Treatment of ADSC with IL-1β for 24 or 48h induced respectively 53-fold and 31-fold 
upregulation of IL-6 gene expression level (p< 0.05, Figure 3A). 
3Adipose stromal cells primed with hypoxia and inflammation enhance cardiomyocyte proliferation 





Figure 3 Hypoxia and pro-inflammatory mediators upregulate IL-6 secretion by 
ADSC. A, B) Quantitative RT-PCR analysis of gene transcript levels of IL-6 normalized to 
GAPDH expression. Gene transcript levels of IL-6 were strongly induced by stimulation with 
pro-inflammatory mediators (IL-1β) both under normoxia and hypoxia conditions within 
24h and 48h (p< 0.05). The increase of IL-6 gene transcript level was far stronger after IL-1β 
stimulation (p< 0.05). C, D) Secreted IL-6, quantified by ELISA, was significantly increased 
after pre-stimulation of ADSC with the pro-inflammatory cytokine IL-1β (p< 0.05). Graphs 
represent triplicates (with SEM) data from n = 3 independent experiments from 3 donors. E, 
F) IL-6 is a positive regulator of cardiomyocyte proliferation. In serum-free medium, 
treatment with IL-6 restored the proliferation of rnCM and HL-1 murine cardiomyocytes 
compared to serum-free and serum (10% FBS) controls (p< 0.05). Similarly, pretreatment of 
human ADSC with IL-1β, yielded conditioned media that increase proliferation of rnCM and 
fully restored the proliferation of HL-1 cardiomyocytes in the absence of serum (p< 0.05). 
Addition of IL-6 neutralizing antibody to the IL-6 or conditioned medium of ADSC treated 
serum-free rnCM and HL-1 cardiomyocytes resulted in a significant decreased proliferation 
of rnCM and HL-1 cardiomyocyte (p< 0.05). Graphs represent triplicates (with SEM) data 
from n = 3 independent experiments, normalized to ADSC cultures before the treatment 
(0h). 
 
Under hypoxia, treatment of ADSC with IL-1β for 24 and 48h resulted in higher increase of 
IL-6 gene expression, respectively by 95-fold and 45-fold (p< 0.05, Figure 3B). 
The level of secreted IL-6 showed a similar pattern as the gene expression after stimulation 





increase in IL-6 protein secretion within 24 h, which decreased to approximately 200-fold at 
48 h both under normoxia and hypoxia (p< 0.05, Figure 3C, D). 
IL-6 secreted by ADSC enhances the cardiomyocyte proliferation rate 
Stimulation with IL-6, increased the number of proliferating rnCM from 8% (serum free 
controls) to 9% (p< 0.05, Figure 3E). Addition of IL-6 neutralizing antibody to the IL-6 
treated rnCM reduced the number of proliferating cells to 7% compared to IL-6 treated 
controls (p < 0.05, Figure 3E). Stimulation of rnCM with the serum free ADSC conditioned 
medium resulted in increase of proliferating rnCM to 8.5% compared to serum free controls. 
Addition of IL-6 neutralizing antibody to the conditioned medium of ADSC resulted in 
significant decrease of proliferating rnCM to 7.4% (p < 0.05, Figure 3E). 
Adult HL-1 cardiomyocytes were cultured in the presence of 10% serum. Under serum-free 
conditions, IL-6 and the conditioned medium of ADSC induced a 24% and 27% upregulation 
of the proliferation rate of HL-1 cardiomyocytes respectively, compared to HL-1 serum-free 
control (p< 0.05, Figure 3F). Addition of IL-6 neutralizing antibodies to the IL-6 treated HL-
1 cardiomyocytes reduced their proliferation rate by 42% (p< 0.05, Figure 3E) compared to 
IL-6 treated controls. Treatment of serum-free conditioned medium of ADSC with IL-6 
neutralizing antibodies also reduced the rate of HL-1 cardiomyocyte proliferation rate by 
13% compared to conditioned medium of ADSC (p< 0.05, Figure 3F). 
Conditioned medium of ADSC increase cell cycle progression gene expression 
profile in HL-1 cardiomyocytes 
Cell cycle progression requires activation of cyclin complexes and G1/S phase transition and 
associates with increased expression of c-Myc, while anti-apoptotic genes such as Bclx are 
upregulated. Adult HL-1 cardiomyocytes were cultured in the presence of 10% serum. 
Serum-free HL-1 cardiomyocytes were cultured under normoxia and hypoxia in the presence 
of IL-6 or IL-1β primed conditioned medium of ADSC. Stimulation of HL-1 cardiomyocytes 
with the conditioned medium of ADSC from normoxia and IL-1β primed resulted in 
increased gene expression of cyclin D1 and cyclin D2 compared to serum-free HL-1 cells, yet 
not significant (p< 0.05, Figure 4A). Hypoxia and IL-1β primed conditioned medium from 
ADSC resulted in significant increase in the gene expression of cyclin D1 and cyclin D2 by 
respectively 1.2-fold and 1.3-fold increase compared to serum-free HL-1 cells (p< 0.05, 
Figure 4B). Stimulation of HL-1 cardiomyocytes with IL-6 both under normoxia and hypoxia 
did not significantly affected the gene expression of cyclin D1 and cyclin D2 (p< 0.05, Figure 
4A, B). The elevated gene expression of cyclin D1 and cyclin D2, followed the significant 
increase of c-myc gene expression in HL-1 cells. Stimulation of HL-1 cells with conditioned 
medium of ADSC or IL-1β primed ADSC conditioned medium under normoxia resulted in 
significant increase of c-myc gene expression, respectively by 1.7-fold and 2.2-fold induction 
compared to control HL-1 cells (p< 0.05, Figure 4A). Stimulation of HL-1 cardiomyocytes 
with hypoxia and hypoxia with IL-1β primed conditioned medium from ADSC resulted in 
significant increase in gene expression of c-myc, respectively by 1.2-fold and 1.6-fold 
induction compared to control HL-1 cells (p< 0.05). Addition of IL-6 to HL-1 cells resulted in 
significant increase of c-myc gene expression only under normoxia by 1.3-fold compared to 
control HL-1 cells (p< 0.05, Figure 4A). IL-6 stimulation of HL-1 cells under hypoxia did not 
show significant change in HL-1 gene expression of c-myc compare to serum-free HL-1 cells 
(p< 0.05, Figure 4B). Stimulation of HL-1 cardiomyocytes with ADSC conditioned medium 
or IL-6 did not change expression of the antiapoptotic gene Bclx in HL-1 cardiomyocytes 
either under normoxia or hypoxia compared to control HL-1 cells (p< 0.05, Figure 4A, B). 
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Figure 4 Conditioned medium of ADSC augments the cell cycle progression 
gene expression profile of HL-1 cardiomyocytes. Quantitative RT-PCR analysis of 
gene transcript levels of cyclin D1, cyclin D2 and c-Myc normalized to Beta-2 microglobulin 
expression. A) Gene transcript level of cyclin D1 and cyclin D2 did not change in HL-1 
cardiomyocytes upon stimulation with IL-6 or ADSC conditioned medium in normoxia (p< 
0.05). B) Gene expression of cyclin D2 showed a significant increase upon stimulation with 
IL-1β primed conditioned medium of ADSC under hypoxia (p< 0.05). A) Gene transcript 
levels of c-Myc were significantly upregulated upon stimulation with IL-6 or conditioned 
medium of ADSC and IL-1β primed ADSC conditioned medium under normoxia (p< 0.05). 
B) Under hypoxia gene transcript levels of c-myc in HL-1 cells showed significant 
upregulation upon stimulation with conditioned medium of ADSC and IL-1β primed 
conditioned medium of ADSC (p< 0.05). A, B) Gene transcript levels of apoptotic marker 
Bclx remained unchanged in HL-1 cardiomyocytes upon stimulation with IL-6 or 
conditioned medium of ADSC (p< 0.05). Graphs represent triplicates (with SEM) data from 
n = 3 independent experiments, normalized to serum-free HL-1 cardiomyocytes. 
 
Conditioned medium of ADSC increases autocrine IL-6 gene expression in HL-1 
cardiomyocytes 
HL-1 cardiomyocytes were cultured in the absence of serum as a control. Stimulation of HL- 
cardiomyocytes with IL-6 under serum-free conditions did not effect the gene expression 
profile of IL-6, IL-6 receptor α (gp80) or IL-6 receptor β (gp130) both under normoxia and 
hypoxia compared to a serum-free control (p< 0.05, Figure 5A, B). Addition of ADSC 
conditioned medium to HL-1 cells significantly increased gene expression of IL-6 by 4-fold 
under normoxia and 5.4-fold under hypoxia compared to a serum-free control (p< 0.05, 
Figure 5A, B). Correspondingly, stimulation of HL-1 cardiomyocytes with conditioned 
medium of ADSC resulted in significant increase in gene expression of IL-6 receptor α 
(gp80) and β (gp130) by respectively 1.6 and 3.3-fold under normoxia compared to a serum-
free control (p< 0.05, Figure5 A) and 1.3 and 2.2-fold under hypoxia compared to a serum-
free control (p< 0.05, Figure 5B). Addition of IL-1β primed ADSC conditioned medium to 
HL-1 cardiomyocytes resulted in higher increase of IL-6 gene expression, resulting in 7-fold 
increase under normoxia and hypoxia compared to a serum-free control (p< 0.05, Figure 5A, 





resulted in significant increase in gene expression of IL-6 receptor α (gp80) and β (gp130) by 
respectively 3.5 and 3.9-fold under normoxia compared to a serum-free control (p< 0.05, 
Figure 5A) and 2.6 and 2.2-fold under hypoxia compared to a serum-free control (p< 0.05, 
Figure 5B). 
 
Figure 5 Conditioned medium of ADSC increases autocrine IL-6 signaling gene 
expression in HL-1 cardiomyocytes. Quantitative RT-PCR analysis of gene transcript 
levels of IL-6 and IL-6 receptor complex gp130/gp80 normalized to Beta-2 microglobulin 
expression. A, B) Stimulation of HL-1 cardiomyocytes with conditioned medium of ADSC 
and IL-1β primed ADSC conditioned medium resulted in a significant upregulation in gene 
expression of IL-6 and the IL-6 receptor components gp130 and gp80 (p< 0.05). Gene 
transcript level of IL-6 or gp130/gp80 did not change in HL-1 cardiomyocytes upon 
stimulation with IL-6 alone (p< 0.05). Graphs represent triplicates (with SEM) data from n 
= 3 independent experiments, normalized to serum-free HL-1 cardiomyocytes. 
 
ADSC conditioned medium-dependent signaling pathways targeting the 
increased rate of cardiomyocyte proliferation 
The phosphorylation of STAT3 in rnCM did not depend on the presence of serum (Figure 6A, 
B). Yet, serum free conditioned medium of ADSC resulted in activated STAT3 by 4-fold both 
under normoxia and hypoxia conditions in serum starved rnCM (p< 0.05, Figure 6A, B). The 
peak of activation of p-STAT3 was reached in rnCM by stimulation with conditioned medium 
of ADSC primed with IL-1β both under normoxia and hypoxia resulting in respectively 8.5- 
and 10-fold increase compared to the serum free controls (p< 0.05, Figure 6A, B). In rnCM 
Erk1/2 was strongly phosphorylated in the presence of serum (p< 0.05, Figure 6A, C). Under 
serum free condition the phosphorylation of Erk1/2 was 2-fold decreased compared to serum 
control (p< 0.05, Figure 6A, C). The stimulation of rnCM with the serum free conditioned 
medium of ADSC and the IL-1β primed conditioned medium of ADSC resulted in the strong 
activation of Erk1/2, reaching 1.5-fold increase in compare to serum free controls (p< 0.05, 
Figure 6A, C) both under normoxia and hypoxia. The activation of Erk1/2 in rnCM by the 
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serum free conditioned medium of ADSC was comparable to the level of phosphorylation in 
the rnCM stimulated with serum (Figure 6A, C). In HL-1 cardiomyocytes, STAT3 and Erk1/2 
were both phosphorylated in the presence of serum. After 24h of serum deprivation, the 
phosphorylation i.e. activation, of these transcription factors was only slightly reduced 
(Figure 6D-L). The phosphorylation of STAT3 was decreased by 3-fold in the presence of the 
p-STAT3 inhibitor (Stattic) (p< 0.05, Figure 6D, E), while Erk1/2 phosphorylation was 
reduced by 8- and 4-fold with the MEK inhibitor (U0126) respectively in compare to the 
serum and serum-free controls (p< 0.05, Figure 6G, I). Remarkably, stimulation of HL-1 
cardiomyocytes with serum-free IL-1β-stimulated-ADSC-conditioned medium resulted in a 
2-fold increase in phosphorylation of STAT3 and Erk1/2, that reached higher level than 
serum controls (p< 0.05, Figure 6D-L). Blocking of STAT3 phosphorylation resulted in 
reduced levels of phosphorylated STAT3 and 2-fold increased phosphorylation of Erk1/2 
(Figure 6D, F). In contrast, activation of phosphorylated STAT3 did not depend on activation 
of Erk1/2 phosphorylation (Figure 6D-L). Simultaneous inhibition of JAK/STAT and MAPK 
signaling pathway resulted in reduced levels of phosphorylated STAT3 by 2.7-fold and 








Figure 6.  ADSC conditioned medium-dependent signaling pathways targeting 
increase of HL-1 cardiomyocyte proliferation. Representative examples of western 
blot analyses of phosphorylated STAT3 and phosphorylated Erk1/2 in A, B, C) rnCM 
stimulated with the conditioned medium of ADSC and IL-1β primed ADSC from normoxic 
and under hypoxic cultures. The stimulation of rnCM with the serum free conditioned 
medium of ADSC resulted in activation of STAT3 and Erk1/2. D, E, F) in HL-1 
cardiomyocytes in the presence of STAT3 phosphorylation inhibitor (Stattic) G, H, I) MEK 
inhibitor (U0126) and J, K, L) both inhibitors (Stattic + U0126). Inhibition of STAT3 
phosphorylation resulted in increased of Erk1/2 phosphorylation. Non-phosphorylated 
STAT3 and Erk1/2 levels did not change and indicate equivalent protein controls in all 
samples (n = 3). 
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ADSC-dependent signaling pathways targeting HL-1 cardiomyocyte 
proliferation rate 
In the presence of mitogenic factors such as serum and conditioned medium of ADSC, HL-1 
cardiomyocytes showed an increase in proliferation (25% and 24% respectively, p< 0.05, 
Figure 7A, B). In the presence of serum addition of inhibitors targeting upstream or 
downstream of JAK/STAT (JAK1 and STAT3) and MAPK (MEK1) signaling pathway resulted 
in a decreased proliferation rate of HL-1 cardiomyocytes ranging from 31 to 41 % (p< 0.05, 
Figure 7A). Pre-treatment of HL-1 cardiomyocytes with these inhibitors also reduced the 
mitogenic effect of conditioned medium of ADSC, observed as a significant decrease in the 
fraction of BrdUrd positive cells by 24 to 37 % (p< 0.05, Figure 7B). 
 
Figure 7.  ADSC-dependent signaling pathways targeting HL-1 cardiomyocyte 
proliferation. A) Treatment of serum-free cultured HL-1 cardiomyocytes with FBS or B) 
serum-free conditioned medium of IL-1β stimulated ADSC resulted in enhanced 
proliferation of HL-1 cardiomyocytes (p< 0.05). A, B) Addition of inhibitors of upstream 
and downstream of MAPK (RAS and MEK) or JAK/STAT (JAK1 and pSTAT3) inhibitors all 
resulted in a significant decrease of proliferation of HL-1 cardiomyocytes (p< 0.05). Graphs 







In this study we show that Adipose Derived Stromal Cells (ADSC) enhance the proliferation 
rate of both primary CM and a CM cell line, in a paracrine manner and in direct co-culture in 
vitro. One of the main stimulators secreted by ADSC was IL-6. The in vitro hypoxic and pro-
inflammatory preconditioning of ADSC i.e. mimicking the post-myocardial infarction 
microenvironment (ischemia and inflammation), strongly upregulated the IL-6 production 
by ADSC and further augmented the stimulation of the proliferation of cardiomyocytes. The 
IL-6 stimulated cardiomyocyte proliferation was accomplished through activation of both 
Janus Kinase-Signal Transducer and Activator of Transcription (JAK/STAT) and Mitogen-
Activated Protein (MAP) kinases (MAPK) mitogenic signaling pathways. 
Stimulation of rat neonatal cardiomyocytes or HL-1 cardiomyocytes with conditioned 
medium of ADSC increased their proliferation rate. To mimic the behavior of therapeutic 
cells in the post-infarct cardiac microenvironment, we stimulated ADSC with hypoxia and 
pro-inflammatory mediators, which increased their production of IL-6. Remarkably, 
Efimenko and co-workers, showed that stimulation of MSC from bone marrow or adipose 
tissue with high concentrations of TNF-α, did not alter their profile of pro-angiogenic 
mediators, which paradoxes to our finding that pro-inflammatory stimulation augmented 
regenerative potential of therapeutic cells [14]. The differences may be, that different stimuli 
(TNF-α versus IL-1β) were used and different readouts, i.e. angiogenesis versus 
cardiomyocyte proliferation. Furthermore, our data indicate that hypoxia alone, but in 
particular together with a pro-inflammatory stimulus, augment CM proliferation by ADSC 
conditioned media too. This indicates that hypoxia can further augment the regenerative 
potential of ADSC. In contrast to current data, not only hypoxia may exert a beneficial effect 
on ADSC [15,23]. We found that inflammation had far stronger effect on the ADSC secretion 
profile. Although hypoxia itself did not alter IL-6 gene expression levels by ADSC, in 
combination with inflammatory mediators enhanced regenerative potential of ADSC. 
Stimulation of rnCM and adult HL-1 cardiomyocytes with IL-6 resulted in an enhanced level 
of the cardiomyocyte proliferation rate. Targeting IL-6 with neutralizing antibodies against 
IL-6 in the presence of IL-6 or conditioned medium of ADSC resulted in decreased rate of 
cardiomyocyte proliferation. The blocking of IL-6 in ADSC conditioned medium only 
partially inhibited positive effect of ADSC conditioned medium on cardiomyocyte 
proliferation rate. This suggests that either conditioned medium of ADSC contains additional 
only mitogenic factors or that other factors promote rnCM and HL-1 cardiomyocyte 
proliferation rate synergistically with IL-6. This is corroborated by our observation that 
stimulation of HL-1 cardiomyocytes with conditioned medium of ADSC resulted in a 
significant increase of c-myc and IL-6 receptor complex gp130/gp80, while stimulation with 
IL-6 alone did not show significance gene expressions changes. IL-6 signaling involves 
activation of downstream signaling of two major signaling pathways i.e. JAK/STAT and 
MAPK-Erk1/2 that are mitogenic in various cell types. Thus, we analyzed the significance of 
both of these pathways on cardiomyocyte proliferation rate. Our study identifies a previously 
uncharacterized function of conditioned medium of ADSC signaling in regulating 
cardiomyocyte proliferation. Stimulation of rnCM and HL-1 cardiomyocytes with 
conditioned medium of hypoxically and proinflammatory primed ADSC resulted in strong 
phosphorylation of STAT3 and Erk1/2, the downstream targets of JAK/STAT and MAPK 
activation (Figure 8). 
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Figure 8 Schematic representation of proposed Adipose Stromal Cell-derived 
IL-6 signaling pathway. The ADSC-secreted cytokine IL-6 and growth factors, which 
enhance the proliferation of cardiomyocytes through canonical signaling i.e. STAT3 
activation and through non-canonical signaling i.e. Erk1/2 activation. The balance between 
STAT3 and Erk1/2 signaling is governed by STAT3, which can suppress Erk1/2 activation, 
through an unknown intermediate. In the absence of STAT3 signaling, IL-6-RAS-activated 
Erk1/2 can compensate for the potential loss of stimulatory effect on the proliferation on 
cardiomyocytes. 
 
Similarly, previous studies on skeletal muscle have shown that regular exercise causes 
damage that is followed by increased IL-6 level. The released IL-6 activates the JAK/STAT 
signaling pathway and augments repair of skeletal muscle [24]. Recent clinical therapies 






scar size due to the activation of STAT3 [25] and involvement of IL-6 in this process [26]. In 
addition, pro-inflammatory cytokines such as TNF-α related TWEAK or ligands from EGF 
family such as neuregulin and HB-EGF provided evidence for engagement MAPK in 
induction of the cardiomyocyte proliferation rate [27-29]. Conditioned medium of ADSC 
activated the downstream JAK1 and JAK2/TYK2 that lead to their target STAT3 Tyr705 
phosphorylation in rnCM and HL-1 cardiomyocytes. Blocking of JAK1 with commonly used 
JAK/STAT inhibitor did not diminished the level of phosphorylated STAT3, suggesting that 
JAK/STAT activation can also occur through JAK2/TYK2 [30]. Remarkably, direct 
inhibition of phosphorylated STAT3 with Stattic resulted in reduced STAT3 and increased 
levels of phosphorylated Erk1/2 (Figure 6). This suggests that the stimulated proliferation 
rate of HL-1 cardiomyocytes is a balance between STAT3 signaling and MAPkinase signaling 
[31]. Although prolonged inhibition of one of the upstream or downstream of JAK/STAT or 
MAPK pathways lead to decreased proliferation rate of HL-1 cardiomyocytes either in the 
presence of mitogenic factors or conditioned medium of ADSC. The therapeutic benefit of 
stem cells for cardiac therapy is well-accepted, however the stem cell response to the host’s 
post-MI microenvironment is uncertain [32]. The main mode of action of cardiac stem cell 
therapy is through paracrine mechanisms. Indeed, the intravenous administration of 
conditioned culture media from bone marrow derived MSC in pigs improved cardiac 
remodeling and perfusion [33,34]. To unravel the mechanism of paracrine therapeutic 
benefit of cardiac stem cell therapy, we subjected cardiomyocytes to the conditioned medium 
of ADSC. 
Conclusions 
The post-infarct cardiac microenvironment consists of an imbalanced level of inflammatory 
and anti-inflammatory mediators that correlate with the outcome of diseased myocardium. 
Cytokines might exert different function in time and dose dependent manner. Prolonged 
chronic high levels of IL-6 after MI are considered as a cause of hypertrophy and heart 
failure. Recent studies demonstrate that pro-inflammatory cytokines can activate 
cardioprotective signaling pathways in the post-infarct heart. IL-6 though might exert 
dynamic actions and act as a potent “myokine”, where in a rapid response to acute 
myocardial infarction it activates cardioprotective pathways [35], resulting in increase in 
cardiomyocyte proliferation. Application of the conditioned medium derived from 
therapeutic cells rather than cells themselves would circumvent the problem of retention in 
cardiac stem cell therapy. Additionally, the current approach of use of primed conditioned 
medium of therapeutic stem cells offer “off -the-shelf” product, which may be used for 
multiple injections. 
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Introduction: The regeneration of adult cardiac tissue is limited after acute myocardial 
infarction (aMI). The lack of compensatory proliferation to replace lost cardiomyocytes 
warrants the need for regenerative therapies, such as stem cell therapy. The adipose tissue is 
a reservoir of stem cells, which show benefit in clinical experimental cardiac therapy. The 
post-aMI microenvironment is characterized by tissue hypoxia, cells death and influx of 
inflammatory cells. Factors secreted by therapeutic cells may facilitate tissue repair and 
regeneration. However, little is known about the microenvironmental influences of the 
damaged heart on the regenerative potential of these (stem) cells. Methods: We investigated 
the influence of hypoxia and inflammatory cytokines (i.e. TNF-α and IL-1β) on the 
regenerative potential of Adipose Derived Stromal Cells (ADSC). Results: Direct co-culture of 
ADSC with adult HL-1 cardiomyocytes resulted in an enhanced cardiomyocyte proliferation 
rate under hypoxic and inflammatory conditions. Moreover, the conditioned medium of 
ADSC also stimulated the HL-1 cardiomyocyte proliferation rate, indicating that trophic 
factors are responsible for the increased proliferation rate. Epithelial growth factor (EGF) 
ligands are pivotal in maintenance of the adult cardiac tissue and cardiomyocyte 
proliferation. In vitro, inflammatory cytokines increased the gene expression of heparin-
binding EGF (HB-EGF) in ADSC, regardless of hypoxia. The stimulated CM proliferation 
rate by ADSC depended on activation of Erk1/2 by HB-EGF. Conclusions: In vitro mimicking 
the post-MI microenvironment by priming of ADSC with hypoxia and inflammation resulted 
in increased cardiomyocyte proliferation rate. This suggests that ADSC are potent 
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Recent data indicate that the adult heart represent a highly plastic organ with the dynamic 
renewal rate of the cardiac cellular compartment such as cardiomyocytes (CM), fibroblasts 
and endothelial cells. The adult CM or existing cardiac progenitor cells do proliferate in 
adults and lead to total replacement of CM every eight years during healthy life span [1, 2]. 
Yet, the cardiac replicative potential is not sufficient to fully regenerate the severely damaged 
heart such as after aMI.  The early post-aMI microenvironment is characterized by 
insufficient perfusion (hypoxia), which coincides with a massive CM death, activation of the 
surviving CM and influx of inflammatory cells [3]. Simultaneously, in the absence of 
sufficient CM proliferation, compensatory cardiac hypertrophy and formation of scar tissue 
occurs. To prevent the formation of scar tissue, it is essential to differentiate CM from 
precursor cells or to induce or enhance CM proliferation in the early phase of aMI. Although 
the latter process has long thought to be impossible because of the static nature of adult 
cardiomyocytes, recent literature indicates that adult cardiomyocytes can proliferate and 
that even the induction of adult CM proliferation is feasible [4]. Pivotal cardiogenic factors 
are mitogens of the EGF family such as Neuregulin, HB-EGF, and TGF-α. Treatments using 
EGF ligands after murine aMI increases CM numbers reduces scar formation and improves 
cardiac function [5, 6].  
The adipose tissue is a reservoir of multipotent mesenchymal stromal cells, which are 
advantageous for immediate cardiac interventions due to their plethora of trophic 
therapeutic factors and their ease to be isolated in large numbers [7, 8].  The administration 
of ADSC in animal models of aMI improves cardiac remodeling and cardiac function [9, 10]. 
Yet, the mechanism that underlies the regenerative potential of ADSC is only partially 
understood. In vitro, ADSC secrete factors that are mitogenic to CM [11-13].  
In the present study, we investigated the influence of ADSC and their secreted factors on the 
proliferation of CM under culture conditions that mimic the post-aMI microenvironment. 
We demonstrate that hypoxic and inflammatory stimuli caused increased secretion of HB-
EGF by ADSC. Co-culture of ADSC with HL-1 CM resulted in an increased proliferation rate 
of cardiomyocytes. Moreover, treatment of HL-1 CM with the conditioned medium of ADSC 
resulted in increased CM proliferation, partially due to the presence of HB-EGF. Stimulation 
of HL-1 CM with the conditioned medium of ADSC resulted in activation of EGF-MAPK-
Erk1/2 signaling in HL-1 CM resulting in increased proliferation rates.  
Materials and Methods 
CELL CULTURE 
ADSC were isolated from human adipose tissue as described previously [14]. Cells were 
seeded in culture flask at 4·104/cm2 in DMEM (Lonza Biowhittaker, Verviers, Belgium) 
containing 10% FBS (Thermo Scientific, Hemel Hempstead, UK), 100 U/ml penicillin, 100 
mg/ml streptomycin (Gibco, Invitrogen, Carlsbad, CA). The informed consent of the 
Bergman Clinics clients for Plastic Surgery’ (http://www.bergmankliniek.nl) have been 
signed. The Medical Ethical Committee (Medisch Ethische Toetsingsingscommissie) of the 
University Medical Center Groningen (UMCG) approved the procedure, because the adipose 





Adult HL-1 cardiomyocytes were a kind gift of Dr. William C. Claycomb (Dept. 
Biochemistry and Molecular Biology, Louisiana State University Health Science Center, New 
Orleans, LA, USA). Cells were maintained according to the instructions. To mimic the post-
MI microenvironment, HL-1 CM were cultured at ambient oxygen tension (21% O2, 
normoxia or at 2% O2, hypoxia). The inflammation was mimicked by treatment with TNF-
alpha or IL-1 beta (both 10 ng/ml Peprotech, Rocky Hill, NJ) for 24h. 
CO-CULTURE  
ADSC were treated with 10 µg/ml of Mitomycin C (Sigma-Aldrich, Boston, MA) for 
3h, to block DNA synthesis. HL-1 CM were seeded at 6,000 cells/cm2 in a 1:1 ratio with 
mitomycin C-treated ADSC for all experimental conditions (normoxia, hypoxia, 
inflammation) in 96-well plates for 24h. Co-cultured cells were labeled with 10 µM BrdU for 
an additional 24h. Proliferation was determined by BrdU Elisa (Roche Diagnostic, 
Mannheim, Germany) according to the manufacturer’s instructions.  
PARACRINE EFFECT OF ADSC 
ADSC were seeded at 20,000 cells/cm2 in DMEM 10% FBS for 24h. Next, ADSC were 
pre-conditioned with TNF-alpha or IL-1beta (both 10 ng/ml, Peprotech Rocky Hill, NJ) 
under normoxia or hypoxia for 24h. Afterwards, the medium was replaced for 0% FBS 
Claycomb medium for 24h. Serum-free ADSC conditioned medium was collected. To asses 
the influence of ADSC conditioned medium on cardiomyocytes, HL-1 cells were cultured at 
8,000 cells/cm2 in Claycomb serum-free medium or serum-free ADSC conditioned medium 
and labeled with 10 µM with BrdU for 24h. Proliferation readout was determined by BrdU-
Elisa assay (Roche Diagnostic, Mannheim, Germany) according to the manufacturer’s 
instructions.  
GENE TRANSCRIPT ANALYSIS BY QUANTITATIVE RT-PCR  
ADSC were seeded at 10,000 cells/cm2 in DMEM supplemented with 10% FBS and treated 
according to the experimental procedures (normoxia, hypoxia, TNF-alpha, IL-1beta) 
described above. HL-1 CM were seeded at 10,000 cells/cm2 in 5% FBS Claycomb medium, 
afterwards cells were incubated with control 10 and 0% FBS Claycomb medium or 0% FBS 
ADSC conditioned medium for 24h and treated according to the experimental procedures. 
Cells were harvested at the pre-determined time points, RNA was extracted using Trizol 
Reagent (Life technologies, Carlsbad, CA) according to manufacturer’s protocol. Total RNA, 
1 µg was reverse transcribed using the First Strand cDNA synthesis kit (Fermentas UAB, 
Vilnius, Lithuania) according to manufacturer’s instructions. The cDNA equivalent of 5 ng 
RNA was used for amplification in 384-well microtiter plates in a TaqMAN ABI7900HT 
cycler (Applied Biosystem, Foster City, CA) in a reaction volume of 10 µl containing 5 µl 
SyberGreen universal PCR Master Mix (BioRad, Richmond, CA) and 6 µM primer mix 
(forward and reverse, Table 1). Beta-2 microglobulin and GAPDH were used as reference 
genes.  Cycle threshold (CT) values for individual reactions were determined using ABI Prism 
SDS 2.2 data processing software (Applied Biosystem, Foster City, CA). The CT values were 
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Table 1. Primer sequence for qRT-PCR. 
Mouse Primer Forward Reverse 
HB-EGF 5'-GTTCCCAGACAGGATCTCAC-3' 5'-CAGATCTGTCCCTTCCAAGT-3' 
ADAM 17 5'-GAAGTGCCAGGAGGCTATTA-3' 5'-CCAAGCACACAGTGTCATCT-3' 
EGFR 5'-CCAGGTCTTCGATCTTCCTA-3' 5'-TGTGAGGATGATTGAGTTGG-3' 
B2M 5’-AGAATGGGAAGCCGAACATA-3’ 5’-CCGTTCTTCAGCATTTGGAT-3’ 
Human Primer Forward Reverse 
HB-EGF 5'-GGGACTGCTACCTCTGAGAA-3' 5'-GCACTTGAAGGCTCTGGTAT-3' 
GAPDH 5’-AGCCACATCGCTCAGACAC-3’ 5’-GCCCAATACGACCAAATCC-3’ 
 
HB-EGF ELISA 
The conditioned media of ADSC alone under all experimental conditions were collected and 
assessed by enzyme-linked immunosorbent assay (ELISA) (R&D Systems, Minneapolis, MN) 
according to manufacturer’s protocol. Absorbance values for individual reactions were 
determined using VersaMax™ Microplate Reader with SoftmaxPro 3.0 data processing 
software. To assure statistically relevant data, samples were run in triplicate from three 
independent donors.   
IMMUNOBLOT ANALYSIS 
HL-1 CM were cultured in serum-free Claycomb Medium overnight. Afterwards, samples 
were stimulated with 10% FBS and 0% FBS Claycomb medium as controls. Next, 0% FBS 
Claycomb medium HL-1 cardiomyocytes were cultured in the presence of 50 ng/ml HB-EGF 
(R&D Systems, Minneapolis, MN), serum-free conditioned media of ADSC, IL-1β primed 
conditioned medium of ADSC and all of these conditions supplemented with HB-EGF 
neutralization antibody (3 µg/ml) (R&D Systems, Minneapolis, MN) under normoxia and 
hypoxia for 30 min. Whole cell lysates were prepared in RIPA buffer supplemented with 1% 
proteinase inhibitor cocktail and 1% phosphatase inhibitor cocktail (Sigma Aldrich, Boston, 
MA). Cell lysates (40µg/lane) were separated on a 10% polyacrylamide gel and subsequently 
blotted onto nitrocellulose according to standard protocol. Membranes were blocked in Tris-
buffered saline (TBS) containing 5% BSA (Sigma-Aldrich, Boston, MA) for 1h. Subsequently, 
membranes were incubated in TBS-1% Tween containing 5% BSA with primary antibodies to 
human p-Erk1/2 (Thr 202/Tyr 204), Erk1/2 (42/44) (Cell Signaling Technology, Beverly, 
MA), GAPDH (Abcam, Cambridge, UK) diluted 1:1000, overnight. Afterwards, blots were 
incubated with alkaline phosphatase-conjugated antibodies to mouse or rabbit IgG, at the 
dilution 1:2000 for 1h. NBT/BCIP (Bio-Rad, VA) was used as a substrate for detection.  
IMMUNOFLUORESCENCE MICROSCOPY AND IMAGE ANALYSIS 
HL-1 cardiomyocytes were seeded onto 8-chamber slides (Thermo Scientific, Hemel 
Hempstead, UK). Subsequently, cells were kept in serum-free Claycomb Medium overnight. 
Afterwards, cells were stimulated with 50 ng/ml HB-EGF (R&D Systems, Minneapolis, MN), 
conditioned media of ADSC, IL-1β primed conditioned medium of ADSC and both 
conditioned media of ADSC supplemented with HB-EGF neutralizing antibody (3 µg/ml) 
under normoxia and hypoxia for 24h. Simultaneously, cells were labeled with 1 µM BrdU 
(Sigma-Aldrich, Boston, MA) for 6h. Next, cells were fixed using 2% paraformaldehyde at 
room temperature for 20 min and permeabilized with 0.5% Triton X-100 in PBS (Sigma-
Aldrich, MA). Samples were incubated with 0.7 M HCl and 0.05% pepsin at 37˚C and post-





antibody sheep polyclonal biotinylated α-BrdU (Abcam, Cambridge, UK) diluted 1:100 in 
PBS with 10% goat serum (First Link Ltd, UK) overnight. Next, samples incubated with 
secondary antibody Streptavidin-FITC (Dako, Carpinteria, CA) diluted 1:400 in 3 µM DAPI 
in PBS with 10% mouse serum (Sanquin, Amsterdam, The Netherlands) for 30 min. 
Quantification was performed by TissueFAXS using a Zeiss AxioObserver.Z1 microscope and 
TissueQuest cell analysis software (TissueGnostics). 
STATISTICS 
All the data are presented as a means +/- SEM and were analysed by GraphPad Prism 
(version 5, GraphPad Software Inc.). Statistical significance was determined using one-way 
ANOVA with Bonferroni post hoc analysis. Values of p<0.05 were considered statistically 
significant. 
Results 
ADSC stimulate the proliferation rate of adult HL-1 cardiomyocytes which is 
augmented by hypoxic and inflammatory preconditioning.  
The pro-inflammatory and ischemic post-aMI cardiac microenvironment was modeled in 
vitro by culturing under hypoxia (2% O2) and addition of the pro-inflammatory cytokine 
TNF-α to HL-1 cardiomyocytes (CM). Although this cell line has virtually unlimited 
proliferation capacity, it is suitable to assess the influence of ADSC, on its proliferation rate 
under limiting conditions i.e. no or low serum. Under these conditions HL-1 CM were co-
cultured with mitotically arrested ADSC or treated with serum-free conditioned medium of 
ADSC. Under normoxia, addition of ADSC to the HL-1 CM inhibited the proliferation rate by 
10%, although stimulation with the conditioned medium of ADSC resulted in 10% increase of 
HL-1 proliferation rate (p<0.05, Fig. 1 A). TNF-α treatment of HL-1 CM under normoxia 
reduced the proliferation rate of HL-1 CM by 30% (p<0.05, Fig. 1 A). Under these conditions, 
addition of ADSC restored the proliferation rate of HL-1 CM by 20%, to near normal levels. 
The conditioned medium of ADSC primed with TNF-α resulted in a 50% increase in HL-1 
proliferation rate compared to the TNF-α treated HL-1 control (p<0.05, Fig. 1 A). Under 
hypoxia, both ADSC and the conditioned medium of ADSC stimulated the proliferation rate 
of HL-1 CM by respectively 23% and 61% compared to the control (p<0.05, Fig. 1 B). 
Stimulation of HL-1 CM with TNF-α resulted in 50% decrease of the proliferation rate of HL-
1 CM compared to control HL-1 CM (p<0.05, Fig. 1 B). Addition of ADSC or the conditioned 
medium of ADSC primed with TNF-α resulted in increased proliferation of HL-1 CM by 
respectively 50 and 100% compared to the control HL-1 CM (p<0.05, Fig. 1 B). 
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Figure 1. Hypoxia and inflammation in vitro augment ADSC-stimulated 
proliferation of adult HL-1 cardiomyocytes. Determination of the proliferation of HL-
1 cardiomyocytes by BrdU ELISA at 24h, A) under normoxia, B) hypoxia; alone or in the 
presence of mitomycin C treated ADSC or the conditioned medium of ADSC for 24h. The 
post-Mi microenvironment was modeled by addition of pro-inflammatory (10ng/ml) TNF-α 
to the experimental conditions. Addition of ADSC to the HL-1 CM resulted in enhanced HL-1 
proliferation under inflammatory and hypoxic conditions (A, B p<0.05). The strongest effect 
on enhancement of HL-1 CM proliferation was mediated by paracrine effect of the 
conditioned medium of ADSC. Hypoxia and inflammation reduced proliferation rate of HL-1 
CM, which was restored and further promoted by the conditioned medium of ADSC (B 
p<0.05). Graphs represent triplicates (with SEM) data from three independent experiments 
from 3 donors.  E) Representative HL-1 CM, co-culture of HL-1 and mitomycicn C treated 
ADSC 1:1, mitomycin C treated ADSC 
and control ADSC view under light microscopy, 100x magnification.         
 ____________________________________________________________ 
 
Hypoxia and pro-inflammatory cytokines augment secretion of HB-EGF by 
ADSC. 
Treatment of ADSC with the pro-inflammatory cytokines TNF-α or IL-1β under normoxia 
resulted in respectively 3-fold and 5-fold upregulation of HB-EGF gene expression level 
within first 24h (p<0.05, Fig. 2 A). Under hypoxia, treatment of ADSC with TNF-α or IL-1β 





fold and 6-fold (p<0.05, Fig. 2 B). The level of secreted HB-EGF in the conditioned medium 
of ADSC significantly increased by 20%  after preconditioning ADSC with IL-1β both under 
normoxia and hypoxia for 24h. (Fig. 2 C, D). 
 
 
Figure 2. Hypoxia and pro-inflammatory cytokines augment expression of HB-
EGF by ADSC. A, B) Quantitative RT-PCR analysis of gene transcript levels of HB-EGF 
normalized to GAPDH expression. Transcript levels of HB-EGF were induced by stimulation 
with pro-inflammatory mediators (TNF-α or IL-1β) both under normoxia and hypoxia for 24 
(p<0.05). The increase of HB-EGF gene expression was strongest after IL-1β stimulation 
(p<0.05). C, D) Significantly, increase of secreted HB-EGF (ELISA quantification) by ADSC 
after stimulation with either TNF-α or IL-1β for 24h. The increased secretion of HB-EGF was 
upregulated by IL-1β (p<0.05). Graphs represent triplicates (with SEM) data from three 
independent experiments from three donors. 
_______________________________________________________________ 
 
Conditioned medium of ADSC stimulates autocrine activation of EGF signaling 
in HL-1 cardiomyocytes.  
Adult HL-1 CM were cultured under hypoxia and nomoxia in the presence or absence of 
serum. Stimulation of serum-free HL-1 CM  with the conditioned medium of ADSC 
significantly increased gene expression levels of HB-EGF, ADAM17 in HL-1 CM under 
normoxia, while EGFR expression was increased both under normoxia and hypoxia  
(p<0.05, Fig. 3 A,B,C). Serum-free conditioned medium of ADSC primed with IL-1βhad the 
strongest effect on autocrine stimulation of EGF signaling in HL-1 cells and resulted in 
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increased gene expression of HB-EGF (2-fold), ADAM17 (1.5-fold) and EGFR (4.5-fold, all 
p<0.05, Fig. 3 A,B,C). 
Serum activated mitogenic pathways in HL-1 CM as reflected in the increased 
phosporylation of MAPkinases Erk1/2 compared to serum-free control medium (Fig. 3 D). 
Stimulation of serum-free HL-1 CM with HB-EGF or the conditioned medium of ADSC both 
resulted in increased phosphorylation of Erk1/2. Stimulation of HL-1 cardiomyocytes with 
the serum-free conditioned medium of ADSC primed with IL-1β increased Erk1/2 
phosphorylation compared to serum controls (Fig. 3 D). In contrast, neutralization of HB-
EGF with antibodies reduced phosphorylation of Erk1/2 (Fig. 3 D). Remarkably, the 
phosphorylation of Erk1/2 was not affected by HB-EGF neutralizing antibody in the 
presence of the conditioned medium of ADSC or conditioned medium of IL-1β primed ADSC 















       
__________________________________________________________
Figure 3. Conditioned medium of ADSC stimulate autocrine activation of EGF 
signaling in HL-1 cardiomyocytes. Quantitative RT-PCR analysis of gene transcript 
levels of HB-EGF, its activator ADAM17 and its receptor EGFR normalized to β-2 
microglobulin expression. White bars represent normoxia, black bars hypoxia cultured HL-1 
CM. A) Gene transcript level of HB-EGF and ADAM17 indicated significant increase upon 
stimulation with the conditioned medium from normoxia and both conditioned medium of 
ADSC and IL-1β primed conditioned medium of ADSC under hypoxia (p<0.05). B) Gene 
expression of EGFR show significant increase upon stimulation with conditioned medium of 
ADSC and IL-1β primed conditioned medium of ADSC under  normoxia but under hypoxia 
only IL-1β primed conditioned medium of ADSC show significant increase  (p<0.05). Graphs 
represent triplicates (with SEM) data from three independent experiments, normalized to 
serum free HL-1 cardiomyocytes.  D) Representative examples of western blot analyses of 
phosphorylated phosphorylated Erk1/2 in the presence of HB-EGF or conditioned medium 
of ADSC and IL-1β primed conditioned medium of ADSC from normoxia and hypoxia for 30 
min. Blocking of HB-EGF by preconditioning with HB-EGF neutralizing antibody resulted in 
decrease Erk1/2 phosphorylation but did not change Erk1/2 phosphorylation upon 
stimulation with the conditioned medium of ADSC. GAPDH (loading control) shows 
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ADSC conditioned medium and HB-EGF-dependent signaling pathways 
targeting increase of HL-1 cardiomyocyte proliferation.  
Mitogenic stimuli such as serum and HB-EGF both stimulated the HL-1 CM proliferation 
rate both under normoxia and hypoxia (30%, p<0.05, Fig. 4 A,B) compared to their serum-
free controls. Stimulation of HL-1 cardiomyocytes with serum-free conditioned medium of 
ADSC or the conditioned medium of ADSC primed with IL-1β resulted in 10% increase in 
proliferation rate compared to serum-free controls under normoxia and hypoxia (p<0.05, 
Fig. 4 A,B). Neutralization of HB-EGF in serum-free medium supplemented with HB-EGF 
inhibited proliferation of HL-1 cardiomyocytes, observed as a significant decrease in the 
fraction of BrdU positive cells by 10%. Yet, this effect was not observed in cultures with the 














Figure 4. ADSC conditioned medium and HB-EGF-dependent signaling 
pathways targeting increase of HL-1 cardiomyocyte proliferation.  
A, B) Treatment of serum-free cultured HL-1 cardiomyocytes with FBS, HB-EGF or 
conditioned medium of IL-1β stimulated ADSC resulted in enhanced proliferation of HL-1 
cardiomyocytes both under normoxia and hypoxia (p<0.05). Addition of HB-EGF 
neutralizing antibody resulted in a significant decrease of proliferation of HL-1 
cardiomyocytes stimulated with HB-EGF but not in the presence of conditioned medium of 
IL-1β stimulated ADSC  (p<0.05). Graphs represent triplicates (with SEM) data from three 
independent experiments. Proliferation was assessed by immunofluorescent detection of 6h 
incorporated BrdU and quantification with Tissue Gnostics Tissue FAXS equipment. C) 
Representative micrographs of immunofluorescent stainings of HL-1 cardiomyocytes in 
normal serum (10% FBS), serum-free (0% FBS), serum-free stimulated with HB-EGF or with 
serum-free ADSC conditioned medium after stimulation with IL-1β as well in the presence of 
HB-EGF neutralizing antibody. Proliferation, i.e. BrdU incorporation – red, nuclei (DAPI) – 
blue. Graphs represent triplicates (with SEM) data from three independent experiments 
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In this study, we show that Adipose Derived Stromal Cells (ADSC), in particular their 
conditioned medium, stimulate the proliferation rate of HL-1 cardiomyocytes. The EGF-
receptor family ligand HB-EGF was one of the factors that contribute to this stimulation. 
Conditioned medium of ADSC proved a versatile stimulator of the proliferation rate of CM, 
because antibody-dependent neutralization of HB-EGF could not completely prevent the 
stimulation of CM proliferation. In another study (submitted elsewhere), we have shown that 
IL-6 has similarly potent mitogenic effects as HB-EGF.  
Previous studies have shown that EGF receptor ligands play an important role in cardiac 
development.  Yet, some of these factors, such as Neuregulin, also partially facilitated 
myocardial regeneration after murine aMI [15]. Here, we show that stimulation of ADSC 
with hypoxia and pro-inflammatory mediators increase the gene expression and secretion of 
the cardiomitogenic factor HB-EGF. This extends on observations by others that various 
mitogens are upregulated in ADSC by hypoxia or inflammatory stimuli [16, 17].  The hypoxic 
and pro-inflammatory stimuli employed in this study, modeled the post-aMI 
microenvironment. In contrast to our presumptions, these conditions augmented the pro-
mitogenic capacity of ADSC. Adult HL-1 CM showed a decreased rate of proliferation under 
hypoxia and inflammation that was restored to normal levels by addition of ADSC or their 
conditioned medium. ADSC-augmented proliferation of cardiomyocytes involved HB-EGF-
MAPK-Erk1/2 signaling. The mitogenic effect of ADSC conditioned media on HL-1 CM, at 
least partly, was mediated by HB-EGF, because neutralizing antibodies against HB-EGF only 
partially reduced proliferation of HL-1 CM. Recent data indicate that hypoxia changes the 
EGF signaling system in the heart, leading to decreased CM proliferation that can be 
restored by addition of HB-EGF [18]. Stimulation of HL-1 cardiomyocytes with the 
conditioned medium of ADSC primed with pro-inflammatory IL-1  activated autocrine EGF 
signaling in HL-1 CM by increased gene expression of HB-EGF and the matrix 
metalloproteases ADAM17 that cleave the membrane bound HB-EGF from the cell surface. 
The soluble HB-EGF primary bound to the ErbB1/EGFR, which was activated in HL-1 CM by 
stimulation with the conditioned medium of ADSC. The induction of the HL-1 proliferation 
rate by addition of the conditioned medium of ADSC might be also due to the autocrine 
stimulation of EGF signaling in HL-1 cardiomyocytes. The HB-EGF ligand binding and its 
receptor dimerization activates the tyrosine kinase and its downstream MAPkinase pathway 
through intermediates of the Ras family, with Erk1/2 as the major downstream target. The 
Erk1/2 phosphorylation was upregulated by HB-EGF and even stronger by (pre)conditioned 
medium of ADSC. This indicates that in HL-1 CM, HB-EGF predominantly acts as a mitogen. 
Conclusions 
 We demonstrated that hypoxia and inflammation decrease the proliferation of HL-1 CM, 
which can be restored by application of ADSC. Most remarkably, we show that in vitro model 
of post-MI microenvironment (hypoxia and inflammation) has beneficial effect on ADSC 
guided induction of cardiomyocyte proliferation rate through activation of EGF signaling. 
The presence of HB-EGF and other multiple cardiomyogenic factors in the conditioned 
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Adipose Derived Stromal Cells (ADSC) are relevant therapeutic agents to treat myocardial 
infarction (MI) in clinical trials. Soluble factors secreted by ADSC, such as growth factors 
and cytokines, suppress inflammation and apoptosis while promoting angiogenesis and the 
proliferation of cardiomyocytes. Moreover, ADSC synthesize ECM components into the 
intercellular space which might contribute to their therapeutic capacity. Thus ADSC might 
directly modulate the post-MI microenvironment through a combination of paracrine and 
juxtacrine signaling. In this study the juxtacrine role of ADSC and ADSC-derived ECM on the 
organization and maturation of cardiomyocytes was investigated. Human ADSC synthesized 
and deposited a heterogenous and complex mixture of ECM components such as collagen I, 
III, IV, fibronectin, elastin as well as the matricellular protein periostin. Co-cultures of 
rodent cardiomyocytes with human ADSC or with human ADSC-derived ECM components 
enhanced the cardiomyocyte alignment, their intercellular connections and the maturation 
of their sarcomeres, while the proliferation rate of the cardiomyocytes was increased and 
their level of hypertrophy reduced. The use of human ADSC-derived ECM could serve both 
to augment in vitro tissue-engineered myocardial constructs and to improve myocardial 
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Despite immediate interventions and the advance in the follow-up treatment of myocardial 
infarction (MI), the development of cardiac failure constitutes a serious threat. Immediately 
after myocardial infarction, the heart acute ischemia and tissue damage initiate a complex 
cascade of physiological repair processes that involve inflammation, wound healing and 
tissue remodeling (1, 2). The loss of myocardial tissue cannot be compensated. Therefore, it 
is replaced by scar which supports the structural integrity of the myocardium. The spared 
myocardium engages in tissue remodeling which comprises of hypertrophy of the surviving 
cardiomyocytes (CM) and is associated with remodeling and degradation of their 
surrounding extracellular matrix (ECM). This type of cardiac fibrosis results in cardiac 
dilatation and occurring arrhythmia (3). Without appropriate intervention, fatal cardiac 
failure may occur.  
Mesenchymal stem cells from e.g. bone marrow or adipose tissue (ADSC–adipose derived 
stromal cells) qualify as potent in experimental cardiac therapies. Several studies showed 
that ADSC augment post-aMI tissue regeneration e.g. through improved remodeling (4). 
Previously, we have shown that in vitro preconditioning e.g. by hypoxia or with pro-
inflammatory factors, boosts the regenerative capacity of ADSC as the secretion of beneficial 
paracrine factors was increased (5). Secreted factors in the conditioned medium of ADSC i.e. 
IL-6 enhanced the proliferation rate of CM through MAPK and JAK-STAT signaling 
activation in a paracrine manner (6). Furthermore, current data and clinical trials for MI 
stem cell based therapies indicate that ADSC are a promising cell type for cardiac repair (7, 
8). In a porcine model of myocardial ischemia/reperfusion, the injection of ADSC indicated 
long term improvement of cardiac function (9). In the randomized clinical trial, the 
intramyocardial administration of ADSC immediately after aMI resulted in long term 
improvement of cardiac function, enhanced perfusion and reduced scar size (10). Yet, it 
remains unclear whether this is accomplished through paracrine action of growth factors and 
immune-active factors or it is also related to juxtacrine interactions and ECM synthesis by 
ADSC.  
Recently ECM components have gained interest in the repair of tissue damage i.e. after the 
aMI or skin damage (11, 12). Intramyocardial injection of bone marrow-derived ECM after 
cardiac injury in rats resulted in improved cardiac function (13). In the post-MI 
microenvironment ECM components are associated with resolution of the acute 
inflammatory phase, followed by activation of survival phase (14). The deposition of ECM 
components such as collagen I and collagen III by myofibroblasts in the infarcted area 
contribute to the development of the scar which prevents rupture (15). However, excessive 
deposition of collagen I, III and no elastin based ECM components renders this scar and the 
surrounding myocardium motionless, which is undesirable. Therefore, an adjustment of 
post-aMI remodeling phase and deposition of the heterogenous ECM components is 
warranted.  
We hypothesized that ADSC-derived ECM components promote CM proliferation, reduce 
CM hypertrophy, enhance CM maturation and alignment. Therefore, in this study CM 
behavior was investigated after culture on tissue culture polystyrene, on fibronectin/gelatin 
coated dishes as well as in direct co-culture with ADSC or onto ADSC-derived ECM. We have 
previously shown that ADSC induce CM proliferation in a paracrine manner. In addition to 
that, here we show the beneficial juxtacrine effect of ADSC and ADSC-derived ECM on CM 
architecture in vitro.  





Cell isolation and culture. Human subcutaneous adipose tissue samples from subjects 
with BMI<30, were obtained after liposuction surgery and donated after informed consent 
(Bergman Clinics, The Netherlands). Adipose tissue was processed as previously described 
(11). Mouse and rat neonatal cardiac tissues (postnatal day 1) were isolated and cultured as 
previously described (11). In our long term experience, no differences were ever found 
between mice and rat neonatal cardiomyocytes with respect to proliferation and other 
parameters tested in this study. Institutional guidelines demand to share sacrificed animals 
with other groups as was done here too. HL-1 murine adult CM were a kind gift of Dr. 
William C. Claycomb (Department of Biochemistry and Molecular Biology, Louisiana State 
University Health Science Center, New Orleans, LA, USA). HL-1 cells were maintained as 
previously described (11). HL-1 CM have been characterized as similar to adult primary 
cardiomyocytes (16). HL-1 CM are spontaneously contracting and preserve a differentiated 
cardiac phenotype in culture. Moreover, HL-1 CM have been already extensively studied in 
the context of cardiac biology at cellular and molecular level in vitro (17), thus indicating the 
relevance of use HL-1 CM. To compare the effect of the ECM on the function and 
proliferation of CM, these were cultured on tissue culture polystyrene (TCPS) or on coating 
comprised of 25µg/ml fibronectin (Harbor Bio-products, Norwood, MA) in 0.02% gelatin in 
PBS (Fn-Gel) and on dishes coated with decellularized ADSC i.e. ADSC-derived ECM. "All 
subjects enrolled in this research have responded to an Informed Consent which has been 
approved by my Institutional Committee on Human Research and that this protocol has 
been found acceptable by them."   
Gene transcript analysis. ADSC were seeded at 10,000 cells/cm2 in triplicate and 
harvested in 350µl per well of cold lysis buffer after 24h. RNA isolation was performed using 
the RNeasy Mini Kit (Qiagen Inc., CA, USA) according to the manufacturer’s protocol. Next, 
0.5µg of total RNA was reverse-transcribed using the FirstStrand cDNA synthesis kit 
(Fermentas, Lithuania) according to the manufacturer’s instructions. Real-time PCR was 
performed by using the Sybergreen method. The cDNA-equivalent of 5ng RNA was used per 
well for amplification in 384-well microtitre plates in a TaqMan ABI7900HT cycler (Applied 
Biosystems,CA, USA) in 10µl PCR mix. Cycle threshold (CT) values for individual reactions 
were determined and normalized against GAPDH expression. Relative expression was 
calculated using the delta CT method. All cDNA samples were amplified in triplicate. Table1. 
Primer sequences.  
Immunofluorescence Microscopy. ADSC were plated on 15mm Thermanox coverslips 
(NUNC, Rochester, NY) at 10,000 cells/cm2 in DMEM, 10% FBS for 24h. Samples were 
washed with PBS and fixed in 2% paraformaldehyde in PBS at RT for 30min. After extensive 
washing with PBS, the samples were incubated with primary antibody to rabbit-anti-human 
collagen I, III, IV, laminin, fibronectin, periostin and tenascin C (1:100, Abcam, UK) for 1h. 
Samples were washed with PBS and incubated with the secondary antibody Fluorescein 
conjugated or Cyanine 3-conjugated goat antibody to rabbit IgG (1:400, Jackson 
Immunoresearch, UK). Stained samples were mounted in Citifluor (Agar Scientific, UK). 
Examination was performed using a Leica DMRXA fluorescence microscope and Leica 
software (Leica Microsystems) (magnification 10 or 20x).  
ADSC-derived ECM. ADSC were plated onto polystyrene 8-chamber slides 
(Thermo Scientific, UK) or in 24 well plates at 10,000 cells/cm2 in DMEM supplemented 
with 10% FBS and kept in culture until they reach confluence. The endogenous ADSC-
derived ECM were prepared by treatment of ADSC with sterile hypotonic ammonium 
hydroxide (NH4OH, 20mM) (Merck, Germany) for 10 min. After, the matrices were frozen in 
-20°C overnight. Defrosted samples were washed with PBS. The unoccupied protein-binding 
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sites were blocked by incubation with 0.1% BSA (Sigma-Aldrich, Boston, MA) for 30min. 
Staining with DAPI confirmed that no cellular components remained after this procedure 
(Supplemental Figure 1- 4). For the co-culture of CM on top of the ADSC-derived ECM, the 
matrices were blocked with 0.1% BSA, washed twice with unsupplemented DMEM (Lonza 
Biowhittaker, Belgium), followed by co-culture with CM. 
Assessment of CM proliferation and Image Analysis. HL-1 CM were seeded semi-
confluent onto polystyrene 8-chamber slides (Thermo Scientific, UK). Subsequently, cells 
were starved in serum-free Claycomb Medium overnight. Afterwards, cells were seeded on 
TCPS, FN/Gel coated dishes or ADSC-ECM for 24h. Simultaneously, cells were labeled with 
1µM BrdU (Sigma, Boston, MA) for the last 6h. Next, cells were fixed using 2% 
paraformaldehyde at RT for 20min and stained for BrdU as previously described (11). 
Stained samples were extensively washed and examined using a Tissue FAXS 
(TissueGnostics, Austria) and equipped software to quantify the percentage of proliferated 
i.e. BrdU positive HL-1 CM. Examination was performed using a Leica DMRXA fluorescence 
microscope (magnification 10x) and Leica software (Leica Microsystems), and further 
quantification was performed by TissueFAXS using a Zeiss AxioObserver.Z1 microscope and 
TissueQuest cell analysis software (TissueGnostics). 
Visualization of CM cytoskeleton changes. Micrographs of phalloidin-FITC-stained 
CM cultured directly after isolation for 1 week on TCPS, Fn-Gel coating or on ADSC-ECM 
were washed with PBS and fixed in 2% paraformaldehyde in PBS at RT for 30min. After 
extensive washing with PBS, cytoskeletal organization was visualized using 0.1µM 
fluorescein-conjugated phallotoxin (Invitrogen, OR, USA).  Examination was performed 
using a Leica DMRXA fluorescence microscope (magnification 10x) and Leica software 
(Leica Microsystems), and further quantification was performed with ImageJ software 
(http://imagej.nih.gov) using a digitizer tablet and the build-in measurement applications. 
The ratio of maximal length and minimal width of the cells was used to investigate the 
influence of substrate on cell morphology, while the total perimeter of the cell was 
determined to assess the cell size. At least 50 randomly chosen cells were measured. 
Transmission electron microscopy. Mouse neonatal CM, rat neonatal CM and ADSC 
were cultured directly after isolation for 1 week according to the cell culture experimental 
procedure. Next samples were fixed in 2% Glutaraldehyde (Merk, Germany) in 0.1M Sodium 
Cacodylate buffer at 4˚C for 24h. After washing with 0.1M Sodium Cacodylate, samples were 
post-fixed using 1% Osmium Tetroxide/1.5% Potassium Ferrocyanide in 0.1M Sodium 
Cacodylate for 30min on ice. Next, samples were dehydrated with ethanol and embedded in 
EPON 812 (Serva, Germany) and polymerized at 37˚C for 16h followed by 56˚C incubation 
for 24h. Half micron sections as well as 60nm ultrathin sections were cut on a Reichert 
ultramicrotome. The half micron sections were stained with 1% Toluidin Blue. The 60nm 
sections were contrasted with 2% uranyl acetate in methanol and 2min in Reynolds lead 
citrate and imaged using a Cm100 Biotwin transmission electron microscope (FEI, The 
Netherlands) operated at 80kV, equipped with a Morada camera (Olympus-SIS, Germany).  
Statistical analysis. All the data are presented as a means +/- SEM and were analysed by 
GraphPad Prism (version 5, GraphPad Software Inc.). Statistical significance was 
determined using one-way ANOVA with Bonferroni post hoc analysis or ANOVA with post-
hoc tested according to Dunnet. Values of p<0.05 were considered statistically significant. 
 
Results 
ADSC secrete a heterogeneous mixture of extracellular matrix components. The 





fibronectin, collagen III, elastin while the basement membrane components i.e. collagen IV 
and laminin had low expression (Fig.1A). The matricellular components profile of ADSC 
showed gene expression of SPARC, thrombospondin-1, periostin, tenascin C and 
thrombospondin-2 with low expression of tenascin X and osteopontin (Fig.1B). The 
immunofluorescent detection on non-permeabilized cells showed that ADSC deposited 
collagen I, III, IV, laminin, fibronectin and elastin (Fig. 1C) as well as matricellular proteins 
such as periostin and tenascin C (Fig.1C). Ultrastructural analysis showed that ADSC 
cultured on TCPS were surrounded and embedded by their deposited matrix comprising of 
fibrous structures that resemble ECM (Fig.1D). Furthermore, the analysis of the 
phosphorylated focal adhesion kinase (p-FAK) (red dots) oriented at the attachment points 
at the adages of fluoresceine conjugated phalloidine-positive F-actin filaments of ADSC 
cultured on TCPS, showed that the ADSC-derived ECM is functional, in that ADSC actively 
interact through integrin signaling with their own secreted ECM (Fig.1D). 
 
__________________________________________________________
Figure 1. ADSC secrete heterogeneous extracellular matrix components. Relative 
gene expression of A) extracellular matrix components and B) matricellular proteins of 
ADSC (n=3; data are represented as +/- SEM). C) Immunofluorescence staining for 
extracellular matrix and matricellular components synthesized by ADSC: collagen I, collagen 
III, collagen IV, laminin, fibronectin, elastin, periostin and tenascin C (magnification 10x). 
D) TEM analysis of ADSC shows fibrous material deposition (arrows). D) 
Immunofluorescence detection of phalloidin positive F-actin filaments (green) and 
phosphorylated focal adhesion kinase (red). Nuclei were counterstained with DAPI (blue) 
(magnification 10x). 
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Components of the ADSC-derived extracellular matrix. Confluent ADSC-layers were 
treated with ammonium solution to accomplish decellularization. Staining of the confluent 
ADSC-layers showed the presence of collagen I, III, IV, laminin, fibronectin and elastin 
(Fig.2A). After decellularization, freezing and washing, the ADSC-derived ECM coating had 
been formed as reflected by presence of collagen I, III and fibronectin (Fig.2B). Collagen IV, 
laminin and elastin were not detected after the decellularization of ADSC.  
 
__________________________________________________________
Figure 2. ADSC deposit heterogeneous extracellular matrix components. 
Immunofluorescence staining of A) ADSC and B) ADSC-derived ECM for extracellular 
matrix components collagen I, collagen III, collagen IV, laminin, fibronectin and elastin. 
Nuclei were counterstained with DAPI (blue) and only present in the ADSC layers (A, 
Supplemental Figure 1- 4) (magnification 10x).  
 
ADSC-derived ECM components enhance the proliferation rate of 
cardiomyocyte. The proliferation of CM was investigated with HL-1 CM cell line. Primary 
CM cultures are strongly enriched, yet are never devoid of contamination with non-CM cells. 
Thus we used adult HL-1 CM cell line to study the effect of ADSC-derived ECM on CM 
proliferation. HL-1 CM were seeded onto TCPS, FN-Gel coated dishes and on ADSC-derived 
ECM for 24h.  HL-1 CM were labelled with Bromodeoxyuridine (BrdU) for the last 6h and 
stained for nuclearly incorporated BrdU. The analysis of serum-starved HL-1 CM indicated 
that ECM mixtures such as FN-Gel significantly enhanced their proliferation rate (1.6-fold) 
in comparison to TCPS (p<0.05, Fig.3). The use of ADSC-derived ECM even further 






Figure 3. ADSC enhance HL-1 cardiomyocyte proliferation. Proliferation of HL-1 
CM cultured on TCPS, FN-Gel or ADSC-derived ECM was assessed by immunofluorescence 
detection of 6h incorporated BrdU and quantification with Tissue Gnostics Tissue FAXS 
equipment. The increase of CM proliferation was detected in the presence of FN/Gel coated 
cultures, which were further increased in the presence of ADSC-derived ECM. Graphs 
represent triplicates (with SEM) data from n=3 independent experiments from 3 donors.  
Values of p<0.05 were considered statistically significant. 
 
ADSC-derived ECM components decrease cardiomyocyte hypertrophy. 
Visualization of the cytoskeleton (F-actin) changes by phallotoxin-FITC immunofluorescency 
confirmed that the different ECM components influence rat neonatal CM (rnCM) cell size i.e. 
hypertrophy (Fig.4A-H). The rnCM cultured for 1 week on TCPS had a highly hypertrophic 
morphology, in particular compared to the use of FN/Gel or ADSC-ECM (Fig. 4A-C). The 
rnCM cultured on FN-Gel showed decreased cell size and more elongated cell morphology 
(Fig.4B,E,G,H). The lowest degree of hypertrophy was observed after culturing rnCM on 
ADSC-derived ECM (Fig.4C,F,G). 
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Figure 4. ADSC-derived ECM positively influence rat neonatal CM morphology 
and organization in vitro. Neonatal cardiomyocytes were cultured on either A, D) tissue 
culture polystyrene (TCPS), B, E) a coating of fibronectin and gelatin (Fn-Gel) or C, F) 
decellularized extracellular matrix of ADSC (ADSC- ECM) directly after the isolation for 1 
week and stained with phalloidin-FITC to visualize the cytoskeleton. On all substrates cells 
were more elongated than rounded, while only on Fn-Gel the cardiomyocytes differed from 
TCPS (G). In contrast, on both types of coating, cardiomyocytes were smaller, i.e. less 
hypertrophic compared to TCPS (H). These coatings did not differ. Qualitatively, both on Fn-
Gel and ADSC-ECM, stretched cardiomyocytes appeared to grow primarily on top of smaller 
cardiomyocytes, while TCPS cultured cardiomyocytes did not reach confluency (A-C). DAPI 
stainings (D – F) reveal the presence of individual cells. Scale bar 100 m. Data are 
represented as mean ± SEM, values of p<0.05 were considered statistically significant, 
(magnification 10x). 
 
ADSC-derived ECM components promote CM maturation. The ultrastructural 
analysis of rnCM cultured for 1 week on TCPS, FN-Gel and ADSC-derived ECM underlined 
the morphological features described above. rnCM cultured on TCPS showed a hypertrophic 
cell shape and only few cells showed well developed mitochondria. Sarcomeres had been 
formed, but many cells showed disintegration of their cytoplasm. In general, the nuclei had 
rounded features and mainly contained euchromatin. However, cell-cell contact was rather 





CM cell-cell organization. Additionally, neonatal primary CM showed cell-cell interactions 
and cellular alignment. Cells were rich in mitochondria and their nuclei also contained 
mainly euchromatin. Disintegration of the cytoplasm was low in comparison to the TCPS 
cultures. However fascia adherences, ribbon like structures that represent adherens 
junctions with the neighboring CM, were only sporadically observed (Fig.5B). CM cultured 
on ADSC-derived ECM showed a more mature tissue like structure with multiple 
intercellular connections. Many fascia adherences were present, which represent the 
intercellular links in which mature myofibrils terminate. Similar to Fn-Gel cultured CM, 
ADSC-ECM cultured CM were also rich in well-developed mitochondria. The nuclei were 
more electron dense i.e. contained more heterochromatin, which indicated a higher degree of 
cellular maturation compared to the FN-Gel coating (Fig.5C).  
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Figure 5. The ultrastructure analysis of cardiomyocytes on top of the 
decellularized ECM. Transmission electron microscopy images of the ultrastructure of 
cultured rat neonatal cardiomyocytes (rnCM) for 7 days on A) TCPS, B) FN-Gel and C) 
ADSC-derived ECM.  A) rnCM cultured on TCPS showed hypertrophic cell shape, poor 
interconnections and cellular organization. B) rnCM cultured on top of FN-Gel coating 
increased cellular interconnections, lowered level of hypertrophy and increase number of 
well developed sarcomeres and mitochondria. C) rnCM cultured on top of the ADSC-derived 
ECM showed highly compacted cellular interconnections with multiple mitochondria, well 
developed sarcomeres and appearance of the fascia adherences. Sarcomeres (s), 






ADSC promote CM alignment. To predict putative in vivo interactions of ADSC and CM, 
a co-culture of ADSC and murine nCM was performed for 1 week. As observed by the light 
microscopy, a confluent layer of mnCM cultured on TCPS formed an only randomly 
spatialized confluent monolayer (Fig.6A). In contrast, mnCM in co-culture with ADSC 
formed spatially aligned layers of interconnected cells (Fig.6B). The co-cultured mnCM also 
contracted in unison, in contrast to TCPS cultured CM that contracted in a random pattern 
(not shown). At ultrastructural level, mnCM and ADSC had formed intimate intercellular 
connections (Fig. 6C). Only in the co-cultures with ADSC, CM showed a mature morphology, 
i.e. prominently assembled sarcomeres, fascia adherences and high numbers of well-
developed mitochondria. In the interconnected spaces between mnCM and ADSC we 
observed deposition of fibrous-like structures that resemble deposited ECM (Fig.6D). This 
indicated that ADSC and ADSC-derived ECM directly interact with CM to promote their 
alignment, organization and maturation. 
 
_______________________________________________________________
Figure 6. ADSC promote murine cardiomyocyte (mCM) alignment and 
maturation in vitro. 1 week culture of A) mCM alone and B) in co-culture with ADSC as 
observed by the light microscopy indicates that ADSC promote mCM alignment 
(magnification 10x). C) At the ultrastructure level, maturation of CM multiple mitochondia 
(m) and sarcomeres assembly (s), formation of facia adherences (F) and tight 
interconnection with ADSC were observed. D) The magnification of the interconnected area 
indicated the extracellular matrix fibrous material in the intercellular space of mature CM 
and ADSC (*). 
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Although the adult human heart possess and accelerates the intrinsic repair programs after 
myocardial injury, this cannot compensate or replace lost CM which requires the formation 
of a protective intramyocardial scar (18, 19). After large infarcts the heart ensues into adverse 
tissue remodeling which may terminate with heart failure. Current therapies based on 
inhibition of specific receptor pathways can only partly alleviate the progression of heart 
failure. In contrast, biological agents such as mesenchymal stromal cells (MSC) can 
reprogram the myocardial microenvironment. Literature shows that ADSC improve post-
aMI cardiac remodeling through unknown mechanisms as yet. The main finding of our study 
is that human ADSC and their ECM promote the architecture and organization of rodent CM 
through improved coupling of CM. The ECM deposited by human ADSC was rich in both 
interstitial and basement membrane components as well as in matricellular proteins. Human 
ADSC influenced CM to rearrange in aligned sheets and to contract in unison. In addition, 
extracellular matrix components could replace ADSC. The in vitro adherence, proliferation 
and maintenance of neonatal primary CM depended on coating of TCPS dishes with 
fibronectin and gelatin. Remarkably, decellularized ADSC i.e. ADSC-derived ECM even more 
strongly supported adhesion, proliferation, maintenance and function of CM. This is at least 
partly caused by the heterogeneous ECM components of the ADSC-derived ECM. ADSC 
synthesize heterogenic ECM such as basement membrane components (collagen IV, 
laminin), ECM components involved in the wound healing (collagen I and III) and ECM 
components such as elastin found in organs that are continuously stretched/relaxed like 
arteries or myocardium as well as pro-angiogenic fibronectin (20). Furthermore ADSC 
synthesize matricellular proteins i.e. periostin, SPARC, tenascin C and tenascin X. 
Matricellular proteins are upregulated during tissue repair, such as cardiac repair (21). 
Moreover, matricellular protein such as periostin is known for immunomodulatory and 
remodeling properties following MI (22). In physiological wound healing, fibroblasts are the 
professional cells to perform the remodeling of the extracellular matrix, through secretion of 
ECM constituents, but also through secretion of ECM converting proteases (23). ADSC 
resemble fibroblasts in their potency to secrete ECM constituents and thus their potential to 
augment wound healing (24, 25). The advantage of ADSC over fibroblasts is their pro-
angiogenic, anti-apoptotic and immunomodulatory properties through secretion of pro-
inflammatory, pro-angiogenic, mitogenic and survival factors (26, 27). It is possible that the 
decellularized ADSC ECM also harbored i.e. sequestered, at least part of the secreted trophic 
factors of ADSC, yet this was not investigated. ECM components have been recognized as the 
key component for cardiac repair (12). Additionally, the ECM components produced by 
ADSC have been demonstrated as one of the factors that increases angiogenesis (28). This 
suggests that improved perfusion coincides with decrease scar size. Here we demonstrate 
that despite of known paracrine mechanism of ADSC in the cardiac repair, the juxtacrine 
signaling i.e. cell-cell and cell-ECM interaction play a role in that process. The repair of MI 
requires reconstitution of the degraded ECM for adequate de novo cardiomyogenesis and 
vasculogenesis. The ECM components play a key role in both of that processes. Here we 
demonstrate that the ADSC-derived ECM components provide a suitable substrate to 
support CM homeostasis i.e. CM alignment, maturation and synchronized contraction in 
vitro.  This finding supports the use of human, autologous, ADSC as promising modality to 
treat MI. Moreover, i.e. lyophilized ADSC-derived ECM or in a form of injectable biomaterial 
i.e. ECM patches or in combination with ADSC (29) could offer an off-the shelf product for 
the treatment of post-MI complications. Alternatively, ADSC-secreted ECM components 





based on e.g. iPSC-derived autologous cardiomyocytes. The ECM components would 
improve the organization and compaction of the cardiomyocytes on scaffolds. 
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Pericytes in the retina differ from pericytes in many other organs by their high density and 
their cooperative role in the neurovascular unit. Their diverse ontogeny and the fact that not 
one pericyte marker identifies the entire population suggest also functional plurality in the 
retina, including invading cells of mesenchymal origin. Further, to establish factors 
determining pericyte recruitment, modifiers of pericyte adhesion and homeostasis, such as 
notch-3 and angpt l-4, have been recently identified, expanding the understanding of 
pericyte function in the retina. Also, the role of pericytes as part of the neurovascular unit 
has been appreciated, given that the neuroglia determines pericyte survival and motility 
under disease conditions. Pericyte dropout is not unique in the diabetic retina, and non-
diabetic animal models may prove useful in the search for mechanisms involved in disease-
associated dysfunction of the neurovascular unit. 






The retina is the organ with the most abundant pericyte decoration. This abundance and the 
combination of accessibility and availability of mouse models have made the mouse retina a 
popular research tool for vascular biologists. As part of the neurovascular unit and as an 
important player in providing a tight blood–retinal barrier, the pericyte attracts interest 
from many disciplines. Pericyte loss in early diabetic retinopathy continues to direct 
attention to pericyte biology in general, as the mechanisms associated with diabetes and 
leading to pericyte loss are far from being understood.The pericyte remains a mysterious cell 
for several reasons: (a) the unclear ontogeny, (b) the lack of a pan-pericyte marker, and (c) 
the functional diversity of the different populations in the body. For the purpose of this 
review, it remains unclear to which extent pericytes in the retina represent pericyte biology 
in general and how much of the in vitro data from pericytes in culture apply to pericyte 
function in the retina. This review will focus on the pericyte in the retina as opposed to 
pericytes in other organs and emphasize distinctive features by which the retinal pericyte is 
characterized. Pericytes may control endothelial cell survival and proliferation, vascular 
tone, and permeability, and therefore emerge as a key player in microvascular homeostasis 
and response to injury. 
Identification and ontogeny 
Pericytes are regular components of capillaries in the retina [17]. They share a common 
basement membrane with endothelial cells, where they communicate with each other via 
physical contacts and paracrine signaling. In contrast to retinal arteries and arterioles, where 
the coverage consists of single or multilayers of vascular smooth muscle cells (vSMC), retinal 
capillaries are covered by individual pericytes. The density of pericyte coverage of capillaries 
varies from organ to organ, and the retina has been reported to host the highest relative ratio 
of pericytes to endothelial cells (1:1), even higher than the brain [65]. The ratio may be 
needed for the tightness of the blood–retinal barrier in the presence of a high blood flow 
[63]. During the early 1960s, Kuwabara and Cogan proposed a method to dissect the retinal 
vasculature from the neuroglia by the differential susceptibility of both compartments 
towards enzymatic digestions [39]. This method yields a definitive specimen for exact 
quantitative analysis of the ratio of endothelial cells to pericytes in different species, since 
pericytes are identified by the protuberant position within the capillary basement membrane 
and the shape [12] (Fig. 1). 
 
Fig. 1. Retinal digest preparation of a rat retina. Asterisks denote pericytes. PAS staining. 





A major limitation in studying pericyte functionality and structure–function relation has 
been the lack of a pan-pericyte marker [25]. Recent reviews have delineated the counts of 
markers that are validated (PDGF-Rß, NG2, CD 13, ASMA, and desmin) and new markers 
with interesting but still incompletely known properties (RGS5, SUR2, Kir6.1, CD248) [4]. 
Several lineage-tracing studies have indicated that due to the multiple and mixed origin of 
mural cells, vascular cells may represent a mosaic [47]. In contrast to the mesenchymal 
origin of mural cells in many parts of the body, which are located at the outside of a vessel, 
most if not all mural cells in the CNS are derived from the neural crest, as summarized by 
Armulik et al. in a recent review [4]. However, as shown by Heglind et al., only brain surface 
vessels of mice with a ß-gal reporter under control of Foxs1 promoter depicted labeling of 
smooth muscle cells (SMCs) and pericytes [32]. Although the retina is an ontogenic 
diencephalic outpouch of the CNS, the cells labeled in the retina by the same marker were 
located in the outer nuclear layer, suggesting that these are not pericytes, but 
neurons. Pericytes which invade the retina during the formation of the primary retinal 
vascular plexus may be derived from two other potential sources. According to detailed 
studies in the mouse by Fruttiger, retinal vessels form through angiogenesis. In this process, 
pericytes co-invade the retina on an astrocytic template together with endothelial cells [22]. 
Their potential derivation from the bone marrow is demonstrated by using mice in which the 
GFP reporter is under control of the bone marrow-specific stem cell antigen-1 promoter (sca-
1) [45]. Sca-1-positive cells were found to invade the retina on the extraluminal surface of the 
primitive vascular system, migrating to the angiogenic front and sites of vascular remodeling 
in physiological postnatal and pathological angiogenesis of the mouse retina suggesting that 
BM-derived cells contribute to pericyte recruitment to developing retinal capillaries (Fig. 2). 
Noteworthy, recruitment of NG2- and PDGFRb-positive pericytes from bone marrow has 
been demonstrated in postnatal angiogenesis in tumors [57]. The alternative origin of 
pericytes is the mesoderm as suggested by studies of Tidhar et al. They demonstrated that 
pericytes marked by a reporter construct under control of an adipose tissue-specific 
promoter (aP2) were present in the sprouting front of the developing retinal capillaries and 
in adult retinal capillaries (Fig. 3) [69]. This XlacZ4 mouse is widely used as a model to study 
the role of pericytes and SMC because it expresses a reporter gene under control of a 
pericyte/SMC-specific promoter. However, according to our analysis, only 52 % of retinal 
pericytes express the XlacZ4, and the expression is context dependent [55]. Common to all 
markers mentioned above is that they fail to recognize all pericytes at all stages [5]. In the 
human retinal vasculature which forms before birth, vasculogenesis dominates [49]. 
 







Fig. 2. Retinal whole mount preparations of a mouse with a sca-1-GFP transgene at 
postnatal day p5, counterstained with isolectin B4 [red]. a Partial overview depicting a GFP-
positive perivascular cell in an arteriole [marked with a white arrow]. b GFP-positive cell in 




Fig. 3. A retinal whole mount preparation of an adult XlacZ mouse. LacZ-labeled cells are 
pinching out towards the midcapillary parts of the superficial capillary layers.  
 
In general, pericytes can transdifferentiate into various other cell types. For instance, in the 
brain, pericytes can assume phagocytotic properties similar to macrophages or 
transdifferentiate into fibroblasts, and pericytes isolated from multiple other human organs 
including skeletal muscle, pancreas, adipose tissue, and placenta showed myogenic, 
osteogenic, chondrogenic, and adipogenic potentials [6, 13, 19, 71]. Specific for the retina, 
pericytes are able to differentiate along the osteogenic pathway in vitro [19, 62]. However, it 
is presently unknown whether retinal pericytes transdifferentiate into mesenchymal and 
neuroglial cells in the retina in vivo. The stromal vascular fraction (SVF) of bone marrow and 





mesenchymal stromal cells but also as mesenchymal stem cells (MSC), based on their 
plasticity towards cartilage, bone, and fat cell differentiation. Moreover, these MSC can 
differentiate into SMC which, in vitro, are difficult to distinguish from pericytes [14]. In 
recent years, the origin of adipose-derived stem cells (ADSC) has been particularly well 
studied. The SVF-derived ADSC are derived either from the perivascular pericytes or from 
adventitial cells [70]. Adventitial cells lack pericytic markers such as NG-2, RGS-5, and 
PDGFRβ. The March lab has shown that endothelial cells interact with ADSC in co-cultures. 
In a study on tissue engineering of vascularized adipose tissue using endothelial cells, ADSC, 
and ADSC-derived adipocytes, the adipocytes physically interacted with and stabilized newly 
formed vascular structures [66]. The molecular phenotype of these pericyte-like adipocytes 
was, however, not dissected. On monolayers of ADSC, endothelial cells form sprouting 
networks that are comparable to sprouting networks on Matrigel [50]. Moreover, a number 
of studies have shown that ADSC and bone marrow MSC integrate into endothelial sprouting 
networks on Matrigel [10, 70]. We have shown that ADSC not only support formation of 
endothelial tubes, but that multicellular vascular structures are formed that are maintained 
for several weeks through interaction with ADSC (Przybyt et al., unpublished data). Solid in 
vivo evidence that ADSC can acquire a pericytic phenotype or even replace pericytes is 
scarce. However, we have shown in a murine model for retinal pericyte loss that ADSC can 
normalize pathologic capillaries. These ADSC acquired a typical pericytic position in the 
vasculature (Przybyt et al., unpublished data). This shows both that there exists a reciprocal 
plasticity between ADSC and pericytes and that ADSC are a promising tool to alleviate retinal 
pericyte loss. Yet, also endothelial plasticity might extend as far as a mural phenotype. We 
have shown that TGFβ can promote endothelial to mesenchymal transition [EndMT] of adult 
as well as precursor endothelial cells. The phenotype of the cells after EndMT was typically 
smooth muscle like [51, 38]. We have shown that conditioned medium of cells after EndMT 
promotes sprouting angiogenesis in a Tie-2-dependent fashion [51]. Yet, it remains to be 
confirmed that upon EndMT, endothelial cells acquire a genuine pericyte phenotype and 
integrate and stabilize newly formed vasculature. Zimmerlin and co-workers recently 
proposed a challenging hypothesis that pericytes are the major source not only of supra-
adventitial arteriolar-derived ADSC, but also of circulating endothelial progenitor cells. This 
again emphasizes the high plasticity of all microvascular cellular constituents. 
Pericyte recruitment signals 
Developmental angiogenesis in the retina defines endothelial heterogeneity with an impact 
on the recruitment of pericytes and is subdivided into two major phases, sprouting 
angiogenesis where endothelial cells differentiate into tip and stalk cells (environment 
sensing/migration and proliferation), leading to an immature vascular plexus, and 
maturation, which involves recruitment of perivascular cells, arrangement of the basement 
membrane, and formation of junctions and transport systems [15]. 
Pericytes express PDGFRβ, and their attachment to vessels is dependent on PDGF released 
from endothelial cells [43]. During developmental angiogenesis, tip cells express 
more PDGF-B than stalk cells which is consistent with the observation that pericytes 
immediately co-migrate with the angiogenic sprout [25]. During this phase, the PDGF-ß 
receptor is most prominently expressed on pericytes, while it is not detectable in pericytes of 
the adult retina. Perinatal death of mice with a genetic ablation of PDGF-B or 
receptor PDGFR-ß precludes retinal studies. Studies in the brain of homozygous PDGF-B 
mice showed impaired pericyte recruitment and microaneurysm formation which is highly 





reminiscent of early diabetic retinopathy [43]. In subsequent studies using 
heterozygous PDGF-B mice, it was indicated that recruitment of pericytes was defective and 
that a secondary effect of pericyte coverage on endothelial survival was observed in adult 
mice [30]. Mice with an endothelium-restricted ablation of PDGF-B revealed a dose-
dependent effect on pericyte recruitment and vasoregression. Pericyte loss up to 50 % in 
brain capillaries was accompanied by capillary dropout in the retina, whereas pericyte 
deficits exceeding 50 % in the brain induced secondary proliferative retinopathy [18, 68]. 
A second receptor–ligand system exists which determines pericyte recruitment in the retinal 
microvessels. Current data suggest that angiopoietin-1 (Ang-1) is produced by pericytes in 
the retina which provides stabilizing signals to endothelial cells, thereby reducing 
permeability and promoting vascular maturation [27,23]. The reciprocal orientation of the 
Ang-Tie and the PDGFB/PDGF-ßR system with overlapping functional roles underlines the 
importance of a stable microvascular network in the retina [23]. Ang-1 signals via the 
receptor tyrosine kinase Tie2 whose signaling is differentially regulated through the natural 
antagonist angiopoietin-2 which can inhibit phosphorylation of Tie2, induced by Ang-1 [46]. 
Injection of recombinant Ang-2 into the vitreous of a non-diabetic rat reproduces pericyte 
dropout, and constitutive overexpression of Ang-2 in the posterior retina induces pericyte 
reduction in the adjacent deep capillary layer of the retina [31]. The expression of Tie2 may 
not be endothelial cell specific as evidence by Tie2 reporter mice which demonstrated Tie2 
expression in pericytes of angiogenic vessels ([9]; HP Hammes and U Deutsch, 
unpublished). In turn, Ang-1 overexpression or absence of Ang-2 results in increased 
vascular branching and remodeling into larger capillary diameters on the arteriolar site of 
the network suggesting that the ratios of growth factors rather than absolute levels 
determine pericyte function in vivo [21]. 
Recently, another player of the angiopoietin family, angiopoietin-like-4 (ANGPTL4), was 
identified as having a role in pericyte recruitment, physiological and pathological 
angiogenesis, and permeability. ANGPTL4 knockout mice presented with a 20 % reduction 
in NG2-positive pericytes, a pertubation of caveolae, and adhesion molecules such as VE-
cadherin and ZO-1, and substantially increased leakage of retinal capillaries. It was noted 
that ANGPTL4 is not involved in pericyte recruitment per se, but pericytes fail to spread on 
angptl4-deficient endothelial cells [54]. 
Yet another ligand which determines retinal pericyte investment is Notch3, which regulates 
arterial–venous differentiation within developing arteries. In the human cerebral autosomal-
dominant arteriopathy with subcortical infarcts and leukoencephalopathy, Notch3 is 
mutated leading to degeneration of mural cells. In the retina of Notch3 knockout mice, 
pericyte apoptosis is increased, and the numbers of ASMA-positive pericytes are reduced 
[40, 34, 59]. Co-validation with the pericyte marker NG2 revealed a 58 % loss of mural cells 
[vSMCs and pericytes] in retinal vessels. Concomittantly, pericytic Ang2 expression was 
reduced in Notch3−/− mice indicating a mediator function, in particular since angiogenesis 
in the ROP model was reduced [44]. 
It is long known that TGF-ß, which is produced both in endothelial cells and in mesenchymal 
cells, is involved in the final stabilization of microvessels (see [33] for an overview). The 
collaborative expression and functional activation of TGF-ß requiring both cell divisions 
underscore the complexity of TGF-ß function which is further augmented by the 





genetic ablation of TGF-ß, its receptors, and the downstream signaling pathways are 
embryonically lethal, a distinct role in the retina is difficult to identify. In the brain, some 
link to reduced mural cell coverage in TGF-ß receptor signaling [SMAD-4] knockout mice 
has been identified [41]. 
Despite differences between the retina and brain with regard to the pericyte ontogeny and 
function, like the blood–brain barrier, the blood–retinal barrier integrity depends on tight 
inter-endothelial and endothelial–pericyte connections [1]. Of particular importance for the 
cohesion of adjacent capillary endothelial cells is VE-cadherin, while N-cadherin promotes 
the attachment of pericytes to the underlying endothelium and thereby ensures the integrity 
of BRB [16, 25]. VE- and N-cadherin are regulated by S1P, a sphingolipid metabolite found in 
high concentrations in platelets and blood and on pericytes. Studies in mice in which the 
receptor for S1P is specifically deleted from endothelial cells demonstrated that S1P-receptor 
signaling in the endothelium is critical for the regulation of pericyte recruitment, 
attachment, and vascular maturation [3]. More recently, McGiure demonstrated that retinal 
pericyte-derived sphinogosine 1-phosphate increases the barrier properties of endothelial 
cells by induction of VE- and N-cadherin and downregulation of Ang-2 [48]. Whether 
pericyte-derived S1P and subsequent expression of N-cadherin are altered in the diabetic 
retina is not clear so far. 
Pericytes in the neurovascular unit 
Pericyte coverage of retinal capillaries and proper function of the blood–retinal barrier are 
closely linked. Like in the brain, the BRB consists of the endothelial lining of retinal 
capillaries, pericytes in basement membrane pockets, enwrapped by glial cells (astrocytes in 
the superficial layer and Müller cells in the deep capillary layer), neurons, and microglia 
around the superficial vascular layer [11]. In general, the tight association between retinal 
vascular and glial cells implies a close functional relationship between these two cell types 
and suggests that changes in one have profound consequences for the other. Like the brain, 
the retina contains glial cells, which are normally quiescent but adopt a reactive state during 
infection, injury, and also diabetes. In diabetic rats, activation of the principle glia cell, the 
Müller cell, induces the expression of a variety of angiogenic growth and trophic factors, 
cytokines, acute-phase response proteins, and other inflammatory genes, which can have an 
impact on retinal vasculature [8]. 
As mentioned above, tightness of the BRB depends on several factors including proper 
function of junctional molecules between endothelial cells, undisturbed heterotypic cell 
contacts between endothelial cells and pericytes, and regular perivascular cell homeostasis. 
These characteristics preclude passive transport of cells and proteins, but also of therapeutic 
agents from into retinal tissues. The dominant role in BRB tightness is played by the 
endothelium, and multiple components have been identified whose disturbance is associated 
with a breakdown of the blood retinal barrier (reviewed in [11]). The most prominent role for 
pericytes in this context relates to the production of basement membrane components, 
adhesion, and tight junction molecules, including proteoglycans, N-cadherin, claudins, 
JAMs, ZO 1 and 2, and occludin. These cells also express several barrier-related transporters 
like ABCG2, P-gp, MRP 1, and GLUT-1 suggesting an active role in NVU communication 
[61]. The strongest permeability-enhancing cytokine—vascular endothelial growth factor—
does not cause changes in pericyte recruitment, indicating that permeability-enhancing 
mechanisms targeting the endothelium overrule mechanisms affecting pericyte survival 





[67]. Pericytes can respond in vitro to inflammatory stimuli by production of cytokines such 
as interleukins, NO, and CCLs, at least in the brain, suggesting that, under disease 
conditions, pericytes can affect BRB patency [37]. Contractility of pericytes has been invoked 
as an essential property of the cells that determines capillary permeability 
[26, 56]. Pericytes contain both smooth muscle and nonsmooth muscle isoforms of actin and 
myosin, however, with an uneven distribution within the pericyte population [52]. Several 
factors have been identified that regulate pericyte contractility. Among the vasoconstrictive 
cytokines and hormones are alpha 2-adrenergic agonists, cholinergic agonists, histamine, 
serotonin, angiotensin II, and endothelin-1, whereas beta-2 adrenergic agonists, NO, and 
atrial natriuretic peptide lead to a dilatation of the pericyte-covered capillaries [60]. As 
demonstrated in in vivo studies, pericytes in brain and retinal capillaries constrict in 
response to electrical stimulation, superperfusion with ATP and noradrenalin. These data 
suggest that pericytes control capillary blood flow in response to local modulation by 
vasoactive mechanisms [53]. However, Armulik et al. have expressed concern about 
pericytes controlling blood flow, which applies in particular to the retina [4]. The absence of 
in vivo data showing blood flow changes in retinal capillaries, the difficulty to unequivocally 
identify pericytes in vivo, and the physical constitution of midcapillary pericytes in the retina 
represent some of the concerns which have to be addressed by future research. 
Lessons from animal models 
Pericytes are lost during aging and in all diabetic models studied so far in our laboratory, 
using retinal digest preparations and quantitative retinal morphometry [27, 20]. In rodent 
models, the pericyte dropout starts around 2 months after diabetes induction and thus 
precedes the development of acellular capillaries (vasoregression) by several months. 
Vasoregression is considered the most predictive diabetes-induced lesion in the retina apart 
from increased vascular permeability. However, since rodents do not have a macula, their 
type of capillary leakage may not directly correspond to the type of leakage in diabetic 
macular edema in humans. 
 
__________________________________________________________
Fig. 4. Postmortem retinal digest preparation of a type 2 diabetic patient. Note the capillary 






Pericyte dropout in diabetes occurs throughout the entire retina at a comparable extent, 
indicating a causal link to the metabolic changes that appear in diabetes [35]. As the 
perimacular retinal network is particularly sensitive to increased leakage, the question was 
raised whether pericyte dropout occurs preferentially in this area. However, preliminary 
studies in retinae of human type 2 patients revealed that pericytes drop out in the 
perimacular network at the same level as in the rest of the retina (R Schlingemann, I 
Klaassen, and HP Hammes, unpublished). 
The onset and time course of pericyte loss in the human aging and diabetic retina are 
unknown as appropriate tissue samples are missing. However, in rodent animal models of 
DR, either spontaneously diabetic or by chemical induction, a significant loss of pericytes 
occurs already after 2 to 3 months depending on the strain used and severity of 
hyperglycemic metabolism. After 6 months of experimental diabetes, pericyte numbers are 
reduced by 15–50 % (Pfister et al., unpublished observations; [36, 31]), and other typical 
morphological signs of DR, such as acellular capillaries, develop [27]. The underlying causes 
and mechanisms of early pericyte dropout in DR and the aging retina remain still unclear. 
On one side, biochemical alterations, such as increased production of ROS, AGEs and the 
activation of biochemical pathway as the hexosamine pathway and the PKC pathway, directly 
damage vascular and nonvascular cells of the retina [28]. However, there is only little 
information whether and how retinal microvascular pericytes in situ are specifically 
damaged by hyperglycemia, and reports about hyperglycemia-induced apoptosis are 
contradictory. Activation of pro-apoptotic signaling and apoptosis in pericytes, but also in 
endothelial and neuroglial cells, has been documented in diabetic retinas of rodents and 
patients [29, 42,58]. Biochemical changes, such as intracellular ROS, AGE, and other 
aforementioned bioactive intermediates of glycolysis, are themselves harmful for cells when 
present in abundance, and activation of downstream targets of these biochemical changes, 
such as RAGE, PKC, and NF-κB, might contribute to the activation. In vitro, AGEs can 
induce dose- and time-dependent apoptotic effects on pericytes, and it has been recently 
demonstrated that AGEs, like tumor necrosis factor TNF-α, induce pericyte apoptosis 
through activation of the transcription factor FOXO1, mediated in part by p38 and JNK MAP 
kinases [2]. Repeated injection of high doses of AGE-modified proteins can induce selective 
pericyte loss in non-diabetic rats after 2 weeks [73]. Moreover, endogenous AGEs can 
accumulate in pericytes [7]. It is thus speculated that pericytes take up AGEs from the 
circulation or from the direct vicinity suggesting a clearing function under specific 
conditions. Since the tissue load with AGEs changes over time in the aging retina and 
diabetes, the role of pericytes as AGE removing cell compartment becomes increasingly 
relevant. However, the time course of AGE accumulation in pericytes is inconsistent with the 
time course of pericyte loss in diabetes, indicating that AGEs are not solely responsible for 
pericyte loss. Furthermore, NF-κB activation and increase of extracellular matrix protein 
βIG-H3 is regarded as key mediator for retinal cell apoptosis, but more recently, it has been 
demonstrated that hyperglycemia persistently activates PKC-δ and p38 mitogen-activated 
protein kinase [MAPK] leading to pericyte apoptosis and vasoregression independently 
of NF-κB [24]. Altogether, a number of possible mechanisms have been suggested to explain 
vascular cell apoptosis in the diabetic retina. It is clear, however, that the frequency of 
apoptotic pericytes in retinal digest specimens is low and does not explain the number of 
pericytes lost after several months of diabetes. Alternatively to early pericyte loss in diabetic 
retinopathy being the result of hyperglycemic injury, a different concept was proposed. It is 
possible that pericyte loss is an active process involving migration of pericytes away from the 





capillaries, driven by the angiopoietin-Tie system. As described above, gain of function 
experiments in non-diabetic animals revealed the induction of pericyte dropout in the 
vicinity of the Ang-2 overexpressing site. Superimposition of diabetes aggravated the most 
important vascular readout, i.e., the formation of acellular capillaries. Loss of function 
studies in the presence of diabetes yielded the prevention of pericyte dropout and the 
reduction of acellular capillary formation [55]. Ang-2 is expressed in three cell types of the 
retina, i.e., the endothelial cell, the Müller cells, and the horizontal cells. In situ hybridization 
of diabetic retinae with Ang-2 yielded the expression particularly in Müller cells. The 
regulation of Ang-2 in chronic hyperglycemia has been recently addressed, and it was found 
that increased glucose flux in renal microvascular endothelial cells caused increased 
modification of the corepressor mSin3A by methylglyoxal resulting in recruitment of the 
enzyme O-GlcNAc transferase to an mSin3A-Sp3 complex. Subsequently, Sp3 modification 
by O-linked N-acetlyglucosamine decreased its binding to a glucose-responsive GC box in the 
Ang-2 promoter and the activation of Ang-2 transcription [72]. The same mechanism was 
operative in retinal Müller cells consistent with in vivo data from retinae of diabetic rats and 
mice. These data are consistent with the novel hypothesis, i.e., that pericyte loss is actively 
induced by glial cells overexpressing Ang-2 in response to high glucose. 
Future questions 
From the above, it shines through that the retina and its pericytes may be different from 
other tissues, given the facts about ontogeny, relative density on the capillaries, and 
communication within the neurovascular unit. Even more complexity is added in disease, in 
particular when considering two recent observations. Simonavicius et al. reported that 
pericytes are able to promote endothelial cell death in an endosialin-dependent fashion, 
suggesting that pericytes have opposing effects on endothelial cells [64]. In line with this 
study in preclinical models of physiological and pathological angiogenesis, we observed in 
human retinae of type 2 diabetes capillary areas which were devoid of endothelial cells, but 
not of pericytes (Fig. 4). This strongly votes for a differentiated view on pericyte pathobiology 
in the retina. 
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Abstract            
Diabetes-induced micro- and macrovascular complications include vasoregression and 
impaired neovascularization, which affects all organs including the eye. Pericytes are 
important in angiogenesis, vessel maturation and maintenance. Similarly, adipose-derived 
stem cells (ADSC) are proangiogenic, yet little is known about their pericytic capacity or the 
influence of inflammation and hypoxia on ADSC function. We hypothesized that ADSC 
induce promote hypoxia-induced angiogenesis and vascular stabilization. ADSC acquired a 
pericytic phenotype in vitro and in vivo. Co-culture of ADSC and endothelial cells resulted in 
formation of stable vascular structures. ADSC injected intravitreally in the oxygen-induced 
retinopathy model (OIR) enhanced angiogenesis and co-localized with capillaries at a 
pericyte-specific position. This associated with increased expression of Ang-1, FGF-2, TNF-α, 
IL-8 and reduction of Ang-2 in OIR retinas. Similarly, ADSC upregulated Ang-1, FGF-2 and 
VEGF-A under hypoxic and inflammatory conditions in vitro. ADSC promote vessel 
formation and stabilization by acquiring pericyte properties. In recent years ADSC have 
entered clinical trials for cardiac stem cell therapy. Thus, this easily accessible source of stem 
cells is promising to treat vascular complications of diabetes such as diabetic retinopathy or 
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Diabetics have an increased risk for cardiovascular complications due to diabetes-
induced endothelial dysfunction. The continuous exposure of the vasculature of diabetics to 
hyperglycemia causes significant vasculopathies that range from atherosclerosis of large 
vessels to microvascular disease such as diabetic retinopathy (DR) [1].  The microvascular 
complications are characterized by pathomechanisms including ROS- and AGE-induced cell 
damage, vascular destabilization and impairment of specialized endothelial barrier [2,3]. The 
lack of pericytes associates with leaky vessels in edema and in DR. The loss of pericytes 
initiates breakdown of the blood-retinal barrier and endothelial cell (EC) apoptosis [4]. 
Resulting local tissue hypoxia switches retinal capillaries to a pro-angiogenic mode, which 
results in extensive endothelial proliferations [5]. These neovascularizations are fragile and 
commonly lead to repeated bleedings followed by scar formation, which may cause 
blindness. Thus, in adjunction to conventional therapies of diabetes type 2 and its 
complications, pro- and anti-angiogenic agents, as well as vasoprotective therapeutics are in 
focus of diabetes research. 
In the healthy mature microvasculature, pericytes protect and control EC survival and 
proliferation, vessel integrity and susceptibility of vascular cells to environmental stimuli 
[6,7]. During angiogenesis, pericytes are recruited to growing vessels by secretion of PDGF-B 
from tip cells of the angiogenic front to stabilize microvessels and maintain vessel barrier 
[8]. The Tie-2-angiopoeitin system is pivotal in the maintenance of pericyte-endothelial 
interaction [9]. In established capillary networks pericyte-derived angiopoeitin-1 mediates 
maturation and quiescence of the microvascular endothelium by suppression of endothelial 
activation, proliferation and induction of cell contact. In contrast, the antagonist of Ang-1, 
angiopoietin-2 is upregulated under hypoxic, inflammatory and hyperglycemic conditions, 
inducing vascular destabilization and endothelial proliferation, thereby promoting 
angiogenesis and vascular leakage. Hyperglycemia induced upregulation of Ang-2 in the 
diabetic retina leads to pericyte loss and subsequently vasoregression of retinal capillaries 
[10]. Thus, restoration of pericyte function is pivotal for treatment of diabetic microvascular 
complications. 
Application of cells that share a pericytic origin has emerged as an approach for 
vascular repair [11,12]. For instance, co-implantation of bone marrow mesenchymal stem 
cells (BM-MSC) with HUVEC or ADSC with EPC in a collagen-based construct induced 
stable vascular network formation in SCID mice [13,14]. Clinical data on patients with 
infusion of bone marrow MSC show augmented vascular network formation [15,16]. Adipose 
tissue represents a vast reservoir of MSC i.e. Adipose-Derived Stem Cells (ADSC). 
Meanwhile, ADSC have reached experimental clinical stem cell therapy for treatment of 
cardiovascular disease [17]. Several studies indicate that ADSC are of perivascular origin [18-
20]. The question arises whether cultured ADSC could acquire pericyte function and thus 
promote vessel stabilization and protection in vascular complication of diabetes.  The 
microenvironment of the host tissue dictates the plasticity and the regenerative potential 
administered therapeutic cells [21,22]. The local microenvironment in the diabetic retina like 
other diabetic tissues is characterized by hyperglycemia, hypoxia and inflammation [23]. 
Remarkably, hypoxic and proinflammatory preconditioning augments the regenerative 
potential of ADSC [24-26]. This potential comprises of secretion of pro-angiogenic factors 





We hypothesized that ADSC support vascular network formation in vitro and in vivo, 
through paracrine and juxtacrine mechanisms, i.e. through acquisition of pericyte 
properties. The hypothesis was tested in vitro through co-culturing and monitoring ADSC 
and EC interactions in vascular network formation. Furthermore, the angiogenic potential of 
ADSC in hypoxia-driven neovascularization was analyzed in the OIR model and expression 
of angiogenic growth factors, such as VEGF-A, Ang-1, Ang-2 and FGF-2 were assessed in OIR 
retinas and in ADSC cultured under hypoxic and proinflammatory conditions.  
Research Design and Methods 
Cell isolation and culture 
ADSC were isolated from human adipose tissue as described previously [30]. Cells 
were seeded in culture flask at 4·104/cm2 in DMEM (Lonza Biowhittaker, Verviers, Belgium), 
10% FBS (Thermo Scientific, Hemel Hempstead, UK), 100 U/ml penicillin, 100 mg/ml 
streptomycin (Invitrogen, Carlsbad, CA). 
Human umbilical cord endothelial cells (HUVEC) were cultured on gelatin-coated 
culture flasks in EC medium (ECM-RPMI1640 (Lonza Biowhittaker Verviers, Belgium), 20% 
FBS (Thermo Scientific, Hemel Hempstead, UK), 100 U/mL penicillin, 100 mg/mL 
streptomycin (Invitrogen, Carlsbad, CA), 2 mM L-glutamine (Lonza Biowhittaker, Verviers, 
Belgium), 5U/ml heparin (Leo Pharma, The Netherlands) and  5µg/ml of EC growth factor 
(ECGF, [31]) .  
Immunofluorescence analysis 
Freshly isolated ADSC (30,000 cytospined cells/slide) and ADSC p1 (10,000 cells/cm2) were 
fixed in 2% paraformaldehyde at RT for 20 min. Next, cells were permeabilized with 0.5% 
Triton X-100 in PBS (Sigma-Aldrich, MA). Subsequently, samples were incubated with 
primary antibody to goat-anti-human-RGS5, to rabbit-anti-human PDGFRβ (both 1:100, 
Santa cruz, Heidelberg, Germany) and to rabbit-anti-human-NG-2 (1:100, Millipore, 
Darmstadt, Germany) for 1h. Samples were washed with PBS and incubated with 
fluorescein-conjugated goat-anti-rabbit antibody or rabbit-anti-goat-IgG (1:400, Jackson 
Immunoresearch, UK). Stained samples were mounted in Citifluor (Agar Scientific, UK). 
Examination was performed by immunofluorescence microscopy using a Leica DMRXA 
microscope and Leica software (Leica Microsystems).  
Immunofluorescence analysis of co-culture 
ADSC were plated on 15 mm Termanox coverslips (NUNC, Rochester, NY) at 10,000 
cells/cm2 in DMEM, 10% FBS for 24h. Next, medium was replaced with ECM for 5 days. 
HUVEC were seeded in on ADSC monolayers or on gelatin-coated coverslips at 10,000 
cells/cm2 in ECM and cultured 5days after which vascular networks had formed. Post-
processing was as described in the previous section. Staining was performed with goat-anti-
human-RGS5 (1:100, Santa cruz, Heidelberg, Germany), mouse-anti-human-CD31 (1:100, 
Dako, Glostrup, Denmark), rabbit-anti-human-N-cadherin (1:100, Abcam, Cambridge, UK) 
and rabbit-anti-human-Connexin43 (1:100, Invitrogen, CA) for 1h. Samples were washed 
with PBS and incubated with the Cyanine3-conjugated-rabbit-antibody to goat-IgG (for 
RGS5) and fluorescein-conjugated-donkey-antibody to mouse-IgG (for CD31) (1:400, 
Jackson Immunoresearch, UK) and to fluorescein-conjugated-goat-to-rabbit IgG (for Cx43 
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and N-cadherin) (1:400, Jackson Immunoresearch, UK). Post-processing for microscopy was 
as described above.  
Sprouting assay 
ADSC and HUVEC were labeled respectively with the CM-DiI-red and CFDA-SE -green 
according to the manufacturer’s instructions (both Invitrogen, Grand Island, NY). 
Angiogenesis was determined using 15 well angiogenesis μ-slides (Ibidi GmbH, Martinsried, 
Germany) coated with growth factor reduced Matrigel (Becton Dickinson, Bedford, MA)  
according to the manufacturer’s instructions. HUVEC and ADSC were seeded alone or in 1:1 
ratio of total 10,000 cells/well and monitored by fluorescent microscopy over a period of 
12h. Sprouting networks of HUVEC had formed after 6h. At that point 5,000 ADSC or 
culture medium were added to the sprouted HUVEC and monitored for another 6h.  
Ultrastructure analyses 
Cell culture samples of HUVEC, ADSC and co-cultures were fixed in 2% Glutaraldehyde 
(Polysciences, Germany) in 0.1M Sodium Cacodylate buffer at 4˚C for 24h. After washing 
with 0,1M Sodium Cacodylate, samples were post-fixed using 1% Osmium Tetroxide/1.5% 
Potassium-Ferrocyanide in 0.1M Sodium-Cacodylate for 30 min on ice. Next, samples were 
dehydrated with ethanol and embedded in EPON 812 (Serva, Germany) and polymerized at 
37˚C for 16 h followed by 56˚C for 24h. Thick sections (0.5 m) and ultrathin sections (60 
nm) were cut on a Reichert ultramicrotome and stained respectively with 1% Toluidin-Blue 
and 2% Uranyl-acetate in methanol and in Reynolds-lead-citrate for 2 min.  Imaging was 
performed using a Cm100 Biotwin transmission electron microscope (FEI, The Netherlands) 
operated at 80 kV, equipped with a Morada camera (Olympus-SIS, Germany).  
Animals and OIR model 
C57Bl/6J mice were housed in groups in cages with free access to standard chow and water 
under a 12h light and 12h dark rhythm. To study the effect of ADSC on hypoxia-driven 
angiogenesis, newborn mice were subjected to the model of Oxygen-Induced Retinopathy 
(OIR) [32]. Mice at postnatal day 7 were exposed to 75% oxygen atmosphere for five days 
with their nursing mother, and then returned to room air at postnatal day 12 (see Fig. 5). 
Directly after return to room air, randomly selected mice were intravitreally injected under 
anesthesia with either 1µl of PBS containing approx. 10,000 ADSC or 1µl of PBS alone as 
control (Hamilton, Microliter Syringes). Eyes were enucleated under deep anesthesia at p14 
for immunofluorescence analysis, at p14 and p19 for quantitative PCR analysis and at p17 for 
quantification of neovascularization. After collection, eyes were immediately fixed in 4% 
buffered formalin or stored at -80° for following analysis. All animal experiments in this 
study were approved by the Institutional Animal Care and Use Committee and were 
performed according to guidelines of the statement of animal experimentation issued by the 
Association for Research in Vision and Ophthalmology (ARVO). 
 
Quantification of hypoxia-driven neovascularization 
Neovascularization in retinas was assessed in paraffin sections of p17 animals injected with 
ADSC or control at p12. To this end, sections (6μm) were stained with Periodic-Acid-Schiff 
(PAS).Nuclei of neovessels at the vitreous side of the inner limiting membrane of the retinas 
were counted as described previously on blinded specimens [33]. Data were expressed as 
mean number of nuclei per section per animal. 





Whole mount retinas from p14 animals were permeabilized and treated with 1% BSA and 
0.5% Triton-X100 at room temperature for 1h. Overnight staining was with FITC- or TRITC-
labeled isolectin-B4 (Sigma, 1:50) at 4°C. After PBS washes retinas were flat-mounted in 
50% glycerol and micrographs were obtained with a fluorescence microscope (Lectin-
FITC/ADSC-Dil red staining; Leica BMR, Bensheim, Germany) or a confocal microscope 
(Lectin-TRITC/ADSC-GFP staining; Leica TCS SP2 Confocal Microscope, Leica, Wetzlar, 
Germany). ADSC’s presence was revealed through their pre-injection label, which was either 
CM-DiI-red or EGFP (lentiviral tag).  
 
Gene transcript analysis  
The gene expression profiles of pericytic and mesenchymal markers of freshly isolated ADSC 
and plastic adherence selected fraction after passage 1 were compared. ADSC (p1) were 
cultured under normoxia (21% O2) or hypoxia (2% O2). Inflammation was mimicked by 
continuous stimulation with IL-1β (10 ng/ml Peprotech, Rocky Hill, NJ) or none as a control 
for 24 and 48h. RNA was extracted using Trizol Reagent (Life technologies, Carlsbad, CA) 
according to the manufacturer’s protocol. Retinae were isolated from frozen eyes of OIR 
exposed and control mice at p13 (n=5) and OIR exposed at p19 in a presence of ADSC 
injection or PBS as a control (n=5). Retinae were homogenized and total retinal RNA was 
isolated from individual retinae using the RNeasy Mini Plus kit (Qiagen, Leusden, The 
Netherlands). Afterwards, 1µg of total RNA was reverse transcribed using the First Strand 
cDNA synthesis kit (Fermentas UAB, Vilnius, Lithuania) according to manufacturer’s 
instructions. The cDNA equivalent of 5ng RNA was used for amplification in 384-well 
microtiter plates in a TaqMAN ABI7900HT cycler (Applied Biosystem, Foster City, CA) in a 
final reaction volume of 10µl containing 5µl SyberGreen universal PCR Master Mix (BioRad, 
Richmond, CA) and 6 µM primer mix (forward and reverse). Cycle threshold (CT) values for 
individual reactions were determined using ABI Prism-SDS 2.2 data processing software 
(Applied Biosystem, Foster City, CA). The CT values were normalized to GAPDH as a 
reference gene using the ΔΔCt method, normalizing for the expression of the reference gene 
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Table 1. Primer sequence for qRT-PCR  
Human  Forward Reverse 
CD 31 5'-ATAGCCTCAAAGTCGGACAG-3' 5'-CTGGGCATCATAAGAAATCC-3' 
CD34 5'-ACTCTTTTTGGGCTCCTTTT-3' 5'-AGCCTCAGAGGAAGAGGATT-3' 
CD105 5'-GGAAGGGAGAACTTGAAACA-3' 5'-CTCCCCTGCCAGTTAGTTAG-3' 
SM22alpha 5’-GGCCAAGGCTCTACTGTCTG-3’ 5’-CCCTTGTTGGCCATGTCT-3’ 
Calponin 5’-TGAAGTACGCAGAGAAGCAG-3’ 5’-CAGCTTGGGGTCGTAGAG-3’ 
Desmin 5’-CATCGCGGCTAAGAACATTT-3’ 5’-TGTTGTCCTGGTAGCCACTG-3’ 
Angiopoetin-1 5'-CTACTGGGCCTCCTCTCATA-3' 5'-TCTCAAATGGAGGAAACCAT-3' 
Angiopoetin-2 5'-CAGTTCTTCAGAAGCAGCAA-3' 5'-TTCAGCACAGTCTCTGAAGC-3' 
VEGF-A 5'-CCTGAAATGAAGGAAGAGGA-3' 5'-AAATAAAATGGCGAATCCAA-3' 
FGF-2 5'-CTGTACCCATACAGCAGCAG-3' 5'-CGCCTAAAGCCATATTCATT-3' 
GAPDH 5'-GATCCCTCCAAAATCAAGTG-3' 5'-GCAGAGATGATGACCCTTTT-3' 
Murine Forward Reverse 
Angiopoetin-1 5'-GCCAACATGTGTGTAGCAAT-3' 5'-CTAATTTTTCTGCCCTGCAT-3' 
Angiopoetin-2 5'-TAAGTAGCATCAGCCAACCA-3' 5'-GCAGATGCATTTGTCATTGT-3' 
VEGF 5'-TTGCTAACACTCAGCTCTGC-3' 5'-TTTCAAAGGAATGTGTGGTG-3' 
FGF-2 5'-TACTTACCGGTCACGGAAAT-3' 5'-TTCGTTTCAGTGCCACATAC-3' 
PDGF-B 5'-GCACAGACTGGAGGAACTCT-3' 5'-TCCATCAGAGAAGGTGTGTG-3' 
TGF-β1 5'-ACAATTCCTGGCGTTACCT-3' 5'-CAGTGACGTCAAAAGACAGC-3' 
CD31 5'-TCAAATTGCAGGAGTCAGAA-3' 5'-GTGTCCACTGTACTCGACCA-3' 
Collagen IV 5'-ACGTGCAATTACTACGCAAA-3' 5'-TGGACAGTGAGGTACACAGG-3' 
IL-1β 5'-TGTACAAGGAGAACCAAGCA-3' 5'-TGTGCCGTCTTTCATTACAC-3' 
TNF-α 5'-ATTCCTGAGTTCTGCAAAGG-3' 5'-AAGGTAGGAAGGCCTGAGAT-3' 
IL-8 5'-ATACTGCCTCCTACCCATCA-3' 5'-CACTTGCCATTTTCTCTCCT-3' 
MCP-1 5'-GATGATCCCAATGAGTAGGC-3' 5'-TACAGCTTCTTTGGGACACC-3' 
GAPDH 5’-AGCTTGTCATCAACGGGAAG-3’ 5’-TTTGATGTTAGTGGGGTCTCG-3’ 
 
Statistical analysis 
All the data are presented as a means +/- SEM and were analysed by GraphPad Prism 
(GraphPad Software Inc.). Statistical significance was determined using one-way ANOVA 
with Bonferroni post-hoc analysis. Values of p<0.05 were considered statistically significant. 
Results 
ADSC plastic adherence fraction acquire mesenchymal and pericyte phenotype 
Prior to seeding, freshly isolated ADSC expressed EC markers genes i.e. CD31 and CD34, that 
were lost during culturing of the first passage (P1) (Fig. 1A). Simultaneously, P1 ADSC 
increased gene expression of the mesenchymal cum pericytic markers CD105, SM22alpha, 
Calponin and Desmin (Fig. 1A). Freshly isolated ADSC did not express the pericyte markers 
NG2 and PDGFRβ, however RGS5 was weakly expressed (Fig. 1B). Upon culturing, ADSC 







Figure 1. ADSC plastic adherence fraction acquire mesenchymal and pericyte 
phenotype. A) Gene transcript analysis of freshly isolated ADSC and after culture (passage 
1) based on adherence to tissue culture plastic. Concomitantly with a decrease of EC markers 
CD31, CD34 in passage 1 in compare to freshly isolated ADSC, the mesenchymal gene 
expression markers i.e. CD105, SM22α, Calponin and Desmin increased.  Gene expression 
was normalized to GAPDH. Graphs represent triplicates (with SEM) data from n=3 
independent experiments from 3 donors.  B) Representative images of freshly isolated 
fraction of ADSC and after culture based on adherence to plastic from passage 1 probed for 
pericyte markers NG2, PDGFRβ and RGS5 (all: green). ADSC acquired a mesenchymal-
pericytic phenotype in culture.  
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Supplementary Figure 1. ADSC plastic adherence fraction mentains 
mesenchymal and pericyte phenotype in culture. Representative images of freshly 
isolated fraction of ADSC and after culture based on adherence to plastic from passage 1 to 
passage 3 probed for pericyte markers NG2, PDGFRβ and RGS5 (all: green). ADSC acquired 
a mesenchymal-pericytic phenotype in culture.  
 
Monolayers of ADSC induce formation of vascular networks 
The seeding of EC on a confluent layer of ADSC resulted in spontaneous formation of 
vascular network-like (VN) structures that did not form in control cultures of either EC or 
ADSC (Fig. 2A). In contrast to the underlying layer of ADSC, only the VN expressed CD31 
which confirmed their endothelial nature (Fig. 2B). In control mono-cultures of ADSC no 
expression of endothelial markers such as CD31 was detected and HUVEC never expressed 
RGS5. Within the VN, EC had established cell-cell contacts including adhesion junctions as 
shown by pronounced cell membrane-associated expression of N-cadherin (Fig. 2C) and gap 
junctions as shown by connexin-43 expression (Fig. 2D). This is reminiscent of adhesions in 








Figure 2. Monolayer of ADSC induce formation of vascular networks. A) 
Representative light microscopy images of confluent layers of ADSC, HUVEC and co-cultures 
of HUVEC seeded on top of a confluent layer of ADSC. Within 5 days of co-culture the ADSC 
layer guided HUVEC to form vascular network.  B) On protein level, the samples of ADSC, 
EC and in co-culture identified expression of pericyte marker RGS5 (red) in the ADSC and 
endothelial marker CD31 (green) only in the endothelial layer and in the endothelial vascular 
network. C) To validate the junctions formation in the vascular network of HUVEC cultured 
on top of ADSC layer, the samples were probed with the C) N-cadherin (green) and D) 
connexin-43 (red) and prominently found between the EC within the vascular network.  
 
Ultrastructure of ADSC-induced vascular networks 
The 0.5 µm cross sections showed that interconnected laminar structures (dotted lines) had 
been formed by co-cultures of EC (arrows) and ADSC (closed arrow heads) at day 5 (Fig. 3A).  
By the longitudinal sections the build up of the 3D structures, i.e. many vessel-like structures 
with lumen (L) surrounded and tightly aligned by ADSC could be observed (Fig. 3B, C). 
Electron-microscopy revealed that real vascular networks were formed by; the organization 
of EC with their specific cell-cell junctions (Fig. 3E- I, open arrow heads), basement 
membrane formation (Fig. 3F- I, black asterisks) and maturation of the adjacent ADSC into 
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muscle like and pericyte like cells (Fig. 3G, white asterisks). The latter characterized by the 
typical “peg-and-socket” processes of ADSC connected to the endothelium (Fig. 3F, G, 
lightning symbol). 
________________________________________________________ 
Figure 3. Ultrastructure of ADSC-induced vascular network. 
Light microscopical overview and ultrastructure of the ADSC-induced vascular networks in 
co-cultures of HUVEC and ADSC at day 5. A-C) Representative light microscopy images of 
the co-cultures: A) Representative parallel-section (i.e.top view of the culture) shows the 
formation of a vascular network (arrows – EC) demarked by the dotted lines, lumen (L) has 
been formed with ADSC (black arrow heads) aligning vascular structures in close contact. B) 
Representative cross-section of the lumen-containing (L) 3D vascular structures in between 
(interrupted) layers of ADSC. C) Enlargement of a vascular structure with alignment of 
several ADSC (arrows – EC, black arrow heads – ADSC).  D- I) Transmission electron 
microscopical images of the ultrastructure of the vascular structures. D) A vascular structure, 
consisting of EC (arrows) and lumen (L) is depicted by the dotted lines with surrounding 
ADSC (black arrow heads). E) Shows the specific cell-cell connections with tight junctions 
between EC (white arrow heads) with lumen (L) formation. On top ADSC are present. F) 
ADSC deposited extracellular matrix components which forms a basement membrane in 
between the EC and ADSC (black asterisks). F, G) Peg and Socket connections are shown by 
the lightning signs, and the inset in G shows intracellular filaments, representative for 





connections and basal membrane formation around the EC, i.e. the vascular structure with 
connected ADSC.  
Lumen (L), Endothelial cells (EC, black arrows), ADSC (black arrow heads), Endothelial cell-
cell connections (white arrow heads), Extracellular matrix formation (black asterisks), 
Intracellular filaments representative for smooth muscle cell phenotype (white asterisks), 
Peg and Socket connections of ADSC with EC (lightning signs). 
 
ADSC extend the stability of pre-formed vascular network in 3D matrigel assay 
In the ‘classic’ angiogenic sprouting assay of EC on Matrigel, networks started to form within 
2h and were mature at 6h (Fig. 4A, B). Interestingly, sprouting of EC co-seeded with ADSC 
occurred already at 2h, with the ADSC integrating into these networks (Fig. 4A). Without co-
seeded ADSC, the sprouting networks disintegrated readily within 12h (Fig 4C). Remarkably, 
preformed sprouting networks of only EC (t=6h) were stabilized for at least another 6h after 
addition of ADSC (Fig. 4D). These ADSC had integrated into the formed sprouting network, 
very similar to the co-seeded ADSC and EC. Singly seeded ADSC did not from sprouting 
networks on matrigel (Fig. 4). 
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Figure 4. ADSC extend the stability of pre-formed vascular network in a 
sprouting assay. The function of ADSC as pericytis was determined in a Matrigel 
angiogenesis assay. CFDA SE labeled (green) HUVEC, CM-DiI labeled (red) ADSC, either 
singly or mixed in a 1:1 ratio, were seeded onto a layer of Matrigel and monitored by 
fluorescent microscopy over a period of 12h. A) Sprouting networks of HUVEC started form 
at 2 h and B) fully formed after 6h. C) At 6h 5,000 ADSC or culture medium were added to 
the sprouted HUVEC and monitored for another 6h. D) Addition of ADSC to the already 
assembled sprouts promoted their stabilization. ADSC co-localized with the angiogenic 
sprouts at a pericyte position (D, enlarged).  
 
ADSC enhance hypoxia-driven angiogenesis in the OIR-model 
In order to study the effect of ADSC on hypoxia-driven angiogenesis in vivo, ADSC were 
injected intravitreally in eyes of C57Bl/6 mouse pups at P12 in the OIR model (Fig. 5A). In 





return of animals to room air, leads to extensive retinal neovascularization which reach a 
maximum around p17. At p14 injected ADSC were present in angiogenic sprouts and had 
attached to EC of maturating capillaries in a pericyte-like position (Fig. 5B). Quantification 
of hypoxia-induced pre-retinal neovascularization at p17 showed that injection of ADSC in 
the OIR model significantly increased neovascularization by 54% (PBS vs. ADSC: 8.3±0.63 
and 12.8±0.96, p<0.05). Using confocal microscopy, we demonstrated that ADSC also 
aligned and attached to maturating intra-retinal capillaries at pericyte-specific perivascular 
positions at vascular branches and in direct contact to the endothelium.  
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Figure 5. ADSC enhance hypoxia-driven angiogenesis in the OIR-model. 
A) Scheme of the OIR model. Mouse pups were exposed hyperoxia (75% O2) from p7 to p12 
and transferred to the room air (21% O2) subsequently. This causes hypoxia at room air, 
which results in extensive retinal neovascularization at p17. ADSC were intravitreally 
injected into the retinas at p12 to evaluate induction of hypoxia driven neovascularization. B) 
Representative confocal laser scanning microscopy images of CM-DiI labeled ADSC (red, 
white arrows) co-localization with the endothelial layer visiualized by Lectin (green). 
Hypoxia-driven neovascularization in the retinas was enhanced in p17 animals injected with 
ADSC compared to the control at p12. Graphs represent expression of mean number of 
neovascularization nuclei per section per animal (PBS vs. ADSC, p<0.05). C) Confocal 
microscope images of eGFP-tagged ADSC co-localization with the endothelial layer (Lectin, 
red) in the pericytic position.  
 
ADSC modulate OIR microenvironment  
 
The influence of ADSC intravital injection on the expression of angiogenic and inflammatory 
associated genes in the OIR microenvironment was assessed by qRT-PCR. In order to 
examine the microenvironment to which ADSC in the OIR model were exposed; OIR (p13) 
and control (p13) retinas were analyzed.  At p13, i.e. 24h after return to ambient oxygen from 
hyperoxia, Ang-1 expression had slightly decreased in OIR retinas, while Ang-2 had 
increased 1.3-fold compared to the non-OIR controls at p13 (p<0.05, Fig. 6A). This was 
accompanied by a 2-fold of VEGF-A, 3.5-fold of FGF-2, 1.6-fold of PDGF-B, 1.8-fold of TGF-
β1 and 1.5-fold of collagen IV in OIR p13 compared to control p13  (p<0.05, Fig. 6A). The 
analysis of the inflammatory genes demonstrated significant increases by 1.4-fold of IL-1β, 2-
fold of TNF-α, 1.4-fold of IL-8 and 2.8-fold of MCP-1 gene expression compared to the 
control group from p13 (p<0.05, Fig. 6A). Comparison of OIR retinas with-and-without-
ADSC injection revealed that injection of ADSC on p12 resulted in a significant increase of 
1.6-fold of Ang-1 and decrease of Ang-2 (p<0.05, Fig. 6B). Furthermore, the gene expression 
level of FGF-2 was significantly increased by 1.5-fold in OIR p19 with ADSC compared to the 
control-OIRp19 without ADSC (p<0.05, Fig.  6B). Injection of ADSC into the OIR resulted in 
a significantly increased expression of inflammatory genes such as TNF-α, IL-8 and MCP-1 
by respectively 1.6-fold, 1.3-fold and 3-fold (p<0.05, Fig. 6B). A slight decrease in the 
expression of pro-angiogenic VEGF-A was observed in ADSC injected-OIRp19-retinas, albeit 
not significant (Fig. 6B). No differences in the expression of PDGF-B, Collagen type IV and 








Figure 6. ADSC modulate the OIR microenvironment. 
Gene expression analyses normalized to GAPDH of A) OIR retinas at p13 compared to the 
control retinas at p13. The expression levels of Ang-2, VEGF-A, FGF-2, PDGF-B and 
Collagen IV were increased (p<0.05). In addition, the inflammatory response was induced as 
measured through increased expression of IL-1β, TNF-α, IL-8 and MCP-1. To assess the 
ADSC-guided changes to the OIR microenvironment B) At p19, OIR retinas with and without 
ADSC injection showed increased expression of Ang-1, FGF-2 and decreased expression of 
Ang-2, VEGF-A. The expression of PDGF-B and Collagen IV were similar to controls. The 
inflammatory response was modulated by normalized IL-1β expression, the TNF-α, IL-8 and 
MCP-1 expression remained increased (p<0.05). Graphs represent triplicates (with SEM) 
data from n=3 from retinas of 5 animals in each group. 
Hypoxia and inflammation renders ADSC proangiogenic and pericytic.  
As expected, prolonged culturing of ADSC under normoxia did not alter their the expression 
of Ang-1, VEGF-A and FGF-2, while Ang-2 expression levels increased albeit insignificantly 
(Fig. 7A). Under normoxia, IL-1β treatment significantly reduced Ang-2 (respectively 5-fold 
and 6-fold) gene expression levels while it induced the expression of Ang-1 (by respectively 
8-fold and 5-fold) , VEGF-A (2-fold at both time points) and FGF-2 (by respectively 3.5-and 
2.5-fold) both after 24h and 48h ( p<0.05, Fig. 7A). Hypoxia by itself caused (Fig. 7B), a 
decrease of Ang-2 and increase of VEGF-A in ADSC. The expression of Ang-1 and FGF-2 
gene levels did not change under hypoxia.  Interestingly, hypoxia and exposure to IL-1β for 
24h or 48h  significantly reduced Ang-2 (by respectively 2.5-and 4-fold) gene expression and 
induced Ang-1 (by respectively 15-fold-and 8-fold), VEGF-A (by respectively 10-and 4.5-fold) 
and FGF-2 (by respectively 8-and 4-fold) compared to the control (p<0.05, Fig. 7B). 
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Figure 7. ADSC acquire proangiogenic and pericytic profile under hypoxia and 
inflammation. 
Quantitative RT-PCR analyses of gene transcript levels of Ang-1, Ang-2, VEGF-A and FGF-2 
in ADSC under A) normoxia and B) hypoxia normalized to GAPDH expression. Gene 
transcript levels of Ang-1, VEGF-A and FGF-2 were induced and Ang-2 decreased by 
stimulation with pro-inflammatory mediators (IL-1β) under normoxia and even stronger 
after hypoxia conditions within 24h and 48h (p<0.05). Graphs represent triplicates (with 
SEM) data from n=3 independent experiments from 3 donors.  
Discussion  
The main finding of this study is that human ADSC promote vascular network 
formation in vitro and hypoxia-driven angiogenesis in the OIR murine model through 
acquisition of a pericyte phenotype and property. We show that ADSC in vitro and in vivo 
are in intimate contact with EC and induce vascular stability. This effect is associated with 
the upregulation in ADSC of the angiogenic growth factors like Ang-1, VEGF-A and FGF-2 
expression and the downregulation of Ang-2, while ADSC also modulate and inflammatory 
microenvironment of OIR.   
Healthy and mature microvessels in the retina and other organs consist of EC and pericytes, 
which keep intimate contact and depend on proper function of each other [34]. Impairment 





numerous genetic mouse models and a number of human pathological conditions, including 
tumor angiogenesis, sepsis and diabetic macro- and microangiopathies. In fact, impaired 
angiogenesis and vascular destabilization contributes essentially to the progression of 
diabetic complications, such as wound healing, reduced collateralization after arterial 
occlusion and specific microvascular complications like DR [35]. Therefore normalization 
and stabilization of the interaction of EC and pericytes and development of vascular 
networks are major therapeutic targets for adjunctive treatment of diabetic vascular 
complications. Among the therapeutic modalities, cell-based strategies which primarily aim 
on repair of dysfunctional endothelium and restoration of blood flow in damaged tissues 
gain in importance [36]. 
ADSC share phenotypically and functional similarities to capillary pericytes that have a 
potential to accelerate wound healing and restore blood flow to ischemic tissues by improved 
vascularization [37-40] and promote vessel-like structure formation in in-vitro fabricated 
adipose tissue [41], indicating their potential suitability for treatment of complications of 
diabetes. More recently, it has been demonstrated that intravenous injection of ADSC in a 
chemically induced rat model of diabetes reduced blood glucose levels and improved blood-
retinal-barrier function, possibly by differentiation of ADSC into retinal neurons and glial-
like cells [42]. However, the mechanisms how ADSC promote vessel protection and 
formation remained unclear.  
In this study, the pro-angiogenic potential of ADSC was tested in vitro and in an in vivo 
model of hypoxia-driven angiogenesis in the mouse eye. ADSC used in this study acquired 
pericyte properties by expression of the pericyte and smooth muscle cell-like markers after 
the first passage of cell culturing. In contrast to previous reports by Planat-Benard and 
coworkers who described the ability of ADSC to acquire an endothelial phenotype [43], we 
observed a loss of the endothelial markers CD31 and CD34 during the first passage and 
during prolonged culture of ADSC. In a direct interaction with EC, ADSC promoted 
formation of vascular structures with expression of cell contact molecules like N-cadherin 
and connexin-43. Ultrastructure analysis demonstrated that vascular structures observed in 
ADSC-EC co-cultures contained a lumen and provide inter-endothelial contacts typical for 
normal capillary EC. Furthermore, we showed the extra-luminal position of ADSC on 
vascular structures, indicating that the major role of ADSC is the maintenance of the 
vascular architecture.  According to Davis et. al. pericytes are matrix embedded smooth 
muscle-like cells in close contact with the vasculature EC [44,45].  We demonstrated that 
ADSC actively search to contact EC by modification of the cell shape, formation of cellular 
pertusions of intermediate filaments and maturation to the smooth-muscle like phenotype. 
Furthermore, these protrusions of ADSC as observed in pericytes attached to the EC 
resembled the “pocket-and-socket” contact at multiple points along the endothelial layer 
[46]. Concomitantly ADSC deposited extracellular matrix components and formed a 
common basement membrane with EC.  Thus, ADSC in co-culture with EC are pericyte-like 
instructors that govern EC changes through juxtacrine and paracrine interactions. This 
hypothesis was supported by our findings and of others that ADSC co-localize to previously 
assembled sprouts in 3D matrigel assay [47]  but also prolonged the stability of these pre-
formed vascular sprouting networks. In line with this observation, we also show that ADSC 
injected intravitreally into mouse eyes of the OIR, are found on angiogenic sprouts and in 
pericyte-specific extra-luminal positions in the immature vascular tree. In the OIR 
attachment of ADSC to EC resulted in increased numbers of pre-retinal neovascularizations, 
suggesting that ADSC also in vivo increased the stability of newly formed vessels. 
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ADSC are known to release various angiogenic growth factors such as VEGF-A or FGF-2 and 
immunomodulatory factors and chemoatractants involved in angiogenesis [48]. The balance 
of Ang-1 and Ang-2 and the concomitant expression of VEGF-A are among the most 
important regulators of vascular development, maturation and maintenance. While pericyte-
derived Ang-1 induces vessel stabilization and maturation, upregulation of the antagonist 
Ang-2 concomitantly with increased VEGF-A levels induces vessel destabilization and 
sprouting angiogenesis. In addition, in the quiescent vasculature VEGF-A plays a role as 
survival factor for EC, similar to FGF-2. In the present study, we show that ADSC upregulate 
Ang-1, VEGF-A and FGF-2 and down-regulate the expression of Ang-2 under hypoxic and 
inflammatory conditions, which are characteristic for the OIR model [49,50]. In line with 
our  in vitro data, analysis of mRNA of OIR retinas which were injected with ADSC revealed 
that the total retinal mRNA levels of Ang-1 and FGF-2 were increased, while levels of Ang-2 
and VEGF-A were reduced. Of note ADSC injection in the OIR also led to an increase of 
inflammatory molecules like TNF-α, IL-8 and MCP-1. In conclusion, the expression profile of 
ADSC under hypoxic and inflammatory conditions promotes vascular stability and 
homeostasis rather than angiogenesis and endothelial activation. Thus, the pro-angiogenic 
effects of ADSC in co-culture with EC as well as in the OIR model might be mediated by 
stabilizing paracrine signaling pathways, known to be important in the interaction of EC and 
pericytes.  
In summary, the data presented in this study show the pro-angiogenic potential of 
ADSC in hypoxia-driven angiogenesis. ADSC are attracted by EC and induce stabilization of 
EC tubes by acquiring pericyte-like interactions and properties, including paracrine signaling 
for the stabilization of microvessels. The findings indicate the potential use of ADSC in a 
treatment of diseases which require neovascularization, but the fact that ADSC also align 
with preformed vascular structures and stabilize them, render these cells an easily accessible 
adult stem cell source for the treatment of other vasculopathies that are characterized by 
impaired interaction of EC and pericytes or pericyte loss. 
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Abstract    
 
The therapeutic treatment of cardiac ischemia remains a challenge. However, biological 
intervention with stem cells including endothelial precursor cells (EPC) and mesenchymal 
stem cells e.g. from adipose tissue (ADSC) show clinical (experimental) benefit. This is 
primarily through paracrine interactions, yet ADSC-derived pericytes contribute to 
stabilization of vessels. Previously we have shown that, pretreatment of ADSC with 
inflammatory cytokines and hypoxia enhance their regenerative paracrine potential with 
respect to cardiomyocyte fate and function. In the current study we hypothesized that ADSC 
exposed to post-MI conditions,  inflammation, hypoxia, augment vascular network 
formation in a paracrine and juxtacrine way. 
Conditioned medium of ADSC, in particular after priming with inflammatory factors and 
hypoxia, increased angiongenic sprouting of endothelia cells (EC). While, sprouted networks 
in control medium collapsed around 24h after seeding of EC, ADSC conditioned media kept 
networks intact for at least 48h. In direct co-culture with ADSC, EC vascular network 
formation (VNF), distinct from angiogenic sprouting, occurred within 5 days. Enzymatical 
detachment and reseeding of those vascular network structures resulted in accelerated 
reformation of vascular structures. Interestingly, of different stromal cells types i.e. ADSC, 
human dermal fibroblasts (HDF), human cardiac fibroblasts (HCF) and murine fibroblasts 
(3T3), only ADSC supported VNF. However, this could not be explained via differences in  
regulation of pro-angiogenic genes and pro-inflammatory genes by IL-1beta and/or hypoxic 
stimulation or non-stimulated controls. In fact, HDF showed a pattern similar to ADSC, in 
which IL-1beta caused upregulation of e.g. IL1B, CXCL8 (IL-8), CCL2 (MCP-1), IL6, VEGFA, 
FGF1, and TGFB1 (TGF-beta1). In HDF ANGPT2 (Angiopoietin-2) was upregulated, while it 
remained unchanged in ADSC. While HCF overlapped for some genes, murine fibroblasts 
were hardly responsive with the exception of a strong upregulation of CCL2 after IL-1beta 
stimulation. ADSC conditioned media promoted migration of EC, irrespective of stimulation, 
yet hypoxic preconditioning promoted the strongest migration. The secretion of the 
extracellular matrix components collagens I, III and IV, fibronectin differed between ADSC, 
HDF, HCF and 3T3, but no unique ECM ‘profile’ could be attributed to ADSC to explain their 
unique property to support VNF. We conclude that ADSC promote vascular network 
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The repair of ischemically damaged tissue such as after the myocardial infarction 
(MI) relies on revascularization of the ischemic area. Hence, current standard treatment 
focuses on the restoration of the blood flow in order to prevent the ongoing tissue damage. 
Unfortunately, these approaches do not induce tissue repair nor diminish the underlying 
causes of the cardiovascular diseases. Thus the search of the new therapies is required.  
Stem cells therapy emerged as an alternative treatment of the infarcted myocardium 
[1]. Currently, adipose derived stem/stromal cells (ADSC) gain an interest as they are easy 
accessible source of cells that promote wound healing, angiogenesis and cardiac repair [2]. 
Adipose tissue has been recognized as a rich source of pericytes responsible for vascular 
homeostasis [3-7]. Moreover, ADSC in direct contact with EC promote vascular network 
formation, suggesting that ADSC function as pericytes [8-11]. ADSC secrete various growth 
factors, cytokines and extracellular matrix components [12-14]. Previously we and others 
showed that priming of ADSC with factors found in the post-MI microenvironment i.e. 
hypoxia and inflammatory cytokines increase the regenerative potential of these cells i.e. 
leads to increased cardiomyocyte proliferation [15-21]. Furthermore, clinically relevant data 
suggest that intramyocardial administration of ADSC promote repair of infracted cardiac 
tissue mainly due to the increased revascularization of the damaged area [2,22]. 
The novel approach in the field of stem cells regenerative medicine is based on use of 
secretors of therapeutic cells i.e. a conditioned medium of the cells instead of direct injection 
of cells as the retention and reaction to the host environment is not certain [23-25]. As 
previously described, the secretors of human MSC derived from human embryonic stem cells 
improved cardiac function following myocardial infarction due to restoration of the cardiac 
perfusion [26]. Moreover it is already known that treatment of ADSC with hypoxic 
conditions increase their paracrine angiogenic potential [27]. Although the paracrine 
mediated angiogenic potential of ADSC exposed to post-MI conditions that include both 
hypoxia and inflammation is still not fully understood. Thus, we hypothesized that ADSC-
conditioned medium derived from ADSC primed with hypoxia and inflammatory factors will 
enhance vascular network formation of EC in vitro. Furthermore, the conditioned medium of 
ADSC primed with the ischemic and inflammatory conditions could offer an “off-the-shelf” 
product for ischemic tissue therapy to ameliorate wound healing and restoration of tissue 
perfusion.   
Materials and methods 
 
Cell culture 
Human umbilical vein endothelial cells (HUVEC) were obtained from endothelial cell culture 
facility as previously described [28] or purchased from Lonza (MD, USA). Cells were 
cultured in medium consisting of Roswell Park Memorial Institute (RPMI-1640) (Lonza 
Biowhittaker, Belgium) supplemented with 20% fetal bovine serum (FBS, Lonza 
Biowhittaker), 100U/ml Penicillin/Streptomycin (GIBCO/Invitrogen, CA), 2mM L-
glutamine (Lonza Biowhittaker), 5U/ml heparin (Leo Pharma, The Netherlands) and 5μg/ml 
of Endothelial Cell Growth Factor (ECGF) (own isolate according to Burgess et al. [29] at 
37oC, with 21% O2 and 5% CO2. Confluent HUVEC were detached using accutase-solution 






Human subcutaneous adipose tissue samples were obtained after liposuction surgery, which 
was donated upon informed consent of the healthy patients with BMI below 30 (Bergman 
Clinics, The Netherlands). Adipose tissue was stored at 4˚C and processed within 24 h post 
surgery as previously described [20]. 3T3, human dermal fibroblasts (HDF) and human 
cardiac fibroblasts (HCF) cell lines (ATCC, UK) were cultured in Dulbecco's Modified Eagle's 
Medium (DMEM) (Lonza Biowhittaker, Belgium) supplemented with 10% FBS (Thermo 
Scientific, UK), and 100U/ml Penicillin/Streptomycin (GIBCO/Invitrogen, CA).  
Conditioned medium preparation 
Cells were seeded at the density of 10,000 cells/cm2 in DMEM for 3 days. Afterwards, the 
medium was replaced by 20% FBS endothelial cell medium for another 3 days. Next, cells 
were washed with PBS and cultured in serum-free endothelial cell medium. The cells were 
then cultured at 37oC in either normoxia (21% O2) or hypoxia (2% O2) and either in the 
presence of 10ng/ml IL-1β (Peprotech, NJ) for 24h. Afterwards, the conditioned medium 
was collected and filtered with 0.22µm syringe filter. 
Gene Transcript Analysis  
Cells were cultured according to the experimental conditions washed with cold PBS, lysed 
with 250µl of Trizol reagent/well (Invitrogen) and proceed with RNA extraction according to 
the manufacturer’s protocol. Next, 1µg of total RNA was reverse transcribed using the First 
Strand cDNA synthesis kit (Fermentas UAB, Vilnius, Lithuania) according to manufacturer’s 
instructions. The cDNA equivalent of 5ng RNA was used for amplification in 384-well 
microtiter plates in a TaqMAN ABI7900HT cycler (Applied Biosystem, Foster City, CA) in a 
final reaction volume of 10µl containing 5µl SyberGreen universal PCR Master Mix (BioRad, 
Richmond, CA) and 6 µM primer mix (forward and reverse). Cycle threshold (CT) values for 
individual reactions were determined using ABI Prism-SDS 2.2 data processing software 
(Applied Biosystem, Foster City, CA). The CT values were normalized to GAPDH as a 
reference gene using the ΔΔCt method, normalizing for the expression of the reference gene 
and related to the control treatment. All cDNA samples were amplified in duplicate.  
Table 1. Primer sequence for qRT-PCR 
Human primers: 
Primer name Sequence Forward 5'-3' Sequence Reverse 5'-3' 
Angiopoietin-1 CTACTGGGCCTCCTCTCATA TCTCAAATGGAGGAAACCAT 
Angiopoietin-2 CAGTTCTTCAGAAGCAGCAA TTCAGCACAGTCTCTGAAGC 
bFGF CTGTACCCATACAGCAGCAG CGCCTAAAGCCATATTCATT 
GAPDH GATCCCTCCAAAATCAAGTG GCAGAGATGATGACCCTTTT 
IL-1β AAGCTGGAATTTGAGTCTGC ACACAAATTGCATGGTGAAG 
IL-6 ACTTGCCTGGTGAAAATCAT CAGGAACTGGATCAGGACTT 
IL-8 CTTTCAGAGACAGCAGAGCA ACACAGAGCTGCAGAAATCA 
MCP-1 GGCTGAGACTAACCCAGAAA ATGAAGGTGGCTGCTATGAG 
PDGF-b CTGCATTTTCCTCTTGTCCT TTCTGCCCTAGAGAGGAGTG 
TGF-β CCCCATTAAAGATGGAGAGA GAGAGAGAGGGAGTGGGAGT 
VEGF-A CCTGAAATGAAGGAAGAGGA AAATAAAATGGCGAATCCAA 
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Primer name Sequence Forward 5'-3' Sequence Reverse 5'-3' 
Angiopoietin-1 GCCAACATGTGTGTAGCAAT CTAATTTTTCTGCCCTGCAT 
Angiopoietin-2 TAAGTAGCATCAGCCAACCA GCAGATGCATTTGTCATTGT 
bFGF TACTTACCGGTCACGGAAAT TTCGTTTCAGTGCCACATAC 
CXCR2 (IL-8) ATACTGCCTCCTACCCATCA CACTTGCCATTTTCTCTCCT 
GAPDH AGCTTGTCATCAACGGGAAG TTTGATGTTAGTGGGGTCTCG 
IL-1β TGTACAAGGAGAACCAAGCA TGTGCCGTCTTTCATTACAC 
IL-6 TTTCCTCTGGTCTTCTGGAG CTGAAGGACTCTGGCTTTGT 
MCP-1 GATGATCCCAATGAGTAGGC TACAGCTTCTTTGGGACACC 
PDGF-b GCACAGACTGGAGGAACTCT TCCATCAGAGAAGGTGTGTG 
TGF-β ACAATTCCTGGCGTTACCT CAGTGACGTCAAAAGACAGC 
VEGF-A TTGCTAACACTCAGCTCTGC TTTCAAAGGAATGTGTGGTG 
  
Angiogenesis assay 
Angiogenesis, i.e. sprouting of HUVEC, was determined using 15 well angiogenesis μ-slides 
(Ibidi GmbH, Martinsried, Germany) coated with growth factor reduced Matrigel (Becton 
Dickinson, Bedford, MA) according to the manufacturer’s instructions. HUVEC were seeded 
at the density of 10,000 cells/well in a presence of control medium or ADSC conditioned 
medium collected after ADSC culture under normoxic, hypoxic or inflammatory (IL-1β) 
conditions or both. Formation of sprouting networks was monitored by light microscopy 
over a period of 24h. The number of branching points and width of the branches was 
determined by Image J software (http://imagej.nih.gov/ij/).  
Migration analysis 
Migration of HUVEC towards conditioned medium of ADSC was measured using an AP48-
chemotaxis chamber with 8 µm pore size filters (Neuro Probe, Gaithersburg, MD). The lower 
chambers contained control endothelial cell medium supplemented with 20% FBS, serum-
free endothelial cell medium or conditioned medium of ADSC. 25,000 HUVEC cells were 
placed in the upper chamber and incubated in at 37°C for 90 min. Next, filters were fixed 
and stained with Diff-Quik (Medion Diagnostics, Switzerland). Cells were counted manually 
in 10 high power fields (40× objective magnification) per sample. 
Immunoblot of conditioned medium of ADSC 
Protein concentrations in the conditioned medium were determined using a Bradford 
microplate protein assay. Conditioned medium was diluted with RIPA buffer to 250µg 
protein of conditioned medium/ml for equal protein concentration. Next, samples were 
mixed with 5xSDS sample loading buffer (327 mM TrisHCl pH6.8; 10% SDS; 50% Glycerol; 
0.1M DTT; 0.05% bromophenol blue; 6M urea (Merck, Germany). Samples and 5xSDS were 
mixed in a ratio of 4:1 and heated at 100oC for 5 min. Next, 10µg of conditioned medium 
protein was separated in a 7% or 12% SDS gel and transferred to a nitrocellulose membrane 
(Whatman Protran, BA-83). Next, the membranes were incubated in Odyssey blocking 
buffer (Li-cor 927-40000) or in 5% BSA in TBS/Tween and incubation with primary 





Abcam, UK) for 2h. Then, membranes were washed and incubated with secondary antibody 
goat-anti-mouse or goat-anti-rabbit (both 1:400, Jackson Immunoresearch, UK) for 1h. An 
alkaline-phosphatase developing solution with NBT (75mg/ml in 70% DiMethylFormamide, 
DMF) and BCIP-T (50mg/ml in 100% DMF), both from Bio-Rad, was used as a substrate for 
collagen I detection.  All other detection was performed with an Odyssey Infrared Imaging 
system from Li-cor with Odyssey 2.1 software. TotalLab (TL120) software was used to 
determine the peak intensity of the bands. These were normalized with the peak intensity of 
the plain culture medium without FCS (0% ECM) and converted to a fold change of the 
intensity compared to the 0% ECM. 
 
Immunofluorescence Microscopy 
ADSC were seeded onto 15 mm Termanox coverslips (NUNC, Rochester, NY) at 10,000 
cells/cm2 in DMEM, 10% FBS for 24h. Next, medium was replaced with endothelial cell 
medium (ECM) for 5 days. HUVEC were seeded on gelatin-coated coverslips or in the 
presence of ADSC conditioned medium, on top of confluent ADSC monolayers, onto ADSC 
conditioned medium-coated coverslips or onto decellularized ADSC-ECM at 10,000 
cells/cm2 in ECM and cultured 5 days to allow for vascular network formation. ADSC were 
seeded on 15 mm Thermanox coverslips (NUNC, Rochester, NY) at 10,000 cells/cm2 in 
DMEM, 10% FBS for 24h. Samples were washed with PBS and fixed in 2% paraformaldehyde 
in PBS at room temperature for 30min. After extensive washing with PBS, the samples were 
incubated with primary antibody to rabbit-anti-human Collagen I, Collagen III, Fibronectin 
(red) (1:100, Abcam, UK) and CD31 (green)  (Dako, UK) for 1h. Samples were extensively 
washed with PBS and incubated with the secondary antibody Fluorescein conjugated or 
Cyanine 3-conjugated gout antibody to rabbit IgG (1:400, Jackson Immunoresearch, UK). 
The endogenous derived ECM matrices were prepared by treatment of ADSC, 3T3 cells or 
HUVEC with sterile hypotonic ammonium hydroxide (NH4OH, 20mM) (Merck, Germany) 
for 10 min. After freezing-thawing, the matrices were washed with PBS and blocked with 
0.1% BSA (Sigma-Aldrich, Boston, MA) for 30min. Next the ADSC-derived ECM was washed 
twice with unsupplemented DMEM (Lonza Biowhittaker, Belgium), followed by co-culture of 




All the data are presented as a means +/- SEM and were analysed by GraphPad Prism 
(version 5, GraphPad Software Inc.). Statistical significance was determined using one-way 





ADSC primed with hypoxia and inflammation enhance angiogenic sprouting in 
vitro by paracrine mechanisms. During the first 6 hours of the angiogenic sprouting, 
EC migrated towards each other and vascular-like branches were formed (Figure 1). At 6h 
the highest number of branching points had formed in the presence of conditioned medium 
from ADSC primed with IL-1β under normoxia and hypoxia condition or in combination of 
hypoxia with IL-1β (all 2-fold increase, compared to control medium, p<0.05) (Figure 1g). 
Subsequently, these branching points declined in all conditions, first by HUVEC migrating 
towards each other i.e. forming cellular aggregates and later through network collapse, 
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resulting in less branches and branching points after 24 and 48h (Figure 1). The lowest 
number of branching points was observed in the presence of serum-free control medium or 
control medium supplemented with 20% FBS compared to serum-free ADSC-conditioned 
medium from all the groups at 24 and 48h (2 fold increase, compared to control medium, 
p<0.05). After 6 hours the highest branch length was observed in serum supplemented 
control medium. Serum depletion resulted in a 2-fold decrease of branch length compared to 
serum-supplemented control medium, p<0.05. This was only prevented in the presence of 
hypoxia and IL-1β primed ADSC-conditioned medium at the early time point of 6h (Figure 
1h). After prolonged culture in the absence of serum the branch length further declined, 
which was prevented in serum-free ADSC-conditioned medium (Figure 1h).  Moreover, the 
hypoxia groups of ADSC-conditioned medium showed thicker branches than other groups. 
Considering the number of branching points and the thickness of the branches together, 
serum supplemented control medium showed high branch lengths, serum-free control 
medium scored low in both branching points and branch length, while serum-free ADSC-
conditioned medium in general indicated both considerably high branching points and 
branch lengths. The ADSC-conditioned obtained from ADSC primed with hypoxia and IL-1β 
medium formed more complex and more stable endothelial cells networks. Moreover, this 
data was further supported by indication of strong migration of EC towards serum-free 
ADSC-conditioned medium compared to control medium. The strongest chemotaxis of EC 
was observed towards ADSC-conditioned medium primed with hypoxia (3-fold increase, 
p<0.05), then hypoxia and normoxia in combination with IL-1β (2-fold increase, p<0.05) 
and 2 fold increase in ADSC-conditioned medium from normoxia, all compared to serum-













Figure 1. Hypoxia and inflammatory components augment ADSC sprouting 
angiogenesis of HUVEC in vitro in a paracrine manner.  
EC cultured in an ADSC conditioned medium formed longer lasting network compared to 
control medium with or without FBS in a matrigel angiogenesis assay. 
 Depicted are HUVEC on a Matrigel coating in the presence of normal culturing medium 
with or without FBS and in serum-free ADSC conditioned medium cultured in 
normoxia/hypoxia with or without IL-1β. Photographs were made at 6, 24 and 48h after 
seeding HUVEC on the Matrigel. Pictures were taken at an original magnification of 40x.  
 
 
Supplementary Figure 1. The conditioned medium of ADSC primed with 
hypoxia and inflammation increases migration of EC. Chemotaxis of EC towards 
serum-free conditioned medium of ADSC primed with IL-1β under normoxia and hypoxia in 
comparison to serum-free control medium was assessed using an AP48-chemotaxis 
chamber. Migration of EC was significantly increased towards all groups of serum-free 
conditioned medium of ADSC in comparison to serum-free control medium. The strongest 
migration of EC was observed towards conditioned medium of ADSC primed with hypoxia 
(3-fold increase) and hypoxia with IL-1β (2.5-fold increase) compared to serum-free control 
medium.  
 
ADSC promote vascular network formation by juxtacrine and paracrine 
interactions with endothelial cells  
 
As previously have been shown, ADSC promote vascular network formation in direct co-
culture with endothelial cells (EC), possible due to the synthesized ECM components by 
ADSC [30]. Here we confirm that ADSC guide EC (CD31, green) to form vascular networks in 
the direct vicinity of Collagen I and Fibronectin deposited by ADSC (Figure 2a, in red). This 
might indicate a role for these extracellular matrix (ECM) proteins in vascular network 
formation (VNF) of EC. The formation of vascular structures becomes visible from 5 days 
after the initial seeding of EC on top of a confluent layer of ADSC. Interestingly, after the 
enzymatical deatachment and re-seeding of the acquired single cell suspensions of these 
vascular structures onto tissue culture polysterene (TCPS) resulted in “vascular-like” priming 
of cells and formation of vascular structures already within 24h (Figure 2b, left). Moreover, a 
re-seeding of these vascular structures onto confluent layer of ADSC resulted in increased 
ADSC promote vascular network formation through juxtacrine and 





number of vascular branches (Figure 2b, right), suggesting that cell-cell contact is beneficial 
for the guidance of EC to form stable vascular structures. We show that EC cultured on TCPS 
formed vascular-like network in the presence of ADSC-conditioned medium (Figure 2c), 
albeit less strongly pronounced in structure. In addition, vascular networks of HUVEC 
readily formed (24h) on ECM derived from decellularized ADSC (Figure 2d). Nevertheless, 
these structures were unstable in the absence of ADSC. This indicates that paracrine 
signaling by secreted molecules of ADSC such as growth factors and ECM molecules suffice 
to initiate VNF, but that juxtacrine interaction is required to stabilize these networks. In all 
conditions we detected the presence of Collagen I and Fibronectin in the co-cultures of EC 
with ADSC or ADSC secretors, although EC cultured on TCPS also produce these ECM 
components without formation of vascular structures observed in co-culture of EC on top of 
confluent layer of ADSC (Suppl. Figure 2). Although HUVEC normally require a Collagen or 
Gelatin coating for efficient proliferation, these can adhere to TCPS and actually deposit their 
own matrix (Suppl. Figure 2). However, to form networks additional, exogenous, paracrine 
and juxtacrine stimuli are required, such as delivered by ADSC. We conclude that ECM 
components by themselves do not play a major role in vascular network formation of EC 






Figure 2. ADSC promote vascular network formation by juxtacrine and 
paracrine interactions with endothelial cells. Representative fluorescence microscopy 
images for fibronectin and collagen I (both red) of: a) EC (CD31, green) in direct co-culture 
on top of confluent layer of ADSC for 5 days, b, left) EC (CD31, green) Enzymatic detachment 
and re-seeding of single cells suspension of previously formed vascular structures onto TCPS 
and b, right) again onto confluent layer of ADSC 24h after the initial seeding, c) EC (CD31, 
green) cultured in the presence of serum-free conditioned medium of ADSC for 24h, d) EC 
(CD31, green) cultured on top of ADSC-derived ECM components for 24h.  
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Supplementary Figure 2. ECM components alone do not promote vascular 
network formation of EC. Representative fluorescence microscopy images for 
fibronectin and collagen I (both red) of: ADSC-derived ECM (Lack of DAPI staining indicate 
the effectiveness of the decellularization procedure) and EC (combined with CD31, green) 
cultured on TCPS.  
 
ADSC and fibroblastic cells share similar angiogenic gene expression profiles, 
yet only ADSC acquire pro-angiogenic potential 
ADSC, human cardiac fibroblasts (HCF), human dermal fibroblasts (HDF) and murine 3T3 
fibroblasts share the same embryonic origin i.e. belong to the mesenchymal fibroblast-like 
family. In contrast to the other fibroblastic lineages, only ADSC supported the formation of 
vascular networks by HUVEC (Figure 3b, CD31, green). However, a low frequency of what 
appeared as small and stunted vascular structures also formed on monolayers of primary 
human dermal fibroblasts (Figure 3e). No vascular network formation was observed in the 
co-culture of EC with 3T3 fibroblasts or human cardiac fibroblasts (Figure 3c, d). 
Interestingly, when assessing the influence of ECM components (collagen type III and 
fibronectin) on VNF of HUVEC, we corroborated the only ADSC-derived acellular matrix 
supported VNF, while ECM from 3T3 fibroblasts or HUVEC themselves did not (Suppl. 
Figure 3). The HUVEC deposited significantly less collagen type III and fibronectin 
compared to ADSC or 3T3 fibroblasts did secreted similar amounts (Suppl. Figure 3). 
Additionally we determined that probably ECM components do not play a major role in this 
process as no significant differences of the ECM components were found in the serum-free 








Figure 3. ADSC represent the most promising cells for vascular network 
formation. Representative fluorescence microscopy images of EC (CD31, green) cultured 
on top of the confluent layer of 3T3, HCF, HDF and ADSC. ADSC in direct co-culture 
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Supplementary Figure 3. Representative fluorescence microscopy images of Collagen I 
and Fibronectin (green) and CD31 (red) of A) 3T3 cells and 3T3 cells together with HUVEC, 
B) 3T3-derived ECM and 3T3-derived ECM together with HUVEC, C) ADSC-derived ECM 
and ADSC-derived ECM together with HUVEC, D) HUVEC-derived ECM and HUVEC-
derived ECM together with HUVEC. The vascular network formation of EC was not observed 
in the presence of 3T3 cells and 3T3-derived ECM or HUVEC-derived ECM as observed in 
the presence of ADSC-derived ECM.  
 
Secreted extracellular matrix proteins are unresponsive to pro-inflammatory 
or hypoxic trigger in ADSC and other fibroblastic lineages. 
To better investigate the production and secretion of ECM components, conditioned media 
from HUVEC, 3T3 fibroblasts, HDF and ADSC was immunoblotted and the levels of secreted 
soluble fibronectin (Suppl. Figure 4a), laminin (Suppl. Figure 4b), collagen type I (Suppl. 
Figure 4c), collagen type III (Suppl. Figure 4d) and collagen type IV (Suppl. Figure 4e) were 
determined by densitometry. Neither, pro-inflammatory stimulation, nor hypoxic 
stimulation, nor both conditions, caused significant changes in the levels of these secreted, 
soluble ECM molecules. These results suggest that the ECM-augmented stimulation of VNF 










Supplementary Figure 4. ADSC secrete ECM components. Depicted are protein 
levels of Fibronectin (a), Laminin (b) and Collagen I (c), Collagen III (d) and Collagen III (e) 
in 10 µg of conditioned media of HUVEC, 3T3, HDF and ADSC and normal culturing 
medium that was not exposed to cells (0% ECM). Fold changes of the peak intensity of the 
bands were normalized to 0% ECM. ADSC secreted Fibronectin, Laminin and Collagen IV 
but did not secrete more Laminin and Collagen IV than HUVEC, 3T3 and HDF.  3T3 cells did 
secrete more Collagen I and HDF more Collagen III, but ADSC still secreted considerable 
amount of both molecules. For ADSC average fold changes + SEM are shown. n= 3 for ADSC 
and n= 1 for the rest, so statistical analysis could not be done. Group abbreviations: 
normoxia =N-, normoxia+IL-1β=NI-, hypoxia=H-, hypoxia+IL-1β=HI. 
 
Hypoxia and inflammation stimulate a broad range of pro-angiogenic gene in 
ADSC but not in other fibroblastic lineages. 
The influence of inflammatory and hypoxic stimulation on angiogenic gene expression in 
ADSC and other fibroblastic lineages, showed thatthe strongest response to the 
inflammatory conditions (IL-1β) was observed in HDF and ADSC (Fig. 4). Stimulation of 
HDF and ADSC with the pro-inflammatory cytokine IL-1 under normoxia resulted in 
respectively 6-fold and 17-fold upregulation of VEGF and 9-fold and 16-fold upregulation of 
bFGF gene expression level after 24h (p<0.05, Fig. 4b). Under hypoxia, treatment of HDF 
and ADSC with IL-1 for 24h resulted in an even higher increase of VEGF gene expression, 
respectively by 15-fold and 55-fold and bFGF gene expression, respectively by 10-fold and 18-
fold (p<0.05, Fig. 4b). Although, the protein analysis of secreted VEGF and bFGF did not 
show changes related to the hypoxia or inflammatory conditions (Figure 4a). Furthermore, 
levels of VEGF gene expression did not change in 3T3 cells of HCF irrespective of treatment 
(p<0.05, Fig. 4b). There were no differences found in the PDGF-b gene expression between 
all the cells (Fig. 4b). As expected, TGF-β gene expression in general was upregulated after 
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pro-inflammatory stimulation, which in ADSC reached a 2-fold increase under normoxia and 
hypoxia (p<0.05, Fig. 4b). Furthermore, treatment of ADSC with IL-1β under normoxia and 
hypoxia resulted in 1.6-fold increase of Angiopoietin 1 gene expression and 3-fold decrease of 
Angiopoietin 2 gene expression under normoxia and 5-fold decrease of Angiopoietin 2 gene 
expression under hypoxia (p<0.05, Fig. 4b). Data were normalized against the 




Figure 4. Hypoxia and inflammation stimulates a broad range of pro-angiogenic 





Depicted are protein levels of a) VEGF-α and bFGF in 10 µg of conditioned media of ADSC 
under normoxia, hypoxia and inflammatory conditions in compare to normal culturing 
medium that was not exposed to cells (0% ECM).  Fold changes of the peak intensity of the 
bands were normalized to 0% ECM. For ADSC average fold changes + SEM are shown, n=3. 
b) Gene expression analysis of VEGF, bFGF, PDGF-b, TGF-β, Angiopoietin 1 and 2 
normalized to reference gene in fibroblast-like cells 3T3, HDF, HCF and ADSC under 
normoxia, hypoxia and in combination with pro-inflammatory stimulation (IL-1β) for 24h. 
Graphs represent triplicates (with SEM) data from n=4 and for ADSC n=10, values of p<0.05 
were considered significant. All groups were normalized against the group under normoxic 
conditions without IL-1β stimulation of the same cell type. 
 
 
Hypoxia and inflammation induce pro-inflammatory and chemoatractive genes 
in ADSC.  
With respect to responses to pro-inflammatory stimulation or hypoxic stimulation or both, 
HCF and 3T3 fibroblasts were virtually unresponsive, while HDF and ADSC showed a similar 
and strong upregulation of all four representative genes that were assessed. Interestingly, 
this differs from their responses of angiogenic gene expression (Figure 5). Treatment of HDF 
and ADSC with the pro-inflammatory cytokine IL-1 under normoxia resulted in respectively 
72-fold and 200-fold for upregulation of IL-1β gene expression and 10,250-fold and 1,500-
fold upregulation of IL-6 gene expression level after 24h (p<0.05, Fig. 5). Under hypoxia, 
treatment of HDF and ADSC with IL-1 for 24h resulted in increased IL-1β gene expression, 
respectively by 70-fold and 316-fold and IL-6 gene expression respectively by 8,331-fold and 
2,930-fold (p<0.05, Fig. 5). Furthermore gene expression of the chemoattractant IL-8 also 
increased in HDF and ADSC stimulated with IL-1β under normoxia by respectively 1,526-
fold and 782-fold (p<0.05, Fig. 5), which under hypoxia resulted in respectively 1,315-fold 
and 1,120-fold (p<0.05, Fig. 5). Similarly, another chemoattractant gene, MCP-1, was 
strongly upregulation in IL-1β-stimulated HDF and ADSC under normoxia by respectively 
850-fold and 180-fold, which under hypoxia resulted in respectively 460-fold and 143-fold 
upregulation (p<0.05, Figure 5).  
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Figure 5. Hypoxia and inflammation increase a pro-inflammatory and 
chemoatractive gene expression profile of ADSC. 
Gene expression analysis of IL-1β, IL-6, MCP-1 and IL-8 normalized to reference gene in 
fibroblast-like cells 3T3, HDF, HCF and ADSC under normoxia, hypoxia and in combination 
with pro-inflammatory stimulation (IL-1β) for 24h. Graphs represent triplicates (with SEM) 
data from n=4 and for ADSC n=10, values of p<0.05 were considered significant. All groups 
were normalized against the group under normoxic conditions without IL-1β stimulation of 
the same cell type. 
 
Discussion 
Even though the adult human heart has an inborn capacity to regenerate, also after 
MI, this repair potential is not sufficient to overcome the damage that may lead to heart 
failure ultimately [31]. Current early interventions and pharmacological therapies improve 
the therapeutic outcome but still do not cure the damage. Novel therapeutic approach 
includes stem cell therapy as an alternative for treatment of heart damage due to the 
myocardial infarction. Current literature and clinical trials indicate that ADSC are the 
promising cells for these purpose as they positively modulate inflammatory responses 
initiated by the cardiac damage and most of all have beneficial pro-angiogenic properties 
leading to increased tissue perfusion [2,22,32]. Furthermore, current data indicate that 





One of the proposed mechanism includes ADSC-guided juxtacrine stimulation of endothelial 
cells (EC) to form vascular structures through cell-cell contact.  
The main finding of our study is that ADSC beside juxtacrine interactions also 
stimulate EC to form pre-mature vascular networks by paracrine mechanisms. Moreover, the 
in vitro modulated post-MI microenvironment i.e. hypoxia and inflammation positively 
influence pro-angiogenic paracrine potential of ADSC as the branching points, branching 
length and migration of EC reach highest point during stimulation of EC with the 
conditioned medium of ADSC primed with hypoxia and pro-inflammatory cytokine IL-1β. 
These data were also supported by the comparison of pro-angiogenic and pro-inflammatory 
gene expression profile of ADSC with other fibroblast like cells such as 3T3, HDF and HCF. 
Indeed, the gene expression profile of ADSC exposed to hypoxia and inflammatory stimuli 
(IL-1β) indicate that the ADSCs’ regenerative potential is increased as expression of pro-
angiogenic VEGF, bFGF was increased. On the protein level though, the secretion of bFGF 
maintained at the same level. We also observed increases of inflammatory gene expression 
such as IL-1β, IL-6, MCP-1 and IL-8 in ADSC exposed to the hypoxia and pro-inflammatory 
conditions.  
When damage occurs, inflammation is induced to remove debris, pathogens and dead 
cells. Cytokines, such as MCP-1 or IL-8, are secreted to recruit and activate inflammatory 
cells like monocytes or neutrophils [33]. These cells in turn secrete cytokines such as TGF-β, 
TNF-α, IL-1β and IL-8 and (angiogenic) growth factors to orchestrate angiogenesis and 
wound healing [34]. Indeed, depletion of macrophages impairs cardiac wound healing [35]. 
Additionally, CD14 positive monocytic cells are able to differentiate to an endothelial cell 
(EC) phenotype [36,37]. Co-implantation of CD34 endothelial progenitor cells and 
monocytic CD14 cells enhanced paracrine driven neovascularization [38]. All these indicate 
the strong correlation between inflammation and induction of angiogenesis. The vascular 
pro-stabilizing factor Angiopoietin 1 was increased in ADSC exposed to hypoxia and 
inflammation and de-stabilizing Angiopoietin 2 was decreased. Along with that, our previous 
results also suggest that hypoxia and pro-inflammatory conditions affect ADSC to acquire 
perivascular phenotype [6]. Moreover, we compared the pro-angiogenic potential of ADSC 
with other fibroblast-like cells such as 3T3, human dermal fibroblasts (HDF) and human 
cardiac fibroblasts (HCF). EC only in direct co-culture with ADSC assembled into vascular 
network, suggesting that ADSC are one of the most promising cells for therapy required 
revascularization such as after MI. ADSC and HDF had similar responses to the hypoxic and 
inflammatory stimuli, although the conditioned medium derived from ADSC show stronger 
potential to induce a vascular network formation. Interestingly, we also demonstrated that 
early vascular network formation guided by ADSC can be accomplished by paracrine 
stimulation of EC with the conditioned medium of ADSC or by seeding EC onto ADSC-
derived ECM components. This network was formed 5x faster compared to the direct co-
culture of EC on top of confluent layer of ADSC. Although, this pre-mature vascular network 
need to be further stabilized by ADSC through direct juxtacrine interactions (cell-cell 
contact). Our data contradict previously published direct involvement of ECM to guide 
formation of vascular cells [8]. We confirmed that ADSC indeed deposit ECM components 
such as Collagen I and Fibronectin, although endothelial cells (EC) deposit these ECM 
components and do not form vascular network on TCPS. It is possible that the ECM 
components in the conditioned medium of ADSC or ECM derived from decellularized ADSC 
also harbored i.e. sequestered, at least part of the secreted trophic factors of ADSC, yet this 
was not investigated. 
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Furthermore, we also showed that EC can by directly primed by ADSC in direct co-culture. 
The trypsinisation of the previously formed ADSC-EC network and its de novo re-seeding 
resulted in early vascular network formation on TCPS. This was even further accelerated if 
re-seeding was done on the top of confluent layer of ADSC. In vitro priming of EC with ADSC 
or with the conditioned medium of ADSC prior i.e. the intramyocardial injection could 
potentially increase engraftment of EC and its integration into vascular structures. 
Moreover, ADSC or ADSC-derived secretors applied together with the EC in a form of gel 
could alleviate re-vascularization of the engraftment in the damaged area to achieve 
enhanced perfusion.  
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Background: Adipose tissue-derived stromal cells (ADSC) augment wound healing and 
regeneration of the skin. Currently, it is unknown if and how ADSC can also influence dermal 
scarring. We hypothesized that ADSC inhibit adverse differentiation of dermal fibroblasts 
induced by the pivotal factor in scarring i.e. Transforming Growth Factor-β (TGF-β).  
Methods: TGF-β-treated adult human dermal fibroblasts (HDFa) and keloid scar-derived 
fibroblasts (KLF), were incubated with ADSC conditioned medium (ADSC CM) and assessed 
for proliferation and differentiation in particular the production of collagen, expression of 
SM22α and development of hypertrophy and contractility. Results: TGF-β-induced 
proliferation of HDFa was abolished by ADSC CM. Simultaneously ADSC CM reduced 
SM22α gene and protein expression of TGF-β-treated HDFa, while their contractility was 
reduced too. Furthermore, ADSC CM strongly reduced transcription of collagen I and III 
genes as well as their corresponding proteins. On the other hand the ADSC CM tipped the 
balance of matrix turnover to degradation through stimulating gene expression of MMP-1, 2 
and 14, while MMP-2 activity was upregulated too. Even in end stage myofibroblasts i.e. 
KLF, ASDC CM suppressed TGF-β-induced myofibroblast contraction, and collagen III gene 
expression. Conclusion: In this study we show that ADSC inhibit TGF-β-induced adverse 
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Dermal scars are the result of wound healing and remodeling. When dysregulated, they may 
be painful, cause itching and discomfort, and can become disfiguring as hypertrophic scars 
or even keloid. Currently, there is no ideal treatment to reverse or reduce such dermal 
scarring. However, in several clinical reports and clinical trials, it has been reported that 
lipofilling improves the quality of scars. In addition, it has been demonstrated that lipofilling 
improves normal aged skin and burn scars histologically1,2, functionally and aesthetically3-6. 
Among the cellular constituent of fat tissue, we consider adipose tissue-derived stromal cells 
(ADSC) to be a prime candidate for the observed anti-scarring and skin improving capacity 
of lipofilling. 
Adipose tissue-derived stromal cells (ADSC) are multipotent stem cells, which reside 
in the perivascular niche as pericytes or peri-adventitial cells7 in white adipose tissue 
throughout the body8-10.  In vitro, ADSC present as fibroblast-like, spindle-shaped cells. They 
secrete a plethora of trophic factors, which suppress inflammation and apoptosis, yet 
promote angiogenesis and mitosis of parenchymal cells11. Furthermore, ADSC have the 
ability to differentiate into several cell types, among which are adipocytes, chondrocytes, 
osteoblasts, smooth muscle cells and pericytes8-10. In animal models, ADSC speed up wound 
healing12-15. In vitro, ADSC increase proliferation, migration and extracellular matrix 
production of dermal fibroblasts16,17. Furthermore, ADSC have been successfully used for 
organotypic skin culture18 and to tissue engineer skin19. As yet, the influence of ADSC on the 
remodeling phase of wound healing is unknown, in particular with regard to dermal scarring. 
In normal wound healing, haemostasis and inflammation are followed by proliferation, 
remodeling and finally, regeneration or repair. Resident dermal cells, in particular 
fibroblasts and keratinocytes respond to the inflammatory cues by restoring dermal 
integrity20. Transforming Growth Factor-β (TGF-β) is the key inflammatory cytokine in 
wound healing, regeneration and remodeling. During haemostasis and inflammation, TGF-β 
is secreted by activated platelets and immune cells. In response to TGF-β, fibroblasts 
differentiate into myofibroblasts21-23, which contract the wound and aid in remodeling of the 
extracellular matrix (ECM)21,22,24,25. Important ECM molecules secreted by myofibroblasts 
are collagen types I and III, which are also the main proteinaceous constituents of scars. 
During the resolution phase of normal wound healing, the morphology of the skin is restored 
and the myofibroblasts resolve from their transient function21. However, in the presence of 
chronic pro-inflammatory and/or pro-fibrobrotic stimuli, wound healing may become 
disturbed and dysregulated. TGF-β is then continuously produced, resulting in an on-going 
proliferation of myofibroblasts and subsequently excessive deposition of extracellular matrix 
and contraction of the scar22,26. Based upon clinical observations of the effects of ADSC on 
disturbed wound healing, we hypothesize that ADSC inhibit TGF-β-induced differentiation 
of normal dermal fibroblasts and keloid scar-derived fibroblasts and thereby improve 
dysregulated wound healing. To test this hypothesis in vitro, we investigated matrix 
production and degradation, mesenchymal markers and contractility of TGF-β-stimulated 
normal dermal fibroblasts and keloid fibroblasts, after treatment with ADSC conditioned 
medium (ADSC CM) in order to elucidate the effect of ADSC on myofibroblasts. 
Materials and Methods 
Adipose tissue-derived stromal cell isolation and culture 





as stated in the 1975 Declaration of Helsinki and was approved by the medical ethical 
committee of University Medical Centre Groningen. Human adipose tissue was obtained 
with informed consent from healthy donors undergoing elective abdominal liposuction 
surgery at Bergman Clinics, Heerenveen, the Netherlands. ADSC were isolated from adipose 
tissue as described previously27. ADSC were maintained in Dulbecco’s Minimal Essentials 
Medium (DMEM; Lonza) containing 10% FBS, 100 units/mL penicillin, 100 mg/mL 
streptomycin (DMEM high serum). ADSC were used in experiments up to passage 6. 
Adult human dermal fibroblasts culture 
Human dermal fibroblasts, adult type (HDFa) were purchased from ATCC. HDFa were 
maintained in Eagle's Minimal Essentials Medium (EMEM; Lonza) containing 10% FBS, 100 
units/mL penicillin, 100 mg/mL streptomycin. HDFa used in experiments ranged from 
passage 11-18. 
Keloid scar-derived fibroblasts culture 
Keloid scar-derived fibroblasts (KLF) were provided by the Department of Dermatology, VU 
University Medical Centre, Amsterdam, The Netherlands. KLF were obtained with informed 
consent, the procedure was approved by the medical ethical committee of VU University 
Medical Centre. KLF were maintained in DMEM, containing 1% Ultroser-G (Gibco), 100 
units/mL penicillin, 100 mg/mL streptomycin. KLF were used in experiments up to passage 
3.  
Collection of adipose-derived stromal cell conditioned medium 
When ADSC reached ~90% confluency, cells were incubated with culture medium containing 
2% FBS. After 24h, conditioned medium was removed and fresh DMEM 2% FBS was added. 
This procedure was repeated three times, conditioned medium from three different time 
points was pooled, filtered through a 0.22μm filter and stored at -20°C until experimental 
need. Conditioned medium for experiments with KLF was generated similarly, but using 
KLF culture medium. 
Conditioned medium culture 
HDFa or KLF were seeded at a density of 10,000 cells/cm2 in appropriate culture media. 
HDFa were switched to DMEM containing 5% FBS overnight. KLF were maintained on 
DMEM containing Ultroser-G. 
At day 1 of the experiment, HDFa or KLF were incubated with ADSC CM, with or without 
10ng TGF-β1 (Peprotech) per mL medium. Control groups were incubated with normal 
culture medium with 2% FBS (HDFa) or 1% Ultroser-G (KLF). Fibroblasts were cultured for 
4 days.  
Immunofluorescent staining 
HDFa were seeded on Thermanox coverslips (NUNC Brand Products) in 24 wells plates. KLF 
were seeded in Lab-Tec II 8 well chamber slides (NUNC Brand Products). Cells were fixed in 
2% paraformaldehyde. Endogenous biotin was blocked using avidin (Dako) and biotin 
solutions (Dako). Primary antibodies were rabbit anti-collagen I or rabbit anti-collagen III 
(Abcam) in PBS with 2% goat serum and 1% BSA. Secondary and tertiary antibodies were 
goat anti-rabbit biotin-labeled (Dako) and Cy3-labeled Streptavidin (Invitrogen). Nuclei 
were counterstained using 4′,6-diamidino-2-phenylindole (DAPI; Sigma-Aldrich). 
Cytoskeleton was visualized using FITC-conjugated phallotoxins (Invitrogen). Slides were 
examined using a Leica DMRXA microscope and Leica Software (Leica Microsystems).  
Hypertrophy measurements 
HDFa were seeded in 24 wells plates. After 4 days, cells were fixed in 2% paraformaldehyde. 
Cell outlines were visualized with CellMaskTM Deep Red Plasma Membrane Stain 
(Invitrogen). Nuclei were counterstained using DAPI. Pictures were acquired using a Zeiss 
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Axio Observer.Z1 microscope and TissueFAXS Immunofluorescence Cell Analysis system 
(TissueGnostics USA Inc.). Length and width of HFDa were scored in 10 representative 
images for control groups and 5 representative images for ADSC CM treated groups (n=3), 
using ImageJ (Research Services Branch, National Institute of Mental Health). 
Gene transcript analysis 
Cells were lysed in Trizol Reagent (Invitrogen). Isolation of total RNA and qRT-PCR analyses 
were performed as previously described27, using primer sequences as listed below (Table 1). 
To determine differences in expression of gene of interest, Ct-values were normalized against 
mean Ct-values of GAPDH and β-actin using dCt-method: dCt= Ctgene of interest – Ct mean (GAPDH 
and β-actin). Fold increase was calculated as 2-(ddCt). 
 
Table 1. Primer sequences for quantitative Reverse Transcription-Polymerase 
Chain Reaction 
Primer   Forward   Reverse 
β -actin  CCAACCGCGAGAAGATGA  CCAGAGGCGTACAGGGATAG 
Collagen I   GGGATTCCCTGGACCTAAAG  GGAACACCTCGCTCTCCA 
Collagen III  CTGGACCCCAGGGTCTTC  CATCTGATCCAGGGTTTCCA 
GAPDH  AGCCACATCGCTCAGACAC  GCCCAATACGACCAAATCC 
MMP-1  CTGAAAGTGACTGGGAAACC  GACAAACTGAGCCACATCAG 
MMP-2  GTTCCCCTTCTTGTTCAATG  CTTGCCATCCTTCTCAAAGT 
MMP-14  GGGTGAGGAATAACCAAGTG  CTTCCTCTCGTAGGCAGTGT 
SM22a  CTGAGGACTATGGGGTCATC  TAGTGCCCATCATTCTTGGT 
TIMP-1  CCAGCGTTATGAGATCAAGA  AGTATCCGCAGACACTCTCC 
TIMP-2   GAAGAGCCTGAACCACAGGT   CGGGGAGGAGATGTAGCAC 
 
Immunoblot analysis 
Protein levels of SM22α, collagen I and III were determined by immunoblot analysis. 
Immunoblot procedures were performed as previously described27. As primary antibodies, 
rabbit anti-SM22α (Abcam), rabbit anti-collagen I, rabbit anti-collagen III (Abcam) or rabbit 
anti-β-actin (Cell Signalling) were used. Goat anti-rabbit Irdye680 (Li-Cor Biosciences) was 
used as secondary antibody. Pictures were acquired with Odyssey infrared imaging system 
(Li-Cor Biosciences). Densitometric analysis was performed using TotalLab software 
(Nonlinear Dynamics). Expression of proteins of interest was normalized against β-actin. 
Gelatin zymography 
The presence of gelatinase activity in HDFa was determined according to the method of 
Gogly28. Photographs were acquired using a Nikon D80 camera and were processed with 
Adobe Photoshop CS5.1. The gelatinase MMP-2 appears at two bands around 70kDa: an 
upper band of the pro-MMP-2 and a lower band of active MMP-2. The procedure also 
activates the pro-MMP-2. 
Gel contraction assay 
After 4 days of conditioned medium culture, HDFa were detached and resuspended in 
DMEM 2% FBS. Gel contraction assay was performed as described by Van Beuge and 
colleagues29. All cultures were performed in triplicate. After 24h of culture, gels were 
scanned using a flatbed scanner. Surface area of gels was measured using ImageJ.  
Statistical analysis 
All data are represented as mean±SEM. Data were analyzed by one-way analysis of variance 





P-values<0.05 were considered statistically significant.  
Results 
ADSC CM inhibits TGF-β1-induced proliferation in HDFa 
Under control conditions, HDFa and KLF (Fig.1A) displayed a spindle-like morphology, 
which did not alter by ADSC CM. After TGF-β1-stimulation, HDFa and KLF (Fig.1A) changed 
morphology, they became hypertrophic and by visual inspection had increased proliferation. 
The number of nuclei, as visualized with DAPI, objectively indicating the amount of 
proliferation (Fig.1B), was significantly upregulated in the TGF-β1-treated group (Fig.1B, 
p<0.001 vs. control). However, after TGF-β1-treatment combined with ADSC CM, 
proliferation returned to basal level (Fig.1B, p=0.0921 vs. control and p<0.01 vs. 
control+TGF-β1). 




















Fig. 1. Characteristics of human dermal fibroblasts, adult type (HDFa) and keloid scar-
derived fibroblasts (KLF) cultured with adipose-derived stem cell conditioned medium 
(ADSC CM) and/or TGF-β1. (A) Cell morphology. Scale bar represents 200 μm. (B) 
Proliferation rate of HDFa, calculated as the number of DAPI-stained nuclei per high power 
field at 20x magnification. Data are represented as mean ± SEM. ** P < 0.01, *** P < 0.001.  
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ADSC CM alters cytoskeletal composition and function in control condition and 
after TGF-β1-stimulation in HDFa and KLF. 
The F-actin component of the cytoskeleton was visualized using FITC-conjugated 
phallotoxins. In HDFa (Fig.2A), ADSC CM caused a decrease of F-actin bundles, but not in 
KLF (Fig.2A). However, TGF-β1-treatment caused KLF to retract to the edge of the culture 
vessel. After TGF-β1-treatment, contracted patches of cells had formed in the culture vessel 
(Fig.2A). Treatment with ADSC CM strongly inhibited this TGF-β1-induced contraction of 
KLF in 2 out of 3 ADSC donors. In HDFa, SM22α gene and protein expression (a protein 
associated with F-actin and an established mesenchyme marker to quantify cytoskeletal 
changes) decreased 0.38±0.02 (Fig.2B, p<0.05 vs. control) and 0.45±0.09 fold (Fig.2D, 
p<0.05 vs. control), respectively with ADSC CM alone. After TGF-β1-stimulation, SM22α 
gene and protein expression increased (Fig.2D), which was not altered by ADSC CM. In KLF, 
SM22α gene expression was increased by TGF-β1 to 3.29±0.30 (Fig.2B), which was reduced 






Fig. 2. Cytoskeletal organization of HDFa and KLF is influenced by ADSC CM in presence an 
absence of TGF-β1. (A) Staining of HDFa and KLF with FITC-conjugated phallotoxins 
(green), nuclei counterstained with DAPI (blue). Scale bar represents 300 μm. (B) qRT-PCR 
for SM22α mRNA expression after ADSC CM treatment and/or TGF-β1 stimulation (C) 
Representative images of immunoblotting for SM22α protein expression in HDFa (D) 
Quantification of SM22α protein expression in HDFa. Data are represented as mean ± SEM. 
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ADSC CM reduces contractility in HDFa 
To determine the functional implications of the reduction of cytoskeletal components, we 
performed a collagen gel contraction assay with HDFa (Fig.3A). Under control conditions, 
HDFa already contracted collagen gels to 54.4%±1.1% of their original gel area (Fig.3B). In 
ADSC CM pre-treated group, contraction of gels was reduced to 33.0%±3.6% (Fig.3B, 
p<0.001 vs. control). After TGF-β1 stimulation, contraction of gels increased to 74.7%±1.7%, 


















Fig. 3. HDFa gel contraction assay. (A) Representative images of HDFa (pre-incubated under 
different conditions for 4 days), 24 hours after seeding in collagen gels. (B) Contraction of 
collagen gels, represented as percentage of contraction compared to the original volume. 
Data (n=3) are represented as mean ± SEM. * P < 0.05, *** P < 0.001 
 
ADSC CM prevents hypertrophy in TGF- β stimulated HDFa  
In inverted microscopic view (data not shown), HDFa partly lost their typical ‘hill-and-valley’ 
features after treatment with TGF- β and/or ADSC CM. HDFa shortened and gained width, 
i.e. they became hypertrophic. The degree of hypertrophy was investigated by measuring 
length and width of HDFa after staining with CellMaskTM (Fig.4A). Lengths of HDFa 
decreased 0.80±0.007 fold after ADSC CM treatment only, 0.79±0.008 fold after TGF-β1-
stimulation and 0.80±0.007 fold after treatment with ADSC CM and TGF-β1 (Fig.4B, 
p<0.001 vs. control). Width increased slightly after ADSC CM, to 1.06±0.01 fold (Fig.4C, 
p<0.001 vs. control). After TGF-β1-stimulation, width increased to 1.33±0.01 fold (Fig.4C, 
p<0.001 vs. control), which was only 1.04±0.01 fold with concurrent ADSC CM treatment 
(Fig.4C, p<0.001 vs. control+TGF-β1). Thus, ADSC CM reduced the TGF-β-induced 














Fig. 4. Hypertrophy measurements in HDFa after ADSC CM treatment with TGF-β1 
stimulation and controls. (A) Images of HDFa with immunofluorescent membrane staining 
(red), nuclei counterstained with DAPI (blue). Scale bar represents 200 μm. (B) Relative 
length and (C) relative width of HDFa. Data (n=3) are represented as mean ± SEM. *** P 
0.001.  
Extracellular collagen deposition by HDFa is altered by ADSC CM 
The deposition of collagen types I and III by HDFa was examined by immunofluorescent 
staining (Fig.5A, B). Cells were not permeabilized, thus only extracellularly deposited 
collagen was visualized. ADSC CM strongly reduced the amount of deposited collagen after 
TGF-β-stimulation. In KLF, ADSC CM treatment did not change the deposition pattern of 
collagen I and III (data not shown). 
Adipose-derived stromal cells inhibit TGF-β induced differentiation of 

























Fig. 5. Collagen I and III in HDFa after ADSC CM treatment with TGF-β1 stimulation and 
controls. Immunofluorescent staining for (A) collagen I (red), nuclei counterstained with 
DAPI (blue) and (B) collagen III (red), nuclei counterstained with DAPI (blue). Scale bars 
represent 300 μm. Collagen I and III expression in HDFa and KLF were also investigated on 
(C, D) mRNA level and (E, F) in HDFa also on protein level. Representative images for 
immunoblotting of (G) collagen I and (H) collagen III. Data are represented as mean ± SEM. 
* P<0.05, ** P < 0.01, *** P 0.001.  
 
Collagen I and III gene and protein expression in HDFa are altered by ADSC CM 
treatment 
In HDFa, ADSC CM treatment reduced collagen I and collagen III gene expression 
0.49±0.04 fold (Fig.5C, p<0.01 vs. control) and 0.48±0.06 fold (Fig.5D, p<0.001 vs. control) 
respectively. Upon TGF-β1-stimulation, ADSC CM did not reduce collagen I gene expression, 
yet collagen III gene expression was reduced below basal level, to 0.66±0.06 fold (Fig.5D, 





(Fig.5D, p<0.001 vs. control), yet collagen I increased to 3.59±0.38 (Fig.5C, p<0.01 vs. 
control+TGF-β1). 
As for protein production in HDFa, collagen I was reduced 0.51±0.13 fold (Fig.5E, 
p<0.05 vs. control) after ADSC CM, and increased 1.51±0.05 fold (Fig.5E, p<0.05 vs. 
control+TGF-β1) after ADSC CM treatment with TGF-β1-stimulation. For collagen III, there 
was no significant difference (Fig.5F). 
Production and activation of matrix metalloproteinases is influenced by ADSC 
CM treatment 
In ADSC CM treated HDFa, MMP-1 and MMP-2 mRNA expression increased 3.95±0.36 fold 
(Fig.6A, p<0.05 vs. control) and 1.38±0.02 fold (Fig.6B, p<0.001 vs. control) respectively. In 
KLF, MMP-2 expression increased to 2.53±0.41 fold (Fig.6B, p<0.05 vs. control+TGF-β1). 
Furthermore, we showed increased gelatinase activity in HDFa by means of gelatin 
zymography. Active MMP-2 was increased by ADSC CM, irrespective of TGF-β1-stimulation 
(Fig.6F).  As for MMP-14, gene expression was upregulated by ADSC CM treatment to 
1.40±0.08 fold (Fig.6C, p<0.05 vs. control+TGF-β1). TIMP-1gene expression was increased 
to 1.23±0.06 fold with ADSC CM treatment only (Fig.6D, p<0.05 vs. control). After TGF-β1 
stimulation, TIMP-1 gene expression was decreased to 0.40±0.07 fold compared to control, 
but was partially restored by ADSC CM treatment to 0.65±0.3 fold (Fig.6D, p<0.05 vs. 
control+TGF-β1). TIMP-2 gene expression was also increased by ADSC CM treatment in 
HDFa and KLF, to 1.20±0.04 fold (Fig.6E, p<0.05 vs. control) and 1.78±0.37 fold (Fig.6E, 
p<0.05 vs. control), respectively. 
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Fig. 6 Inventory of matrix degradation by HDFa and KLF. Relative gene expression of matrix 
degrading proteins (A) MMP-1 and (B) MMP-2 and (C) their activator MMP-14. Expression 
of inhibitors (D) TIMP-1 and (E) TIMP-2. Furthermore, proteolytic activity of (F) MMP-2 
protein was analysed. Data (n=5) are represented as mean ± SEM. * P < 0.05, *** P < 0.001.  
 
Discussion 
Our set of experiments clearly demonstrates that TFG-β-induced myofibroblast 
differentiation and function of human dermal fibroblasts is inhibited by ADSC CM and 
thereby underlines the positive clinical effects observed of ADSC on disturbed wound healing 
and aged skin. To our knowledge, this is the first report that demonstrates that ADSC can 
inhibit (dermal) fibroblast differentiation and after TGF-β-stimulation. This implicates that 
ADSC results in inhibition of fibroblast differentiation which might lead to prevention or 
even reduction of dermal scars. The effects of ADSC consisted of inhibition of cytoskeletal 
elements and hypertrophy, ECM secretion, contraction as well as promotion of matrix 
degrading enzymes. End-stage myofibroblasts, i.e. KLF were less refractory to the inhibitory 
influence of ADSC CM. Only TGF-β-stimulated KLF contraction was altered by ADSC CM, 
not the production and degradation of ECM components. In TGF-β-stimulated HDFa, ADSC 
CM appeared to tip the balance of ECM remodeling towards normalization in contrast to 





well as reduced the amount of deposited collagens in a manner that resembles resolution of 
wound healing. Our in vitro model for skin fibrosis is limited to assess on the one hand only 
over short times (days) and with strong stimulators (TGF-β). The role of TGF-β in 
stimulation of collagen incorporation into extracellular matrix, is long known30,31. In our 
research, collagen I was still present intracellularly, yet extracellular deposition was reduced 
by ADSC CM after TGF-β stimulation of human dermal fibroblasts. Remarkably, the gene 
expression of collagen I was also reduced, thus the intracellular presence would merely 
reflect storage instead of actual synthesis. Therefore, our observation that ADSC CM 
interfere with the process of extracellular deposition and turnover of collagen I and III is 
topic of our current research in vivo.The influence of ADSC CM on HDFa was partially 
replicated in KLF. In the absence of TGF-β, ADSC CM was able to reduce collagen III gene 
expression in KLF compared to control. In presence of TGF-β, SM22α mRNA expression was 
decreased too. Collagen production as well as upregulation of the contractile apparatus, are 
hallmark features of the myofibroblast21. It is striking that in KLF, which have already 
undergone myofibroblast differentiation, ADSC CM only seems to inhibit one out of these 
two processes: either matrix production, or contractility. To date, there are no literature data 
available regarding an effect of lipofilling to reduce keloid scars. Our data suggest that KLF 
might be differentiated too far to revert the normal fibroblastic phenotypic by means of 
ADSC. Nevertheless, the ADSC were potent in suppression of various components of 
myofibroblasts differentiation. 
 In this study, the molecular mechanism by which ADSC exert their anti-fibrotic 
influence remains largely unelucidated. In a recent pig study, Yun and co-workers32, showed 
that ADSC improved healing of full thickness skin wounds, while scarring was minimal. This 
was partly attributed to the upregulation of TGF-β3. In scarring, TGF-β3 antagonizes the 
pro-fibrotic action of TGF-β133. Yet, ADSC in our investigations had only very low gene 
expression levels of any of the three forms of TGF-β (data not shown). Thus other paracrine 
factors probably were responsible for the suppressive effects of ADSC CM. Interestingly, the 
immune-modulatory features of ADSC and MSC have been shown to suppress the fibrotic 
phenotype of scar fibroblasts34 and activated hepatic stellate cells35 through secreted 
interleukin-10 (IL-10), Tumor Necrosis Factor-α (TNF-α) and Hepatocyte Growth Factor 
(HGF). Although, IL-10 gene expression was negligible in our ADSC, they expressed strongly 
anti-inflammatory mediators such as IDO and PGE2 (E. Przybyt, unpublished). In vivo, IDO 
and PGE2 upregulate IL-10 production by macrophages, which is important in the resolution 
of wound healing. In contrast, in our experiments the conditioned medium could only 
directly affect HDFa instead of indirectly through macrophage activation. This notion, and 
the ease of the use of conditioned media in terms of generation, standardisation, storage to 
mention, warrants further research in other routes of paracrine communication. In other 
labs, the role of ADSC has been assessed in dermal wound healing12-15, dermal 
rejuvenation16,17 and tissue engineering of epidermis19. Previous studies have demonstrated 
effects of ADSC on proliferation, migration, extracellular matrix production and radical 
oxygen species formation in fibroblasts12-15. Already, improvement of skin quality1 and scar 
reduction2-6 have been reported after fat grafting. It has been suggested by Coleman and 
Mojallal that these regenerative effects can be attributed to ADSC, which are transplanted 
along with the adipose tissue36,37.  
We showed that the paracrine factors secreted by ADSC modulate differentiation of 
fibroblasts and their subsequent function. As fat reduces dermal scarring, our study is a first 
in the understanding which cellular component in adipose tissue is involved in scar 
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reduction. In addition, development towards application of conditioned medium of ADSC 
may help prevent adverse wound healing and scarring. Currently, we investigate the 
molecular mechanisms of the paracrine action of ADSC in wound healing. 
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Summary of the thesis 
Cardiovascular diseases are the leading cause of death globally. Myocardial Infarction 
(MI) occurs due to the occlusion of one of the branches of the coronary artery system. Once 
the coronary artery occludes, the downstream myocardium is deprived of oxygen and 
nutrition, which lead to myocardial ischemia. Prolonged ischemia results in the death of 
cardiomyocytes and surrounding vasculature. Subsequently, the death signals from 
apoptotic and necrotic cells activate rapid inflammatory reaction, which dominates the early 
post-MI murine cardiac microenvironment. Unfortunately, the proliferation capacity of adult 
cardiomyocytes is not sufficient to repair the extensive cardiac damage and current therapies 
do not alleviate the cardiac repair. Insufficient cardiomyocyte proliferation together with 
excessive myofibroblast proliferation leads to irreversible scar formation. This scar, however, 
is required to maintain the heart’s structural integrity. In the subsequent period post-MI, the 
cardiac tissue suffers from lack of synchronized contraction caused by the stiff scarred tissue. 
Moreover, to compensate for the loss of cardiomyocytes, the spared cardiomyocytes respond 
with hypertrophy. This is followed by adverse remodeling: left ventricular dilatation, 
deterioration of cardiac function and eventually heart failure. To prevent the negative cardiac 
remodeling phase, it is essential to provide a new source of cardiomyocytes and increase the 
vascularization of the damaged area. The initiation of the regenerative processes must occur 
in early post-MI: during the inflammatory phase that starts immediately after MI and before 
appearance of scar tissue, thus leaving a small window of opportunity for regeneration [1]. 
Despite early medical intervention and fast restoration of the blood flow to limit the damage 
area, still there is no cure and the number of patients who engage in heart failure post-MI 
increases.  
A recent and promising approach for induction of cardiac repair is (stem) cell-based 
therapy. It is known that adult cardiac tissue has an endogenous repair capacity that leads to 
total replacement of cardiomyocyte every eight years during healthy life span. Moreover, the 
repair is even further enhanced after the incident of MI [2, 3]. Ample reports suggest that 
cardiac repair could be boosted by highly regenerative stem cells or stem cell-secreted 
factors. The application of therapeutic cells could be a tool for modulation of the 
inflammatory post-MI microenvironment in the damaged area and provide the healing 
support. The formation of scar tissue and development of heart failure could be delayed or 
blocked by the rapid induction of cardiomyocyte proliferation and increased revascularized 
area. A promising stem cell type for cardiac therapy could be of mesenchymal origin, the 
same embryonic origin as cardiac tissue. Mesenchyme-derived stem/progenitor cells are 
present in a plethora of tissues such as muscle, bone marrow or adipose tissue. Currently the 
most promising stromal cells are derived from adipose tissue i.e. Adipose-tissue Derived 
Stem/Stromal Cells. Recent clinical trials with intramyocardial injection of freshly isolated 
ADSC demonstrated the improvement of cardiac parameters, increased revascularization 
and finally the quality of life [4].  
An important factor in successful post-MI stem cell therapy is the modulation of the 
cardiac microenvironment. The post-MI microenvironment comprises of hypoxia and 
inflammatory mediators among others. Inflammation should not be completely blocked but 
modulated because this process is essential in cardiac wound healing [5]. The inhibition of 
the inflammatory reactions early after the incident of myocardial infarction actually 
deteriorates the healing processes [6].  
Thus, in this thesis, we investigated the regenerative potential of ADSC exposed to 
the in vitro ischemic and inflammatory conditions. We mimicked and applied the post-MI 
host microenvironment in vivo conditions to validate the ADSC repair potency in the 





inflammatory and hypoxic microenvironment. In the first part of this thesis, we focused on 
stimulation of cardiomyocyte proliferation, maturation and cardiomyocyte cell-cell 
organization. In chapter 2 we describe the functioning of applied therapeutic cells in the 
post-MI host microenvironment and the changes that influence the outcome of 
mesenchymal cell-based therapy. Mesenchymal Stem Cells (MSC) such as ADSC are 
promising because of their simple isolation method and abundant secretion of therapeutic 
factors. Recently, the preconditioning of “naïve” stem cells gained increasing interest: 
previously presumed deleterious stimuli such as hypoxia and inflammation, i.e. causes of 
myocardial damage, have the opposite effect on mesenchymal stem cells. ADSC gain a higher 
therapeutic capacity under hypoxia and inflammatory conditions, which render them 
promising for cardiac regeneration [7]. 
In chapter 3 we investigated the influence of the post-infarction cardiac 
microenvironment on ADSC cardiac repair mechanisms in vitro. Postnatal cardiomyocytes 
have a low to absent proliferation rate, while induction of proliferation seems even more 
rare. In metaplastic diseases, the pro-inflammatory cytokine interleukin-6 (IL-6) has been 
identified as potent mediator of the proliferation rate. IL-6 stimulates the proliferation of 
human muscle satellite cells after acute muscle damage [8]. We identified that ADSC 
upregulate and secrete IL-6 abundantly after exposure to pro-inflammatory cytokines. 
Stimulation of the cardiomyocytes with ADSC conditioned media, i.e. rich in IL-6, from 
hypoxia and IL-1β primed ADSC, strongly enhanced cardiomyocyte proliferation. In contrast 
to current data, not only hypoxia may exert a beneficial effect on ADSC [9-11]. We found that 
inflammation had a stronger positive effect than hypoxia on the ADSC secretion profile. 
Furthermore, in chapter 3, we identified previously uncharacterized function of conditioned 
medium of ADSC signaling in regulating cardiomyocyte proliferation. We demonstrated that 
stimulation of cardiomyocyte proliferation by ADSC conditioned medium was accomplished 
through activation of both Janus Kinase-Signal Transducer and Activator of Transcription 
(JAK/STAT) and Mitogen-Activated Protein (MAP) kinases (MAPK) mitogenic signaling 
pathways. Interestingly, reduction of STAT3 phosphorylation led to increased levels of 
phosphorylated Erk1/2, indicating a feedback loop between these pathways. This suggests 
that the stimulated proliferation rate of cardiomyocytes is a balance between STAT3 
signaling and MAP-kinase signaling [12]. 
Induction of adult cardiomyocyte proliferation has long thought to be impossible 
because of the static nature of adult cardiomyocytes, although recent literature indicates that 
adult cardiomyocytes can proliferate and that even the induction of adult cardiomyocyte 
proliferation is feasible [13]. Pivotal cardiogenic factors are mitogens of the EGF family such 
as Neuregulin, HB-EGF, and TGF-α. Treatment using EGF ligands after murine aMI 
increases cardiomyocyte numbers, reduces scar formation and improves cardiac function 
[14, 15]. Thus, in chapter 4, we investigated the influence of ADSC and their secreted 
factors on the proliferation of cardiomyocytes under culture conditions that mimic the post-
aMI microenvironment. We demonstrated that hypoxic and inflammatory stimuli caused 
increased secretion of HB-EGF by ADSC. The direct co-culture of ADSC with cardiomyocytes 
resulted in an increased proliferation rate of cardiomyocytes. Moreover, treatment of 
cardiomyocytes with the conditioned medium of ADSC resulted in increased cardiomyocyte 
proliferation, partially due to the presence of HB-EGF. Stimulation of HL-1 cardiomyocytes 
with the conditioned medium of ADSC lead to activation of EGF-MAPK-Erk1/2 signaling in 
HL-1 cardiomyocytes resulting in increased cardiomyocyte proliferation rate.  
It is known that the mutual interactions of cells, soluble mediators and extracellular 





outcome of the infarcted myocardium. Thus in chapter 5 we focused on the regenerative 
potential of ADSC-derived extracellular matrix components. ECM components have been 
recognized as key players in cardiomyogenesis and cardiac repair [16]. Injection of bone 
marrow-derived ECM after ischemic injury in rats resulted in improved cardiac function i.e. 
reduced fibrosis [17]. Still the mechanism of the interactions between ADSC and their 
synthesized ECM components with the cardiomyocytes is not known. We demonstrated that 
ADSC in addition to its activation of a paracrine driven regenerative interactions, also secrete 
ECM components in the intercellular space. The extracellular matrix components 
synthesized by ADSC directly influence the cardiomyocyte microenvironment by creation of 
the fibrous scaffold for proper functioning and signaling of the cells into a unified syncytium.  
We demonstrated that in vitro co-culture of neonatal cardiomyocytes with ADSC or with 
ADSC-derived ECM enhanced the cardiomyocyte proliferation, alignment, cellular 
interconnections and sarcomeres maturation. Furthermore, cardiomyocytes cultured on 
ADSC-derived ECM matrices had an increased proliferation rate and decreased cell size 
(hypertrophy) compared to cardiomyocytes cultured on tissue culture polystyrene (TCPS) or 
on a Fibronectin/Gelatin coating [18].  
In conclusion of Part I of this thesis, we demonstrated that ADSC have an enhanced 
repair potential after exposure to the hypoxia and inflammatory mediators found in post-MI 
microenvironment. ADSC promote the proliferation rate of cardiomyocytes by both 
juxtacrine and paracrine interactions and through the deposition of extracellular matrix 
components. One of the therapeutic options to improve the outcome of cardiac therapy 
would implement an ADSC-derived “of-the-shelf” product such as a serum-free ADSC 
conditioned medium or lyophilized ADSC-derived ECM components for the immediate 
treatment of post-MI. Another suggestion to further increase the therapeutic potential of 
ADSC would be to prime ADSC with hypoxia and pro-inflammatory cytokines prior to 
application of ADSC-derived therapeutic secreted factors.  
Recently reported clinical trials that employ intramyocardial administration of ADSC 
in patients post-MI, identified that major improvement is associated with reduction of a scar 
tissue due to improved perfusion. Therefore, in Part II we investigated the role of ADSC in 
vascular network formation and its stabilization. The cells that orchestrate endothelial cells 
proliferation, survival, vascular tone and permeability are known as pericytes [19]. In 
Chapter 6, we reviewed pericyte with respect to their ontogeny, function and regenerative 
prospective of ADSC. In particular, the acquisition of pericyte function of ADSC in the 
presence of endothelial cells [20]. Pericytes are present in the vasculature of all organs 
including retina, brain, skeletal muscle or adipose tissue [21]. Pericytes originate from 
neuroectoderm or embryonic mesenchyme, thus sharing a mesenchymal phenotype with 
ADSC. Adipose tissue is highly vascularized with abundance of the stromal vascular fraction 
derived ADSC, which represent the perivascular pericytes or adventitial cells [22]. 
Endothelial cells directly interact with ADSC in co-cultures [23]. On confluent monolayers of 
cultured ADSC, endothelial cells form vascular-like networks that are reminiscent of 
sprouting networks formed on Matrigel [23]. However, ‘Matrigel sprouting’ is a short term 
angiogenesis process, while vascular network formation on ADSC monolayers requires 
longer time to establish (days instead of hours) and comprises of tubes build up of multiple 
endothelial cells as opposed to single celled capillaries.  Moreover, a number of studies have 
shown that ADSC and bone marrow MSC engraft onto endothelial sprouting networks on 
matrigel [24]. In chapter 7, we show that ADSC acquired pericyte’ function in vitro and in 
vivo. ADSC, when in direct contact with endothelial cells, induced vascular network 
formation. In vitro and in vivo ADSC incorporated into the existing vasculature and 





promoted vessel normalization. Additionally, in the model of oxygen induced retinopathy 
(OIR), ADSC replaced the lost pericytes and promoted vascular normalization by acquisition 
of pericyte’ function as well as by modulation of the damaged microenvironment to drive the 
vasculature homeostasis. This shows both that there exists a reciprocal plasticity between 
ADSC and pericytes and that ADSC are a promising tool to alleviate pericyte loss. Moreover, 
we have shown that ADSC not only support formation of endothelial tubes, but that 
multicellular vascular structures are formed and are maintained for several weeks through 
interaction with ADSC. To achieve the higher therapeutic potential of stem/progenitor cells 
it is possible to instruct the cells in vitro before their administration in vivo. For example, 
creating a pre-mature complex of vascular network associated with their stabilizing adipose 
tissue-derived pericytes prior the injection. The understanding of stem/progenitor plasticity 
in the presence or absence of post-damage microenvironmental factors helps to develop and 
improve therapies. Therefore, in chapter 8 we investigated the influence of  pro-
inflammatory and hypoxic preconditioning of ADSC on the formation of endothelial 
networks. The medium of hypoxic and pro-inflammatory preconditioned ADSC increased 
migration of EC and formation of more stable  vascular networks in-vitro compared to 
control ADSC-conditioned medium. In direct co-culture with ADSC, EC formed vascular 
networks that lasted for several weeks. Other stromal cell types such as human dermal and 
cardiac fibroblasts or mouse 3T3 fibroblastic cells failed to induce vascular networks. We 
concluded that ADSC promote vascular network formation and its stabilisation in vitro 
through paracrine and juxtacrine interactions with EC.  Priming of EC to form vascular 
network by direct co-culture with ADSC or culture of EC in the presence of ADSC-derived 
conditioned medium could offer a potent strategy to revascularize damaged myocardium. 
One of the potential risks in stem cell guided cardiac repair by MSC is accelerated fibrosis. 
The major advance in the cardiac clinical trials with ADSC application indicated reduced 
infarct size and scarring. Thus in Chapter 9, we focused on the impact of ADSC in tissue 
remodeling in vitro. We demonstrated that TGF-β-induced proliferation of primary human 
dermal fibroblasts (HDFa) was abolished by ADSC conditioned medium. Simultaneously, 
ADSC conditioned medium, reduced SM22α gene and protein expression of TGF-β-treated 
HDFa, while their contractility was reduced too. Furthermore, ADSC conditioned medium 
strongly reduced transcription of collagen I and III genes as well as their corresponding 
proteins. On the other hand the ADSC conditioned medium tipped the balance of matrix 
turnover to degradation through stimulating gene expression of MMP-1, 2 and 14, while 
MMP-2 activity was upregulated too. Even in the fully differentiated myofibroblasts such as 
from keloids (KLF), ASDC conditioned medium suppressed TGF-β-induced myofibroblast 
contraction, and collagen III gene expression. In this study we showed that ADSC inhibited 
TGF-β-induced adverse differentiation and function of HDFa and TGF-β-induced 
contraction in KLF, in a paracrine fashion [25]. This might have an impact the development 
therapies that target cardiac fibrosis and scar formation.  
In line of this research, we dissected part of mechanisms that underlie the beneficial 
contribution of ADSC for the treatment of myocardial infarction complications trough 
increase of cardiomyocyte mass, improved re-vascularization and immunomodulatory 
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and diabetes throughout the Old and the New World. The foremost cause of death globally is 
heart failure. Despite immediate interventions and the advances made in the treatment, still 
there is no cure of complications that result from acute Myocardial Infarction (MI). 
Moreover, the adult human heart does not have sufficient regenerative capacity to restore 
the damage. The occlusion of coronary arteries causes loss of cardiomyocytes and 
compromises perfusion. The cardiac ischemia and death signals trigger influx of pro-
inflammatory cells.  Subsequently the debris is cleared and the wound healing processes are 
initiated. Unfortunately, the heart instead of healing, form the scar tissue to maintain tissue 
integrity. The sustained presence of rigid tissue and inflammation lead to deterioration of 
cardiac function. As no conventional therapy can prevent the negative aftermath of MI, 
alternative treatments are warranted.  
Cardiac stem cell based therapy has been put forward over the past decade. Extensive 
comparison of various types of therapeutics cells used in the clinical trials in post-MI 
patients indicated that Mesenchymal Stem Cells (MSC) are promising therapeutic 
agents for cardiac repair. MSC share the same mesodermal origin as of cardiomyocytes, such 
as muscle tissue. MSC are genuine cellular factories of therapeutic molecules such as growth 
factors, cytokines and extracellular matrix components among others. MSC are most 
frequently obtained from bone marrow or adipose tissue. Harvesting therapeutic cells by 
liposuction it is less painful and less invasive procedure compared to bone marrow 
aspiration. Moreover, isolation of therapeutic cells from adipose tissue yield higher clinically 
relevant cell number compared to the bone marrow [26]. The heart itself also contains 
mesenchymal-like stem cells, though more difficult to acquire.  
Mesenchymal stem cells from adipose tissue 
Adipose tissue is an abundant source of mesenchymal stem cells, known as adipose tissue-
derived stem or stromal cells (ADSC) [27]. By definition, ADSC are the plastic adherent 
fraction of the stromal vascular fraction of adipose tissue. This high abundance of cells 
almost contradicts them being named as stem cells. Also their limited number of population 
doublings supports the suggestion to call ADSC adipose tissue-derived stromal cells, more 
than stem cells. Not uncommon for ‘stem’ cells, the origin of ADSC is debated. Similar to all 
other types of MSC, ADSC are per definition in vitro culture artifacts that acquire a 
phenotype that may strongly differ from their in vivo phenotype. To date, the vasculature of 
adipose tissue is thought to give rise of at least three types of multipotent precursor cells. 
Firstly, at luminal side these are endothelial precursor cells, while both other types are either 
supra-adventitial [28] or perivascular [29,30]. These perivascular ADSC are likely a 
subfraction of the pericytes, while the supra-adventitial ADSC may relate to a specific subset 
of advential fibroblasts [31]. Others provide evidence that ADSC originate from perivascular 
and adventitial vascular regions but are more similar to smooth muscle cells [31-34]. It is 
likely that the cells in these locations form a continuum, while the local microenvironment 
dictates their resident phenotype. Once disrupted from their original environment, these 
cells appear to show a high degree of interchangeability [30]. In comparison to BM-MSC, 
ADSC yields are consistently higher, while the growth rate of ADSC in a simple mesenchymal 
medium is higher too [35]. In vitro, ADSC have a mesenchymal phenotype and morphology.  
Tuning the post-MI microenvironment/ Juxtacrine/paracrine interactions 
The previous work showed that cardiac repair must be initiated immediately after post-MI. 
The key factor in cardiac repair is inflammation and following wound healing. van 
Amerongen and others demonstrated that Inhibition of the inflammatory responses, by 
macrophage depletion, resulted in increased cardiac adverse remodeling and deterioration of 
the cardiac tissue [36]. However, sustained inflammation can be deleterious by providing 





non-regenerative signals. Interestingly the cardiac repair system is activated during the early 
phase post-MI, still not sufficient [37]. Both inflammatory and regenerative signals need to 
be tuned to form balance between adverse inflammatory remodeling and regeneration.  
The post-MI hostile microenvironment is characterized by lack of perfusion and massive cell 
death and thus is a non-attractive playground for therapeutic stem cells. The understanding 
of the working mechanism of MSC has greatly increased and led to the discovery that these 
cells can be primed to a higher level a therapeutic capacity by potentially deleterious stimuli 
such as hypoxia and inflammation. The stem cell mediated cardiac therapy might be 
hampered by the post-MI microenvironment. Interestingly, the preconditioning of stem cells 
is gaining more interest: previously presumed deleterious stimuli such as hypoxia and 
inflammation, i.e. causes of myocardial damage, have the opposite effect on mesenchymal 
stem cells.  MSC gain a higher therapeutic capacity under hypoxia and inflammatory 
conditions. We identified that ADSC activate their regenerative potential under in-vitro 
mimicked post-MI pro-inflammatory microenvironment. Adipose stromal cells primed with 
hypoxia and inflammation (2% O2 and IL-1β) enhance cardiomyocyte proliferation rate in 
vitro.  ADSC under pro-inflammatory conditions assessed paracrine-driven and juxtacrine 
driven enhancement of cardiomyocyte proliferation rate and induction of myogenic signaling 
pathways such as JAK-STAT and MAPK by induction of STAT3 and Erk1/2 phosphorylation. 
ADSC despite the activation of the mitogenic signaling pathways also increase the pro-
angiogenic potency. ADSC induce simultaneous growth of cardiomyocytes and vasculature. 
ADSC can modulate the post-MI microenvironment through secretion of the broad range of 
growth factors and cytokines. These trophic factors include mitogens such as hepatocyte 
growth factor (HGF), insulin growth factor (IGF), and fibroblast growth factors (FGF), 
vascular endothelial growth factor (VEGF), but also immunological factors such interleukin-
1β, -6 (IL-1β, IL-6) and transforming growth factor-beta (TGF-beta) as well as matrix 
remodeling enzymes such as matrix metalloproteases (MMPs) [38-40]. ADSC are strongly 
proangiogenic through secretion of e.g. VEGF, FGFs, and angiopoietins. Along with 
paracrine interaction through the secreted mediators, ADSC also promote vessel formation 
and cardiomyocyte proliferation in vitro through juxtacrine interaction with endothelial cells 
and cardiomyocytes. Part of this juxtacrine interaction that promotes stable vessels, is 
governed by secretion of extracellular matrix components by ADSC [23]. Moreover, the 
‘pericytic’ ADSC fraction from adipose tissue stabilize vascular structures in vitro, which 
depended on cell-cell contacts and on mutual signaling with paracrine factors [41]. We have 
shown that ADSC not only support formation of the multi-cellular vascular endothelial tubes 
but also ameliorate its stability for several weeks in-vitro. Furthermore, we have shown in a 
murine model for retinal pericyte loss that ADSC can normalize pathologic capillaries. The 
intra-retinal injected ADSC acquired a typical pericytic position in the vasculature. This 
shows high reciprocal plasticity, functioning and retention of ADSC.     
Despite the known paracrine influence of ADSC in the cardiac repair, the juxtacrine 
signaling i.e. cell-cell and cell-ECM role of ADSC in post-MI repair process is not fully 
understood. The post-MI myocardial repair requires remodeling the ECM for adequate de 
novo cardiomyogenesis and vasculogenesis. The ECM is instrumental in both processes. 
ADSC-derived ECM components provide a suitable substrate to support cardiomyocyte 
homeostasis i.e. cardiomyocyte alignment, maturation and synchronized contraction in vitro.  
This finding supports the use of human, autologous, ADSC as a promising modality to treat 
MI. Moreover, i.e. lyophilized ADSC-derived ECM or in a form of injectable biomaterial i.e. 





treatment of post-MI complications. Alternatively, ADSC-secreted ECM components could 
augment scaffolds used to tissue-engineer myocardial replacement patches that are based on 
e.g. iPSC-derived autologous cardiomyocytes. The ECM components would improve the 
organization and compaction of the cardiomyocytes on scaffolds. Moreover, the ADSC-
derived ECM could act as a sponge for capture, trafficking and delivery of the secreted 
paracrine factors, which remains to be investigated.  
Taking together, ADSC are a most promising cell type to augment and orchestrate 
cardiac repair through increase of cardiomyocyte proliferation, angiogenesis and modulation 
of the post-MI microenvironment by tuning the pro-inflammatory reactions. This renders 
ADSC the strong clinical pre-requisite for post-MI cardiac repair.  
  
ADSC in clinical trials 
 
Over the past decade, mesenchymal stem cells emerged as a most promising type of stem cell 
for cardiovascular regeneration. Besides bone marrow and cardiac cells, scientists focused on 
other tissue sources for mesenchymal stem cells with a high regenerative potential [43]. For 
example, adipose tissue contains 500-fold more MSC than adult bone marrow, while it is 
easier accessible than bone marrow. ADSC can be isolated from liposuction aspirates and 
prepared as fresh cells for immediate administration in cell therapy. In our experience, up to 
one hundred million ADSC can be easily isolated from as little as one liter of lipoaspirate. 
ADSC have rapidly reached the clinic. The APOLLO double-blind randomized clinical trial 
for treatment of acute myocardial infarction employed autologous ADSC. These ADSC are 
harvested from lipoaspirates and enriched through processing with the Celution system of 
Cytori. This closed system procedure takes only a few hours which allows for administration 
of the ADSC during the early post-MI, while conventional treatment of the acute MI is 
maintained. The clinical trial involved ten patients that received ADSC and four placebo 
group with 36 h after the infarction occurred. APOLLO trial showed two important benefits 
for the intraoperative use of ADSC. Firstly, an up to 60% reduction of infarct size was 
observed and secondly an improved revascularization of the ischemic tissue was observed 
which ameliorated blood flow. In addition, contractility was improved, while no arrhythmia 
was found [44]. According to the investigators not only the short term follow up (six months) 
but also the long term follow up (eighteen months) of the APOLLO clinical trial showed a 
persistent benefit for the patient that had been treated with ADSC. Meanwhile, ADVANCE 
has started which is a follow-up clinical trial focusing to prevent heart failure. It includes a 
near 375 patients that will be treated with ADSC within twenty-four hours after acute 
myocardial infarction. Whereas several trials focus on early intervention, other clinical trials, 
like PRECISE and ATHENA, focus on the aftermath of myocardial infarction i.e. treatment 
of chronic myocardial ischemia with ADSC [45].  Recently published data of the PRECISE 
trial anticipated for the long-term efficacy (up to 36 months) of ADSC-based cardiac stem 
cell therapy. Patients with ischemic cardiomyopathy after trans-endocardially injected ADSC 
showed significant improvements in metabolic equivalents and maximal oxygen 
consumption, increase in total left ventricular mass, reduction in ischemia and no malignant 
arrhythmia compared to the placebo controls patients [46]. These results furthermore 
confirm that ADSC-based stem cell therapy is safe, feasible and may preserve ventricular 









Novel approaches for ADSC-stem cell based therapy 
The results described in this thesis can be implemented to adapt and improve ADSC- based 
therapy for cardiovascular diseases such as myocardial infarction. The best results in the 
treatment of post-MI complications were found after the immediate revascularization of the 
damaged area. Cytori system used in the current clinical trials show that early application of 
ADSC procedure resulted in improved cardiac function. Here we suggest that not only ADSC 
but the frozen or lyophilized ADSC product could offer of the shelf product for early 
application. Furthermore, as described, the increased occurrence of myocardial infarction 
coincides with diabetes, obesity and aging. Indeed, recent reports have been shown that 
ADSC decrease their secretion of pro-angiogenic factors in patients with coronary artery 
diseases or type 2 diabetes [47]. One possibility to overcome metabolic related attenuation of 
ADSC’s repair potential is to prime the cells with the pro-inflammatory and/or hypoxic 
conditions. We identified that ADSC increase their mitogenic and regenerative secretion of 
growth factors and cytokines after stimulation with pro-inflammatory cytokines and hypoxia. 
This led to the “re-juvenation” of the cells used in case of autologous application of ADSC 
from the aged or T2D patients. Moreover, we also showed that there is no need to isolation 
and injection of therapeutic cells but instead could use e.g. conditioned medium or 
extracellular matrix components. As there is no risk of the rejection or foreign body reaction, 
these therapeutic agents could be implemented intramyocardialy right after the primary 
revascularization procedure to modulate acute pro-inflammatory microenvironment, boost 
cardiomyocyte proliferation and increased revascularization of the damaged area to obtain 
enhanced cardiac repair.  
Concluding remarks 
In this thesis we have acquired better understanding of use of Adipose-tissue Derived 
Stem/Stromal Cells in post-myocardial infarction therapy. We have shown that in contrast to 
the previous paradigm, therapeutic cells of mesenchymal origin such as ADSC gain higher 
regenerative potential under hypoxic and pro-inflammatory conditions, which render them 
the most promising cells for cardiac therapy. We have identified that not only ADSC but their 
secreted factors in the conditioned medium or deposited extracellular matrix enhance 
cardiomyocyte proliferation, organization and maturation as well as lead to increased 
vascular network formation. This could help to overcome the costs and the limitation of 
stem/stromal cell therapy as well as offer of the shelf product for immediate application. We 
propose that use of ADSC or ADSC-derived conditioned medium or extracellular matrix 





[1] Vandervelde S, van Luyn MJ, Rozenbaum MH, Petersen AH, Tio RA, Harmsen MC. Stem 
cell-related cardiac gene expression early after murine myocardial infarction. Cardiovasc Res 
2007; 73:783-793.  
[2] Bergmann O, Bhardwaj RD, Bernard S, Zdunek S, Barnabe-Heider F, Walsh S et al. 
Evidence for cardiomyocyte renewal in humans. Science 2009; 324:98-102.  
[3] Kajstura J, Rota M, Cappetta D, Ogorek B, Arranto C, Bai Y et al. Cardiomyogenesis in 
the aging and failing human heart. Circulation 2012; 126:1869-1881.  
[4] Perin E C, Sanz-Ruiz R, Sanchez PL, Lasso J, Perez-Cano R, Alonso-Farto JC et al. 
Adipose-derived regenerative cells in patients with ischemic cardiomyopathy: The PRECISE 





[5] van Amerongen M J, Harmsen MC, Petersen AH, Popa ER, van Luyn MJ. Cryoinjury: a 
model of myocardial regeneration. Cardiovasc Pathol 2008; 17:23-31.  
[6] van Amerongen M J, Harmsen MC, van Rooijen N, Petersen AH, van Luyn MJ. 
Macrophage depletion impairs wound healing and increases left ventricular remodeling after 
myocardial injury in mice. Am J Pathol 2007; 170:818-829.  
[7] Przybyt E, Harmsen MC. Mesenchymal Stem Cells: promising for myocardial 
regeneration?. Curr Stem Cell Res Ther 2013.  
[8] Toth K G, McKay BR, De Lisio M, Little JP, Tarnopolsky MA, Parise G. IL-6 induced 
STAT3 signalling is associated with the proliferation of human muscle satellite cells 
following acute muscle damage. PLoS One 2011; 6:e17392.  
[9] Thangarajah H, Vial IN, Chang E, El-Ftesi S, Januszyk M, Chang EI et al. IFATS 
collection: Adipose stromal cells adopt a proangiogenic phenotype under the influence of 
hypoxia. Stem Cells 2009; 27:266-274.  
[10] Efimenko A, Starostina E, Kalinina N, Stolzing A. Angiogenic properties of aged adipose 
derived mesenchymal stem cells after hypoxic conditioning. J Transl Med 2011; 9:10.  
[11] Przybyt E, Krenning G, Brinker MG, Harmsen MC. Adipose stromal cells primed with 
hypoxia and inflammation enhance cardiomyocyte proliferation rate in vitro through STAT3 
and Erk1/2. J Transl Med 2013; 11:39.  
[12] Fischer P, Hilfiker-Kleiner D. Survival pathways in hypertrophy and heart failure: the 
gp130-STAT3 axis. Basic Res Cardiol 2007; 102:279-297.  
[13] Braun T, Dimmeler S. Breaking the silence: stimulating proliferation of adult 
cardiomyocytes. Dev Cell 2009; 17:151-153.  
[14] Bersell K, Arab S, Haring B, Kuhn B. Neuregulin1/ErbB4 signaling induces 
cardiomyocyte proliferation and repair of heart injury. Cell 2009; 138:257-270.  
[15] Ieda M, Tsuchihashi T, Ivey KN, Ross RS, Hong TT, Shaw RM et al. Cardiac fibroblasts 
regulate myocardial proliferation through beta1 integrin signaling. Dev Cell 2009; 16:233-
244.  
[16] Fomovsky G M, Thomopoulos S, Holmes JW. Contribution of extracellular matrix to the 
mechanical properties of the heart. J Mol Cell Cardiol 2010; 48:490-496.  
[17] Ravi S, Caves JM, Martinez AW, Xiao J, Wen J, Haller CA et al. Effect of bone marrow-
derived extracellular matrix on cardiac function after ischemic injury. Biomaterials 2012; 
33:7736-7745.  
[18] Przybyt E, van Luyn MJ, Harmsen MC. Extracellular matrix components of adipose 
derived stromal cells promote alignment, organization, and maturation of cardiomyocytes in 
vitro. J Biomed Mater Res A 2015; 103:1840-1848.  
[19] Pfister F, Feng Y, vom Hagen F, Hoffmann S, Molema G, Hillebrands JL et al. Pericyte 
migration: a novel mechanism of pericyte loss in experimental diabetic retinopathy. Diabetes 
2008; 57:2495-2502.  
[20] Pfister F, Przybyt E, Harmsen MC, Hammes HP. Pericytes in the eye. Pflugers Arch 
2013; 465:789-796.  
[21] Crisan M, Chen CW, Corselli M, Andriolo G, Lazzari L, Peault B. Perivascular 
multipotent progenitor cells in human organs. Ann N Y Acad Sci 2009; 1176:118-123.  
[22] Traktuev D O, Prater DN, Merfeld-Clauss S, Sanjeevaiah AR, Saadatzadeh MR, Murphy 
M et al. Robust functional vascular network formation in vivo by cooperation of adipose 
progenitor and endothelial cells. Circ Res 2009; 104:1410-1420.  
[23] Merfeld-Clauss S, Gollahalli N, March KL, Traktuev DO. Adipose tissue progenitor cells 
directly interact with endothelial cells to induce vascular network formation. Tissue Eng Part 
A 2010; 16:2953-2966.  





[24] Traktuev D O, Merfeld-Clauss S, Li J, Kolonin M, Arap W, Pasqualini R et al. A 
population of multipotent CD34-positive adipose stromal cells share pericyte and 
mesenchymal surface markers, reside in a periendothelial location, and stabilize endothelial 
networks. Circ Res 2008; 102:77-85.  
[25] Spiekman M, Przybyt E, Plantinga JA, Gibbs S, van der Lei B, Harmsen MC. Adipose 
tissue-derived stromal cells inhibit TGF-beta1-induced differentiation of human dermal 
fibroblasts and keloid scar-derived fibroblasts in a paracrine fashion. Plast Reconstr Surg 
2014; 134:699-712.  
[26] Burk J, Ribitsch I, Gittel C, Juelke H, Kasper C, Staszyk C et al. Growth and 
differentiation characteristics of equine mesenchymal stromal cells derived from different 
sources. Vet J 2013; 195:98-106.  
[27] Daher S R, Johnstone BH, Phinney DG, March KL. Adipose stromal/stem cells: basic 
and translational advances: the IFATS collection. Stem Cells 2008; 26:2664-2665.  
[28] Corselli M, Chen CW, Sun B, Yap S, Rubin PJ, Peault B. The tunica adventitia of human 
arteries and veins as a source of mesenchymal stem cells. Stem Cells Dev 2011.  
[29] Zimmerlin L, Donnenberg VS, Pfeifer ME, Meyer EM, Peault B, Rubin JP et al. Stromal 
vascular progenitors in adult human adipose tissue. Cytometry A 2010; 77:22-30.  
[30] Zimmerlin L, Donnenberg VS, Rubin JP, Donnenberg AD. Mesenchymal markers on 
human adipose stem/progenitor cells. Cytometry A 2013; 83:134-140.  
[31] Lin C S, Xin ZC, Deng CH, Ning H, Lin G, Lue TF. Defining adipose tissue-derived stem 
cells in tissue and in culture. Histol Histopathol 2010; 25:807-815.  
[32] Lin G, Garcia M, Ning H, Banie L, Guo YL, Lue TF et al. Defining stem and progenitor 
cells within adipose tissue. Stem Cells Dev 2008; 17:1053-1063.  
[33] Amos P J, Shang H, Bailey AM, Taylor A, Katz AJ, Peirce SM. IFATS collection: The role 
of human adipose-derived stromal cells in inflammatory microvascular remodeling and 
evidence of a perivascular phenotype. Stem Cells 2008; 26:2682-2690.  
[34] Parvizi M, Harmsen MC. Therapeutic Prospect of Adipose-Derived Stromal Cells for the 
Treatment of Abdominal Aortic Aneurysm. Stem Cells Dev 2015; 24:1493-1505.  
[35] De Ugarte D A, Morizono K, Elbarbary A, Alfonso Z, Zuk PA, Zhu M et al. Comparison of 
multi-lineage cells from human adipose tissue and bone marrow. Cells Tissues Organs 2003; 
174:101-109.  
[36] van Amerongen M J, Harmsen MC, van Rooijen N, Petersen AH, van Luyn MJ. 
Macrophage depletion impairs wound healing and increases left ventricular remodeling after 
myocardial injury in mice. Am J Pathol 2007; 170:818-829.  
[37] Gu X, Liu X, Xu D, Li X, Yan M, Qi Y et al. Cardiac functional improvement in rats with 
myocardial infarction by up-regulating cardiac myosin light chain kinase with neuregulin. 
Cardiovasc Res 2010; 88:334-343.  
[38] Rehman J, Traktuev D, Li J, Merfeld-Clauss S, Temm-Grove CJ, Bovenkerk JE et al. 
Secretion of angiogenic and antiapoptotic factors by human adipose stromal cells. 
Circulation 2004; 109:1292-1298.  
[39] Kilroy G E, Foster SJ, Wu X, Ruiz J, Sherwood S, Heifetz A et al. Cytokine profile of 
human adipose-derived stem cells: expression of angiogenic, hematopoietic, and pro-
inflammatory factors. J Cell Physiol 2007; 212:702-709.  
[40] Blaber S P, Webster RA, Hill CJ, Breen EJ, Kuah D, Vesey G et al. Analysis of in vitro 
secretion profiles from adipose-derived cell populations. J Transl Med 2012; 10:172.  
[41] Traktuev D O, Merfeld-Clauss S, Li J, Kolonin M, Arap W, Pasqualini R et al. A 





mesenchymal surface markers, reside in a periendothelial location, and stabilize endothelial 
networks. Circ Res 2008; 102:77-85.  
[42] Arana M, Gavira JJ, Pena E, Gonzalez A, Abizanda G, Cilla M et al. Epicardial delivery 
of collagen patches with adipose-derived stem cells in rat and minipig models of chronic 
myocardial infarction. Biomaterials 2014; 35:143-151.  
[43] Atsma D E, Fibbe WE, Rabelink TJ. Opportunities and challenges for mesenchymal 
stem cell-mediated heart repair. Curr Opin Lipidol 2007; 18:645-649.  
[44] Houtgraaf J H, den Dekker WK, van Dalen BM, Springeling T, de Jong R, van Geuns RJ 
et al. First experience in humans using adipose tissue-derived regenerative cells in the 
treatment of patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol 
2012; 59:539-540.  
[45] Sanz-Ruiz R, Gutierrez Ibanes E, Arranz AV, Fernandez Santos ME, Fernandez PL, 
Fernandez-Aviles F. Phases I-III Clinical Trials Using Adult Stem Cells. Stem Cells Int 2010; 
2010:579142.  
[46] Perin E C, Sanz-Ruiz R, Sanchez PL, Lasso J, Perez-Cano R, Alonso-Farto JC et al. 
Adipose-derived regenerative cells in patients with ischemic cardiomyopathy: The PRECISE 
Trial. Am Heart J 2014; 168:88-95.e2.  
[47] Dzhoyashvili N A, Efimenko A, Kochegura TN, Kalinina NI, Koptelova NV, Sukhareva O 
et al. Disturbed angiogenic activity of adipose-derived stromal cells obtained from patients 
































Nederlandse samenvatting (Summary in Dutch) 
Hart- en vaatziekten, zoals myocardinfarcten (MI), oftewel hartaanvallen, zijn de 
belangrijkste doodsoorzaak wereldwijd en veroorzaaken 30% van de totale jaarlijkse sterfte 
(www.heartstats.org, www.who.org). De meeste gepubliceerde post-MI interventiestudies 
zijn gericht op het verbeteren van de doorbloeding (perfusie), het verminderen van apoptose 
(celdood) en onderdrukking van sterke ontstekingsreacties. Deze laatste twee benaderingen 
zijn vrijwel uitsluitend farmacologisch van aard en kunnen helaas niet voorkomen dat 
hartspierschade ontstaat, maar induceren ook geen regeneratieve, weefselherstellende 
processen. Ter compensatie van het verlies van cardiale massa is het essentieel om een 
nieuwe bron van cardiomyocyten (hartspiercellen) aan te boren, alsmede post-MI de 
perfusie en weefselremodeling te verbeteren, opdat de toename van verbindweefseling na 
een hartaanval beperkt blijft. Vroege interventies na MI zoals dotteren en het plaatsen van 
stents, hebben de overleving aanzienlijk verbeterd, met name doordat de perfusie hersteld 
wordt. Ook het plaatsen van omleidingen, bypass grafts, heeft de sterfte aanzienlijk 
gereduceerd. Echter, het aantal patienten dat hartfalen ontwikkeld (50% 5 jaarsoverleving) is 
hierdoor juist sterk toegenomen na een infarct. Dit betekent, dat er nog steeds een sterke 
noodzaak bestaat voor het ontwikkelen van nieuwe therapieën, die uiteindelijk leiden tot 
regeneratie van de beschadigde hartspier. De belangrijkste voorwaarde hiervoor is, zoals 
hierboven gememoreerd, nieuwvorming van de spierwand oftewel aanvulling van de 
verloren cardiomyocyten. Dit zou de negatieve remodelling (weefselherbouw) en
verbindweefseling voorkomen en hierdoor ook hartfalen tegengaan.  
Therapie op basis van mesenchymale stamcellen uit vetweefsel.
Stamcellen worden als ‘veelbelovende’ spelers gezien in de ontwikkeling van nieuwe 
behandelmethoden van diverse orgaanziekten, inclusief hart- en vaatziekten. Een bijzonder 
type stamcel, de zg. mesenchymale stamcel, komt voor in vrijwel alle organen van het 
lichaam, maar is het best bestudeerd vanuit beenmerg (BM-MSC) of vanuit vet (adipoos) 
weefsel (ADSC) [1]. De isolatie van therapeutische cellen uit lipoaspiraten na een liposuctie 
procedure is minder invasief en minder pijnlijk in vergelijking met de beenmergpunctie. 
Daarnaast kunnen cellen worden verkregen bij de klinisch relevante getallen of snel worden 
opgeschaald door kweken in vitro. Recente publicaties van experimentele klinische studies 
met intracoronaire, dwz via een kransslagader, infusie van lichaamseigen ADSC geven aan 
dat de procedure veilig is, de hartfunctie enigszins verbetert, vooral de perfusie en 
remodeling verbeteren [2]. Hoewel klinische en preklinische onderzoeken naar de veiligheid 
en efficiëntie van therapie met ADSC voor cardiale regeneratie een consistent beeld geeft, 
zijn de mechanismen waardoor ADSC hartschade herstellen nog lang niet begrepen [3,4]. Dit 
proefschrift heeft tot doel de regeneratieve potentieel van ADSC verder te ontleden onder de 
pro - inflammatoire en hypoxische (zuurstofarme) omstandigheden zoals die zich voordoen 
na acute MI. Verder hebben we de ADSC geleide stimulatie van cardiomyocyt proliferatie, 
organisatie en rijping onderzocht (deel I). Ons onderzoek laat zien dat het voorbehandelen 
van ASDC in vitro, bijvoorbeeld door blootstelling aan hypoxie of biochemische prikkeling 
met ontstekingsfactoren (zoals IL-1β), de regeneratieve capaciteit van ADSC versterkt. Deze 
versterking wordt gemedieerd door de (verhoogde) uitscheiding van zg. paracriene factoren 
die regeneratie bevorderen. Het cytokine IL-6 is een van deze uitgescheiden factoren en 
verhoogd de delingssnelheid van hartspiercellen. Het cytokine IL-6 activeert twee 





Activator of Transcription (JAK/STAT) en de Mitogen-Activated Protein Kinase (MAPK) 
routes. Als cardiomyocyten worden gekweekt, samen met ADSC,  op de bindweefselfactoren 
(extracellulaire matrix, ECM) die door ADSC wordt uitgescheiden en neergelegd, dan 
versterkt dit de orientatie van deze spiercellen (nl in de contractierichting), als ook de 
electrische koppeling (connexines) alsmede de rijping van de contractiele machinerie 
(sarcomeren). Daarenboven, is de deling vergroot en de averechtse hypertrofie (te sterke 
vergroting van het celvolume) verminderd. De therapeutische toepassing van ADSC en ECM 
zou met andere woorden kunnen worden toegepast om myocardconstructen te tissue-
engineeren en ook door directe toepassing in het hart de post-myocardinfarct 
weefselremodelling kunnen verbeteren. 
In deel II bestuderen we de ADSC-gemedieerde vasculaire netwerkvorming, waarin ADSC 
pericyt functie overnemen en vasculaire netwerken stabiliseren. Pericyten zijn gladde 
spierachtige cellen, die rond de kleinste bloedvaten (capillairen) zijn genesteld en deze 
vaatjes ‘besturen’. Onze in vitro resultaten tonen dat ADSC de vorming van capillare 
netwerken uit endotheelcellen ondersteunen. Deze capillairen worden ieder door   n
endotheeelcel gevormd. Echter, ADSC doen meer, ze bevorderen nl. ook de vorming van 
meercellige bloedvatstructuren, die tevens door ADSC worden gestabiliseerd doordat ze 
hierin integreren. Deze in vitro bevindingen konden worden gevalideerd in een neonataal 
retinopathie muismodel, waarin ADSC na intraoculaire (in het oog) toediening werden 
enerzijds de pathologische vaatvorming beïnvloedden en anderszijds integreerden op 
pericytaire locaties. Dit suggereert sterk dat ADSC pericyten kunnen vervangen in 
retinopathie. Deze verbetering ging gepaard met veranderingen in het genexpressie patroon 
van de retinas: Ang-1, FGF-2, TNFα en IL-8 namen toe, terwijl het vaatdestabiliserende Ang-
2 afnam. In retinopathie spelen zowel hypoxie als ontsteking een rol. In vitro, kon het effect 
van retinopathie deels worden herleid naar veranderende genexpressie van ADSC onder 
hypoxie en ontsteking: net als in vivo nam de expressie van Ang-1, FGF-2 en VEGF-A toe. 
Ook deze waarnemingen ondersteunen de gedachte dat ADSC van therapeutisch nut kunnen 
zijn bij ziekten met een verstoorde angiogenese, in het bijzonder vanwege hun zg. juxtacriene 
interactie met nieuwgevormde vaatjes als pericyten. Een andere belangrijk resultaat van 
onze studies is, dat naast de genoemde juxtacriene interacties, door ADSC geconditioneerd 
kweekmedium ook de vorming van capillaire netwerken (sprouting en vorming van 
bloedvatachtige netwerken) kon bewerkstelligen maw via paracriene stimulering. Dit was het 
sterkst onder de omstandigheden zoals die na een acuut hartinfart worden aangetroffen, 
maw hypoxisch en sterk inflammatoir spierweefsel. De in vitro door hypoxie en 
ontstekingsfactoren (IL-1β) gestimuleerde ADSC, produceerden factoren die het aantal 
vertakkingen, de taklengte zowel als de migratie van endotheelcellen sterk stimuleren. Deze 
eigenschap was uniek voor ADSC, want andere typen mesenchym- / fibroblastachtige cellen 
zoals muis 3T3, humane dermale fibroblasten (HDF) en humane cardiale fibroblasten (HCF) 
waren niet in staat de vorming van bloedvatachtige netwerken te ondersteunen. Dit was 
terug te voeren op de verhoogde expressie van VEGF en FGF-2 in ADSC. Echter, was er ook 
een opregulatie van pro-migratoire (MCP-1 en IL-8) en pro-inflammatoire (IL-1β en IL-6) in 
ADSC. Een andere interessante, maar tot dusver onbegrepen, bevinding is dat 
bloedvatachtige netwerken nadat ze eenmaal zijn gevormd onder stimulering van ADSC, na 
trypsinisering (het losmaken van de bodem van het kweekschaaltje) ook weer snel(er) 
nieuwe netwerken vormen. Dit zou therapeutisch toegepast kunnen worden bij ziekten waar 
een verhoogde doorbloeding is gewenst. Te denken valt aan toediening van dergelijk 




Tenslotte hebben we de toepassingen van ADSC voor toekomstige wondgenezing en 
littekenvorming in de huid onderzocht. Het is bekend dat toediening van  de zogenaamde 
lipoaspiraten huidlittekens kan verminderen. De logische gedachte is dat dit 
(mede)veroorzaakt wordt door ADSC. We hebben laten zien dat geconditioneerd 
kweekmedium van ADSC, de vorming van littekenfibroblasten (zg. myofibroblasten) uit 
TGFβ-gestimuleerde huidfibroblasten kan voorkomen. Sterker nog, ook het gedrag van 
bestaande littekenfibroblasten, zg keloide fibroblasten, kon worden ‘verbeterd’: hun 
contractie, alsmede de uitstoot van extracellulaire matrix werd gereduceerd door ADSC-
geconditioneerd medium. Samengevat, suggereert dit een veelbelovende toepassing voor 
ADSC in de behandeling van bindweefsel/littekenvorming, ook in het hart na een infarct.  
Het onderzoek beschreven in dit proefschrift, heeft de kennis vergroot van ADSC en hun 
therapeutisch werkingsmechanismen na een hartaanval. In het bijzonder hebben we 
beschreven dat ADSC onder invloed van de doorgaans als averechts beschouwde post-
myocardinfarctmilieu (hypoxie en ontsteking), juist beter anti-inflammatoir functioneren. 
Dit, door verhoogde aanmaak en uitscheiding van factoren die cardiomyocyten-deling 
bevorderen. Deze tevens de bloedvatvorming versterken en ondersteunen en de 
extracellulaire matrix verbeteren. Ook de potentie voor onderdrukking van verlittekening 
door ADSC is duidelijk vastgesteld. Wij veronderstellen dat het gebruik van ADSC of 
uitgescheiden componenten zoals groeifactoren of extracellulaire matrix componenten een 
haalbare en klinisch relevante toepassing is voor de behandeling van de complicaties van 
hartaanvallen, d.w.z. zeggen voor de reductie van hartfalen. 
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